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Abstract
Background
Primary biliary cirrhosis is a chronic autoimmune-mediated liver disease
characterised by progressive destruction of intrahepatic bile ducts, resulting in
chronic cholestasis, portal inflammation, and fibrosis that can lead to cirrhosis
and, ultimately, liver failure and the need for liver transplantation. The disease
primarely affects middle‐aged women and is associated with osteoporosis ‐
either postmenopausal or secondary to the liver disease. Low bone mass is an
important cause of morbidity in patients with primary biliary cirrhosis, leading
to an increased risk of fractures, pain, and deformity. Treatment of primary
biliary cirrhosis and osteoporosis associated with primary biliary cirrhosis is
complicated. A number of drugs have been evaluated for patients with primary
biliary cirrhosis (glucocorticosteroids, methotrexat, azathioprine, colchicine,
cyclosporin, D-penicillamine, and chlorambucil). Ursodeoxycholic acid is the
only drug approved for primary biliary cirrhosis by the U.S. Food and Drug
Administration. Bezafibrate may be effective for treatment of primary biliary
cirrhosis. Bisphosphonates and hormone replacement may be effective
treatment options for osteoporosis in primary biliary cirrhosis, but the effects
have only had limited assessment in systematic reviews. Therefore,
interventions based on evidence are highly warranted.
Cochrane reviews with meta-analyses and trial sequential analyses of
randomised clinical trials generally provide the best available evidence for
health care interventions and clinical practice. Such Cochrane reviews are used
to assess and summarise benefits and harms of clinical interventions.
Furthermore, Cochrane reviews will also reveal lack of evidence, and define the
specific need for future randomised clinical trials.
Objectives
To summarize the evidence from Cochrane systematic reviews on treatment
options for patients with primary biliary cirrhosis and osteoporosis associated
with primary biliary cirrhosis.
Methods
Four Cochrane systematic reviews of all relevant randomised clinical trials with
meta-analyses and trial sequential analyses were conducted using The
Cochrane Collaboration methodology, the GRADE, and the PRISMA-
guidelines. Three out of four systematic reviews were performed according to
published protocols following the recommendations of the Cochrane Handbook
for systematic reviews of interventions, and one review was updated according
to the same recommendations. Included trials were identified through The
Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded,
LILACS, Clinicaltrials.gov, the WHO International Clinical Trials Registry
Platform, manual searches of bibliographies and journals, authors of trials, and
pharmaceutical companies. Data extraction and the assessment of risk of bias
were conducted by two authors independently of each other.
Results
The four Cochrane systematic reviews included a total of 30 trials with 1,847
participants. Only three trials could be considered low risk of bias regarding all
bias types. The reporting of patient-important  outcomes was in general sparse.
We included 16 randomised clinical trials with 1447 patients with primary
biliary cirrhosis, out of which 14 trials compared ursodeoxycholic acid with
placebo and 2 trials compared ursodeoxycholic acid with no intervention.
Ursodeoxycholic acid versus placebo or no intervention did not significantly
affect all-cause mortality, all-cause mortality or liver transplantation, adverse
events, liver transplantation, pruritus, fatigue, or liver-related morbidity in
patients with primary biliary cirrhosis. Ursodeoxycholic acid seemed to have a
beneficial effect on liver biochemistry measures and on histological progression
compared with placebo or no intervention. According to the results of the trial
sequential analyses, there seems to be firm evidence for a beneficial effects of
ursodeoxycholic acid on decreasing serum bilirubin concentration and the
activity of serum alkaline phosphatases in patients with primary biliary
cirrhosis. All the other biochemical markers assessed showed non-significant
effect estimates.
We included 6 randomised clinical trials with 151 Japanese patients, out of
which 4 trials compared bezafibrate versus no intervention, and 2 trials
compared bezafibrate with ursodeoxycholic acid. Bezafibrate did not
demonstrate any significant effect on mortality, liver-related morbidity, or
adverse events when compared with no intervention, or when compared with
ursodeoxycholic acid. Bezafibrate did not demonstrate any significant effect on
pruritus compared with no intervention. The results of trial sequential analysis
imply that there is firm evidence for a beneficial effect of bezafibrate on
decreasing  the activity of serum alkaline phosphatases when compared with no
intervention, or when compared with ursodeoxycholic acid. The results of trial
sequential analysis imply that there is no firm evidence for a beneficial effect of
bezafibrate on decreasing plasma immunoglobulin M concentration and serum
bilirubin concentration when compared with no intervention. All the other
biochemical markers assessed showed non-significant effect estimates.
We included 6 randomised clinical trials with 200 participants, out of which 3
trials with 106 participants compared etidronate or alendronate with placebo or
no intervention; 2 trials with 62 participants compared etidronate or
alendronate with alendronate or ibandronate; and 1 trial with 32 participants
compared etidronate with sodium fluoride. Having conducted statistical
analyses, we found no evidence of effect of any of the aforementioned three
bisphosphonates on mortality, fractures, adverse events, liver-related mortality,
liver transplantation, liver-related morbidity or bone mineral density (BMD)
measured by dual-energy X-ray absorptiometry (DEXA) in patients with
primary biliary cirrhosis. The results of trial sequential analysis imply that there
is firm evidence for a beneficial effect of bisphosphonates on decreasing urinary
amino telopeptides of collagen I (NTx) concentration compared with placebo or
no intervention. Etidronate compared with sodium fluoride significantly
decreased serum osteocalcin, urinary hydroxyproline, and parathyroid
hormone concentration. All the other assessed biochemical markers of bone
turnover showed non-significant effect estimates.
We included 2 randomised clinical trials with 49 participants, which compared
the effect of hormone replacement in treatment of osteoporosis in women with
primary biliary cirrhosis with placebo or no intervention. We found no
significant effect of hormone replacement on mortality, fractures, lumbar spine
BMD measured by DEXA, liver-related mortality, liver transplantation, or liver-
related morbidity in women with primary biliary cirrhosis. Hormone
replacement significantly increased adverse events and number of patients
having hormone replacement withdrawn due to adverse events. Hormone
replacement may decrease BMD at the proximal femur.
Conclusions
We found no reliable evidence of benefit of the assessed treatments used in
patients with primary biliary cirrhosis and in osteoporosis associated with
primary biliary cirrhosis on patient-important outcomes which were poorly
reported in most of the trials. Almost all of the trials had methodological
limitations leading to systematic errors, small number of participants increasing
the risks of random errors, and short trial duration. None of the treatments can
be recommended for general use in clinical practice. Multi-centre randomised
clinical trials with larger sample sizes and minimised risk of bias would be
appropriate for participant recruitment since primary biliary cirrhosis is a
relatively rare disease.
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Sažetak
Uvod
Primarna bilijarna ciroza je hronična autoimuna bolest jetre koju karakteriše
progresivna destrukcija intrahepatičnih žučnih puteva sa posledičnom
holestazom, portnom inflamacijom, i fibrozom što dovodi do nastanka ciroze
jetre, i hepatičke insuficijencije sa transplantacijom jetre kao jedinom uspešnom
terapijskom metodom. Više od 90% bolesnika su žene, prosečne starosti oko 50
godina. Najvažnija komplikacija bolesti vezana za holestazu je osteoporoza gde
smanjenje koštane gustine dovodi do velikog rizika za nastanak preloma
kostiju, bola i deformiteta. Lečenje primarne bilijarne ciroze, kao i osteoporoze u
sklopu primarne bilijarne ciroze je veoma komplikovano. Za sada nema
zadovoljavajuće specifične medicinske terapije koja se preporučuje za lečenje
ove bolesti. Evaluirani su mnogi lekovi u terapiji ove bolesti (kortikosteroidi,
metrotreksat, azatioprin, kolhicin, ciklosporin, D-penicilamin, i hlorambucil), ali
do sada prikazani trajali su uglavnom bili kratki, mali i slabo kontrolisani.
Ursodeoksiholna kiselina jedini je lek odobren za terapiju primarne bilijarne
ciroze. U nekim kontrolisanim studijama konstatovano je da bezafibrat ima
višestruka pozitivna dejstva kod bolesnika sa primarnom bilijarnom cirozom.
Za bisfosfonate i supstitucionu hormonsku terapiju se očekuje da budu efikasni
u terapiji osteoporoze u sklopu primarne bilijarne ciroze, ali ne postoje za sada
dokazi efikasnoti u sistematskim pregledima.
Kohranovi sistematski pregledi sa meta-analizama i sekvencijalnim analizama
randomizovanih kliničkih studija sintetišu dokaze u cilju dobijanja pouzdanog,
validnog i kompletnog pregleda proverenih dokaza o korisnim i štetnim
efektima terapijskih procedura koristeći metodologiju u kojoj nema pristrasnosti
u tumačenju rezultata i izvođenju zaključaka. Takođe, oni mogu ukazati na
nedostatak dokaza i potrebu za budućim dobro dizajniranim randomizovanim
kliničkim studijama.
Ciljevi
Identifikovati i objediniti sve postojeće dokaze koji se odnose na procenu
povoljnih i štetnih efekata različitih intervencija kod bolesnika sa primarnom
bilijarnom cirozom i osteoporozom u sklopu primarne bilijarne ciroze.
Materijal i metode
Četiri Kohranova sistematska pregleda sa meta-analizama i sekvencijalnim
analizama randomizovanih kliničkih studija su izrađena koristeći
standardizovanu metodologiju Kohranove Kolaboracije, GRADE I PRISMA
vodiča. Tri sistematska pregleda su izvedena prema protokolima objavljenim u
Kohranovoj bazi sistematskih pregleda, dok je jedan ažuriran. Randomizovane
kliničke studije su identifikovane sveobuhvatnom pretragom literature i
sledećih baza podataka The Cochrane Library, Medline, Embase, Science Citation
Index Expanded, LILACS, Clinicaltrials.gov, the WHO International Clinical Trials
Registry Platform, ručnim pretraživanjem literature, ličnim kontaktom sa
glavnim istraživačima identifikovanih randomizovanih kliničkih studija i
farmaceutskim kompanijama koje produkuju ispitivani lek. Ekstrakciju
podataka i procenu rizika od pristrasnosti odnosno metodološkog kvaliteta
uključenih studija su obavljala dva autora nezavisno jedan od drugog.
Rezultati
U doktorsku tezu su uključena četiri Kohranova sistematska pregleda sa
ukupno 30 randomizovanih kliničkih studija i 1.847 ispitanika.
Analiza ursodeoksiholne kiseline je uključila 16 randomizovanih studija sa 1447
pacijenata sa primarnom bilijarnom cirozom, od kojih 14 studija je poredilo
ursodeoksiholnu kiselinu sa placebom a 2 studije su poredile ursodeoksiholnu
kiselinu sa ‘no intervention’. Primena ursodeoksiholne kiseline nije značajno
uticala na ukupnu smrtnost, ukupnu smrtnost ili transplantaciju jetre, neželjena
dejstva, transplantaciju jetre, svrab, umor, ili komplikacije bolesti kod pacijenata
sa primarnom bilijarnom cirozom. Ursodeoksiholna kiselina može povoljno
uticati na biohemijske parametre jetrine funkcije i histološku progresiju u
poređenju sa placebom ili ‘no intervention’.
Analiza bezafibrata je uključila 6 randomizovanih studija sa 151 ispitanika sa
primarnom bilijarnom cirozom, od kojih 4 studije je poredilo bezafibrat sa ‘no
intervention’ a 2 studije su poredile  bezafibrat sa ursodeoksiholnom kiselinom.
Primena bezafibrata nije pokazala nikakav značajan uticaj na ukupnu smrtnost,
komplikacije bolesti, i neželjena dejstva kod pacijenata sa primarnom bilijarnom
cirozom u poređenju sa ursodeoksiholnom kiselinom ili ‘no intervention’. Nije
pokazano da bezafibrati imaju značajan efekat na svrab u poređenju sa ‘no
intervention’. Rezultat sekvencijalne analize studija ukazuje na mogući povoljan
efekat bezafibrata na smanjenje aktivnosti serumske alkalne fosfataze u
poređenju sa ursodeoksiholnom kiselinom ili ‘no intervention’. Na sve ostale
biohemijske markere bezafibrat je bio bez značajnog efekta.
Analiza bisfosfonata je uključila 6 randomizovanih studija sa ukupno 200
ispitanika sa primarnom bilijarnom cirozom i osteoporozom, od kojih 3 studije
sa 106 ispitanika su poredile etidronat ili alendronat sa placebom ili ‘no
intervention’; 2 studije sa 62 ispitanika su poredile  etidronat ili alendronat sa
alendronatom ili ibandronatom, i 1 studija sa 32 ispitanika je poredila etidronat
sa natrijum fluoridom. Za nijedan od navedena tri bisfosfonata nije dokazano
da imaju uticaj na ukupnu smrtnost, nastanak preloma, neželjene efekte,
smrtnost vezanu za bolest jetre, transplantaciju jetre, komplikacije bolesti ili
koštanu mineralnu gustinu merenu dvostrukom X zračnom apsorpciometrijom
kod bolesnika sa primarnom bilijarnom cirozom i osteoporozom. Rezultat
sekvencijalne analize studija ukazuje na mogući povoljan efekat bifosfonata na
smanjenje urinarnog N-terminalnog telopeptida (NTx) u poređenju sa
placebom ili ‘no intervention’. Samo je jedna studija poredila etidronat sa
natrijum fluoridom zbog čega meta-analizu nije bilo moguće sprovesti, a
opisuje da etidronat značajno smanjuje serumski osteokalcin, urinarni
hidroksiprolin, i koncentraciju paratireoidnog hormona. Na sve druge
biohemijske markere koštanog prometa nije bilo značajnih efekata.
Analiza supstitucione hormonske terapije je uključila 2 randomizovane studije
sa 49 ispitanica sa primarnom bilijarnom cirozom i osteoporozom, koje su
poredile supstitucionu hormonsku terapiju sa placebom ili ‘no intervention’.
Dokazano je da supstituciona hormonska terapija ne utiče na smrtnost,
nastanak preloma, koštanu mineralnu gustinu lumbalne kičme merenu
dvostrukom X zračnom apsorpciometrijom, smrtnost vezanu za bolest jetre,
transplantaciju jetre, ili komplikacije bolesti  kod bolesnica sa primarnom
bilijarnom cirozom i osteoporozom. Pokazano je da supstituciona hormonska
terapija može smanjiti koštanu mineralnu gustinu na proksimalnom okrajku
butne kosti. Supstituciona hormonska terapija je udružena sa povećanim
brojem neželjenih efekata.
Zaključak
Izradom Kohranovih sistematskih pregleda te meta-analizom dostupnih
literaturnih dokaza prikazani su podaci efikasnosti i štetnosti primene različitih
intervencija kod bolesnika sa primarnom bilijarnom cirozom i osteoporozom u
sklopu primarne bilijarne ciroze. Ustanovljeno je da se ne može preporučiti
njihova rutinska primena u svakodnevnoj kliničkoj praksi zbog visokog rizika
pristranosti i manjkavosti u dizajnu primarnih studija, kao i zbog malog broja
randomizovanih ispitanika. Dodatne dobro dizajnirane studije su potrebne s
ciljem određivanja njihove stvarne štetnosti, odnosno efikasnosti.
Ključne reči: Kohranov pregled; primarna bilijarna ciroza; osteoporoza
Naučna oblast/uža naučna oblast: Epidemiologija/gastroenterolohepatologija
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1INTRODUCTION
Primary biliary cirrhosis is a chronic inflammatory autoimmune liver disease
characterised by progressive destruction of intrahepatic bile ducts, resulting in
chronic cholestasis, portal inflammation, and fibrosis that can lead to cirrhosis
and, ultimately, liver failure. It remains one of the major indications for liver
transplantation worldwide.
Epidemiology
The disease was first comprehensively described around 1950 (MacMahon and
Thannhauser, 1949; Ahrens et al, 1994). Primary biliary cirrhosis is a rare
disease that primarily affects middle-aged women with a sex ratio of 10:1. Data
about the incidence and prevalence of primary biliary cirrhosis have generally
been obtained passively and might not indicate the true rates of the disease in
the general population. Reported annual incidence of primary biliary cirrhosis
ranges from 1 to 49 persons per million, and the prevalence has been estimated
between 7 to 402 persons per million (Prince and James, 2003; Poupon, 2010).
The disease seems to cluster within specific geographical areas, being most
prevalent in northern Europe (Prince and James, 2003). Risk factors include
history of familial autoimmune disease, history of active or passive smoking
and recurrent urinary tract infections. Coexisting autoimmune diseases among
patients with primary biliary cirrhosis included Sjogren’s syndrome (17.4%),
Raynaud’s phenomenon (12.5%), and autoimmune thyroid disease (11.5%),
with significantly lower frequencies among siblings and healthy persons
(Parikh-Patel et al, 2001). Primary biliary cirrhosis is now a frequent cause of
liver morbidity, and the patients are significant users of health resources,
including liver transplantation (Prince and James, 2003).
Pathogenesis
The etiology of primary biliary cirrhosis is still unclear, but it is thought to
involve multiple genetic factors and environmental triggers leading to an
2intense autoimmune response against the biliary epithelial cells. Pathogenesis is
multi-step that follows from an initial loss of immunologic tolerance to a
ubiquitous antigen all the way through to immune mediated inflammation,
cholestasis and subsequent fibrosis. Environmental factors such as chemicals
likely play a role in causes of the disease. Bacteria have attracted the most
attention because of the reported elevated incidence of urinary tract infections
in patients with primary biliary cirrhosis. Other potential causes include
exposure to environmental chemicals. However, it is unclear whether the
chemical immunisation is serendipitous and capable of eliciting
antimitochondrial antibodies or whether these antibodies are capable of
inducing primary biliary cirrhosis (Leung et al, 2005). Cellular (CD4 and CD8 T
cells) and humoral abnormalities have both been noted. The major finding
associated with humoral immunity in primary biliary cirrhosis resides with
recognition of the antimitochondrial antibody. Formation of this antibody is
presented in more than 95% of patients.
Clinical findings and natural history
The clinical features and natural history of primary biliary cirrhosis vary greatly
between patients. It may manifest as asymptomatic, slowly progressive,
symptomatic, or rapidly evolving. Asymptomatic patients have about
equivalent short-term survival compared to an age-matched and sex-matched
healthy population (Lee and Kaplan, 2005). Most asymptomatic people with
primary biliary cirrhosis will develop symptoms within five years after the
diagnosis has been made. The progress to cirrhosis and end stage liver disease
may necessitate liver transplantation as the only treatment option (Prince et al,
2004). On the other hand, the overall median survival for symptomatic patients
is between 10 and 15 years. Serum bilirubin level is an independent predictor of
survival and is used for prognosis in patients with primary biliary cirrhosis
(Shapiro et al, 1979). The most common symptoms and findings are fatigue and
pruritus, hyperlipidaemia, hypothyroidism, osteoporosis, and coexisting
3autoimmune diseases (Kaplan and Gershwin, 2005). Primary biliary cirrhosis is
associated with features of autoimmune hepatitis in 10% patients.
Diagnosis
Diagnosis is made upon the following criteria: a) abnormal biochemical tests
with preferential elevation of serum alkaline phosphatases and
gammaglutamyltranspeptidases activities; b) presence of detectable serum
antimitochondrial antibodies with M2 specificity as confirmed by ELISA or
immunoblotting; c) evidence of lymphocytic destructive cholangitis (LDC) at
histology. Criteria of a and b or c are sufficient for the diagnosis considering the
high specificity of anti-M2 antibody and LDC (Heathcote, 2000; EASL, 2009).
Characteristic liver histological changes confirm the diagnosis and are used for
staging and assessing disease activity before therapeutic intervention, and can
identify other co-existent diseases such as steatosis or steatohepatitis (Lindor et
al, 2009; Drebber et al, 2009). Histological staging is based on Ludwig’s and
Scheuer’s classifications (Scheuer, 1967), ranging from portal tract inflammation
with predominantly lymphoplasmacytoid infiltrates and septal and interlobular
bile duct loss (stage I) to frank cirrhosis (stage IV). Focal duct obliteration with
granuloma formation has been termed the ‘florid duct lesion’ and is considered
almost pathognomonic for primary biliary cirrhosis when present. Stage II is
characterized by portal expansion with periportal inflammation (interface
hepatitis) and/or ductular reaction, and stage III is dominated by the existence
of bridging fibrosis. Features predictive of a poor outcome include the presence
of an established cirrhosis or marked ductopenia. However, according to the
latest clinical guidelines (EASL, 2009), a liver biopsy shall not necessarily be
used for diagnosis of primary biliary cirrhosis in patients who present with
typical biochemical and serological abnormalities. Therefore, liver biopsy is
now mainly used as a diagnostic investigation in patients presenting with
atypical biochemical or serological findings (e.g. AMA-negative PBC) and those
who are suspected to have an ‘overlap syndrome’’ with autoimmune hepatitis.
4Non-invasive markers, including panels of serum markers and transient
elastography, have been used to a limited degree in patients with primary
biliary cirrhosis to assess disease severity, but further studies are required to
determine their diagnostic utility.
Interventions
Treatment for primary biliary cirrhosis remains presently non-specific, having
essentially remained unchanged for more than a decade, with standard of care
requiring the use of ursodeoxycholic acid. Patients with suboptimal response to
ursodeoxycholic acid deserve trials with adjuvant therapies. However there is
no consensus how to treat these patients.
Several drugs, glucocorticosteroids, methotrexat, azathioprine, colchicine,
cyclosporin, D-penicillamine, and chlorambucil have been evaluated in primary
biliary cirrhosis. Cochrane systematic reviews showed that none of them have
been effective in patients with primary biliary cirrhosis (Gong and Gluud,
2004a; Gong et al, 2004b; Prince et al, 2005; Gong et al, 2007a; Gong et al, 2007b;
Giljaca et al, 2010; Li et al, 2012). Malotilate (1.5 g/day) has been evaluated
versus placebo in a doubleblind multicentre randomised clinical trial including
101 patients. After a mean follow-up of 28 months significant beneficial effects
were found on liver enzymes, immunoglobulin G and M, liver necrosis and
inflammatory cell infiltration, but not on fibrosis, pruritus, disease progression,
or survival. The observed benefits appeared too slight to recommend the drug
as therapy (A European multicentre study group, 1993). Thalidomide 100
mg/day has been tested against placebo in a small double-blind trial involving
18 patients. Except for a possible effect on pruritus no significant effects of the
drug were found, and adverse effects occurred in 40% (McCormick et al, 1994).
Ursodeoxycholic acid
Ursodeoxycholic acid is the only drug approved for primary biliary cirrhosis by
the U.S. Food and Drug Administration. Doses of 13 to 15 mg/kg/day seem to
5cause significant improvements in liver tests and immunoglobulin levels and
reduce titers of antimitochondrial antibodies. The dose of ursodeoxycholic acid
appears to be important. A study comparing three different doses showed that
a dose of 13 to 15 mg/kg of body weight per day appeared to be optimal, as
compared with a dose of either 5 to 7 mg or 23 to 25 mg (Angulo et al, 1999a).
Bile duct destruction leads to the retention of hydrophobic bile acids within the
liver cell. This most likely contributes to the gradual deterioration of liver
function and liver histology observed in patients with primary biliary cirrhosis.
Ursodeoxycholic acid increases the transportation of intracellular bile acids
across the liver cell and into the canaliculus in patients with primary biliary
cirrhosis (Jazrawi et al, 1994). Mechanisms of action of ursodeoxycholic acid in
primary biliary cirrhosis remain unclear, yet the hydrophilic nature of this
agent could lead to a reduction in amounts of primary bile acids, and the
substance might also regulate cellular signalling and protect against apoptosis
(Crosignani et al, 1991; Paumgartner and Beuers, 2002). Ursodeoxycholic acid is
a secondary bile acid, which is a metabolic byproduct of intestinal bacteria.
After oral ingestion and intestinal absorption, the drug enters the portal
circulation and is taken up by the hepatocytes where ursodeoxycholic acid is
conjugated to glycine or taurine and is subsequently transported into the bile
ducts (Kullak-Ublick et al, 2000). Ursodeoxycholic acid undergoes extensive
enterohepatic recycling along with the other bile acids (Hofmann, 1994).
Because of its high first-pass metabolism (70%), the blood level of
ursodeoxycholic acid in the systemic circulation is low (Saksena and Tandon,
1997). In the colon, the unabsorbed ursodeoxycholic acid is transformed to
lithocholic acid by colonic microbial flora and is excreted via the faeces (Kullak-
Ublick et al, 2000). The half life of ursodeoxycholic acid is about 100 hours
(Setchell et al, 1996). The drug acts through several pathways, such as alteration
of the bile-acid pool, choleresis (the flow of bile from the liver), immune-
modulation effects, and cytoprotective mechanisms. One of the main
mechanisms of ursodeoxycholic acid is displacement of endogenous
6hepatotoxic bile by expansion of the hydrophilic bile acid pool which may
correlate with competitive displacement of endogenous bile acids, either at the
level of ileal absorption or at the hepatocyte (Stiehl et al, 1999). Ursodeoxycholic
acid treatment in patients with primary biliary cirrhosis might reduce the serum
level of IgM class antimitochondrial antibodies and IgG antibodies to pyruvate
dehydrogenase. Ursodeoxycholic acid might also reduce the T-cell-mediated
hepatocellular damage by decreasing hepatocellular and biliary expression of
major histocompatibility complex (MHC) class I and MHC class II molecules
(Lazaridis et al, 2001). Ursodeoxycholic acid is theoretically a safe and well
tolerated drug but can induce modest weight gain (2 to 3 kg) during the first
year of treatment (Siegel et al, 2003). The effect of ursodeoxycholic acid on
mortality and histological progression remains still controversial (Goulis et al,
1999; Gluud and Christensen, 2001b; Gong et al, 2008; EASL, 2009; Silveira et al,
2010). Our previously updated Cochrane systematic review did not provide
sufficient information on benefits and harms of ursodeoxycholic acid in patients
with primary biliary cirrhosis to recommend or reject the drug for this
indication (Gong et al, 2008).
Bezafibrate
PPAR alpha agonists (bezafibrate, fenofibrate) are now recognized to have anti-
inflammatory and immunomodulatory properties in experimental models of
autoimmunity. Bezafibrate was first introduced in 1977 by Boehringer
Mannheim Ltd. (Williams et al, 1984). Bezafibrate is a hypolipidaemic agent,
which reduces cholesterol and triglyceride synthesis in the liver by inhibiting
acetyl coenzyme A carboxylase activity. Fibrates are known to reduce the flow
of fatty acids to the liver, decrease very low-density lipoprotein hepatic
synthesis, stimulate lipoprotein-lipase activity, and increase the biliary
excretion of hepatic cholesterol. Bezafibrate is used in treatment of
hypertriglyceridaemia and combined hyperlipidaemia (Vessby et al, 1980).
Bezafibrate effectively reduces low-density lipoprotein and triglycerides, and
7elevates high-density lipoproteins levels thus improving hyperlipidaemia (The
BIP Study Group, 2000). Fibrates are associated with a number of adverse
effects, including liver enzyme elevations, gastrointestinal adverse effects, and
rhabdomyolysis (Muscari et al, 2002). In patients with metabolic syndrome,
bezafibrate decreases the incidence of myocardial infarction and reduces the
risk of cardiac mortality (Tenenbaum et al, 2005). Bezafibrate decreases the
incidence of type 2 diabetes and may delay the onset of type 2 diabetes in
patients with impaired glucose tolerance (Tenenbaum, et al, 2004). Bezafibrate
decreases the activity of the cholestatic liver enzymes (alkaline phosphatases
and gamma-glutamyl transferase) in asymptomatic patients (Fukuo et al, 1996).
In some small studies, biochemical improvement was reported by using
bezafibrate alone or in combination with ursodeoxycholic acid (Kurihara et al,
2000; Nakai et al, 2000; Kurihara et al, 2002). There are two possible mechanisms
of the bezafibrate effects on primary biliary cirrhosis involving multiple drug-
resistant gene (MDR-2) and peroxisome proliferative-activated receptor alpha
(PPAR-α) system pathway. Bezafibrate is a ligand of PPAR-α, which is involved
in immune function and inflammation control by regulation of leukotriene B4
and through this mechanism it improves lipid serum concentration balance
(Devchand et al, 1996; Delerive et al, 2001). Secondly, bezafibrate induces the
expression of MDR-2 and thus controls the balance of biliary phospholipids and
bile acids which prevents biliary cell damage through activation of the MDR-2
gene of a knockout mice (mimicking the human MDR-3 gene) (Smit et al, 1993;
Chianale et al, 1996). In human studies, defects of the MDR-3 gene may produce
progressive familial intrahepatic cholestasis, and in advanced primary biliary
cirrhosis the expression of MDR-3 messenger RNA and proteins is increased
(Jacquemin et al, 2001; Ros et al, 2003). Bezafibrate lowers the proportion of Fas
antigen (surface transmembrane protein that mediates apoptosis)-positive T
cells in the peripheral blood and suppresses the inflammatory response in
patients with primary biliary cirrhosis (Ishimaru and Iino, 2002). Fibrates might
inhibit migration of inflammatory cells by RANTES (hepatic regulated upon
8activation, normal T-cell expressed and secreted) to the liver in patients with
primary biliary cirrhosis (Hirano et al, 2002). The exact mechanisms yielding the
therapeutic benefits of bezafibrate in primary biliary cirrhosis are still to be
understood.
Disease-related complications
A number of systemic complications associated with primary biliary cirrhosis
have been documented that represent disease progression and impair health-
related quality of life in some individuals. Disease-specific complications,
including fatigue, pruritus, and metabolic bone disease, are important to
recognize and treat appropriately.
Metabolic bone disease
Patients with primary biliary cirrhosis are predisposed to develop metabolic
bone disease and premature cortical bone thinning. They often suffer from
postmenopausal osteoporosis due to their age. Bone disease is a major
complication of chronic liver disease with serious clinical consequences,
affecting quality of life, morbidity, and mortality (Luxon, 2011). The term
’hepatic osteodystrophy’ includes bone disease associated with chronic liver
disease (Rouillard and Lane, 2001).
Osteoporosis is a common progressive systemic skeletal disease characterised
by low bone strength and increased fracture risk (WHO, 1994; Klibanski et al,
2001). Bone loss among patients with primary biliary cirrhosis is twice that of
age and sex-matched controls (Eastell et al, 1991), and the prevalence of
osteoporosis among these patients is between 14% and 52% (WHO, 1994).
Osteoporotic fractures of the spine and hip contribute importantly to the
increased morbidity and mortality (Cooper, 1997; Center et al, 1999). More than
200 million people worldwide have osteoporosis (Cooper et al, 1992). Bone
mineral testing by dual-energy X-ray absorptiometry is the current gold
standard for measuring bone mineral density in grams per square centimetre
9(g/cm²) in the lumbar spine (L1-L4), proximal femur, the distal one-third of
radius, and the total hip. The classification of bone mineral density is
determined by the standard deviation difference between the patient’s bone
mineral density and the mean bone mineral density of a young-adult reference
population represented by the T-score (≤ 2.5 ’osteoporosis’, between 1.0 and 2.5
’low bone mass’ or ’osteopenia’, and ≥ 1.0 ’normal’) (Kanis, 1994; WHO, Kanda
1994). Bone mineral density measured by dual-energy X-ray absorptiometry
combined with clinical risk factors for fracture (when available, with electronic
algorithms such as FRAX ®) are widely used to estimate fracture risk (WHO,
1994). According to the American Gastroenterological Association guidelines
bone mineral density should be considered in all patients with primary biliary
cirrhosis at diagnosis (AGA, 2003; Leslie et al, 2003).
The pathogenesis of osteoporosis in primary biliary cirrhosis is complex and
needs further elucidation, but it is thought to be multifactorial. Bone loss is the
result of an imbalance between bone formation and bone resorption (Diamond
et al, 1989; Hodgson et al, 1993). The main risk factors for osteoporosis in
primary biliary cirrhosis include age and severity of liver disease which is
correlated with the severity of bone disease (Menon et al, 2001; Boulton-Jones et
al, 2004). Potential factors that may alter bone mass include insulin growth
factor-1 deficiency, hyperbilirubinaemia, hypogonadism (oestrogen and
testosterone deficiency), alcoholism, excess tissue iron deposition, vitamin D
deficiency, vitamin D receptor genotype, osteprotegerin deficiency, and
immunosuppressive therapy before and after liver transplantation (McCaughan
and Feller, 1994; Sambrook and Cooper, 2006). Furthermore, retained bilirubin
and biliary salts, increased production of fibronectin iso-form, increased
osteoclast formation, calcium malabsorption, and nutritional status have an
influence on the low bone formation (Collier et al, 2002; Smith et al, 2006;
Kawelke et al, 2008; Olivier et al, 2008). Osteoporosis is more prevalent in
women with primary biliary cirrhosis than in the age and sex-matched general
population, and fracture risk in these women is greater than in other patients
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with chronic liver disease (Guañabens et al, 2005; Guañabens et al, 2010).
Interventions for osteoporosis
With the increasing prevalence of patients with primary biliary cirrhosis, there
will be a large number of people with a potential bone disease. Thus, it is of
potential great importance to focus on early recognition of these individuals as
well as define the risk of fracture in each patient in order to treat excessive bone
loss and prevent osteoporotic fractures. Defining optimal treatment regiments
for osteoporosis in primary biliary cirrhosis is a challenge as pathogenesis
remains poorly understood. Patients with primary biliary cirrhosis are mainly
elderly women who are naturally prone to osteoporosis. In general, the
principles of management in postmenopausal osteoporosis also apply in
primary biliary cirrhosis.
Agents shown to be useful in preventing or reducing bone loss in
postmenopausal women include calcium, cyclical etidronate, alendronate,
risedronate, hormone replacement, raloxifene, calcitonin, and combined
vitamin D and calcium (Collier et al, 2002; Wells et al, 2008a; Wells et al, 2008b;
Wells 2008c; Arteh et al, 2010). Current recommendations are that treatment of
osteoporosis should be given for a minimum of five years and bone density
repeated after two years and at the end of treatment (Collier et al, 2002).
Bisphosphonates should be considered in all patients who have had a fragility
fracture or have a T-score below - 2.5 (Collier et al, 2002). Bisphosphonates may
be used with hormone replacement or without hormone replacement. Calcitriol
and calcitonin should be considered in those patients with osteoporosis who are
either intolerant of hormone replacement and bisphosphonates, or whose bone
mineral density worsens despite the use of bisphosphonates or treatment of
hypogonadism (Collier et al, 2002).
Bisphosphonates
Bisphosphonates are the most often used drugs in the treatment of
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postmenopausal osteoporosis. Meta-analyses show that bisphosphonates
increase bone mineral density measured by dual-energy X-ray absorptiometry
and reduce fracture risk (Wasnich and Miller, 2000). Lumbar spine bone
mineral density increased by 8% with bisphosphonate treatment will reduce
vertebral fracture risk by 54% (Wasnich and Miller, 2000; Cummings et al, 2002;
Lewiecki, 2010). Larger increases in lumbar spine and hip bone mineral density
after treatment with bisphosphonates were associated with lower risk of non-
vertebral fractures (Hochberg et al, 2002). Cochrane systematic reviews have
demonstrated that alendronate and risedronate have statistically significant and
clinically important benefit in the secondary prevention of vertebral, non-
vertebral, and hip fractures in postmenopausal women (Wells et al, 2008a; Wells
et al, 2008c). Reductions in wrist fractures were observed only for alendronate
(Wells et al, 2008a). Benefit of etidronate in the secondary prevention of
vertebral fractures was demonstrated as well (Wells et al, 2008b). No significant
reductions in the primary prevention of vertebral and non-vertebral fractures
were observed for alendronate and risedronate with the exception of vertebral
fractures for etidronate, for which the reduction was clinically important (Wells
et al, 2008a; Wells et al, 2008b; Wells et al, 2008c). Bisphosphonates have proven
effective for other forms of osteoporosis (eg, associated with glucocorticoid
administration) (Saag et al, 1998; Homik et al, 1999). This evidence is important
since corticosteroid use is one of the risk factors associated with osteoporosis
among people with primary biliary cirrhosis.
Based on current, limited data, bisphosphonates are the most rational choice for
the prevention and treatment of osteoporosis in primary biliary cirrhosis, both
spontaneous osteoporosis and glucocorticosteroid induced osteoporosis
(Wolfhagen et al, 2000). These drugs have been studied in a small number of
patients with primary biliary cirrhosis (Pares et al, 2006). In a head-to-head trial,
the alendronate group showed better improvement of bone mineral density
compared with the etidronate group (Guanabens et al, 2003). Accordingly, the
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harms and benefits of bisphosphonates for osteoporosis are unclear. Patients
with primary biliary cirrhosis have an increased risk of fractures compared to
the general population (Solaymani-Dodaran et al, 2006). The correlation
between vertebral fracture and a T-score below -1.5 suggests that this
measurement may be useful to decide when to prescribe agents to prevent bone
loss and development of new fractures in patients with primary biliary cirrhosis
(Guañabens et al, 2010).
Bisphosphonates (formerly called diphosphonates) are synthetic compounds
derived from pyrophosphate characterized by a P–C–P group. Bisphosphonates
were synthesised in 1865 in Germany (Menschutkin, 1865). The most important
step toward their clinical use is their potential in preventing the dissolution of
hydroxylapatite, the principal bone mineral, thus inhibiting bone resorption
(Fleisch et al, 1969). Bisphosphonates can be classified into two groups with
different molecular modes of action. Non-nitrogen-containing bisphosphonates
(eg, etidronate, clodronate) inhibit osteoclasts by producing toxic analogues of
adenosine trisphosphate that cause cell death. Nitrogen-containing
bisphosphonates (eg, pamidronate, alendronate, risedronate, ibandronate, and
zoledronate) inhibit an enzyme called farnesyl pyrophosphate synthase (FPPS),
a key branch-point enzyme in the mevalonate pathway. FPPS generates
isoprenoid lipids used for the posttranslational modification of small GTP-
binding proteins essential for osteoclast function. Inhibition of this enzyme
leads to reduced resorptive activity of osteoclasts and accelerated apoptosis
(Russell, 2011).
These agents are of value as treatment for various metabolic bone diseases
associated with increased bone turnover, such as Paget's disease, osteoporosis,
and bone tumours. Bisphosphonates are used for diagnostic purposes as
skeletal markers in the form of 99mTc derivatives (Fleisch, 1991; Papapoulos et
al, 1992). Bisphosphonates can be administered orally or intravenously with a
wide range of doses and dosing intervals, and duration of therapy (Russell,
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2006). Less than 1% of an orally administered dose of bisphosphonates is
absorbed, 50% of the absorbed dose binds to bone surfaces, and the 50% or so
that does not bind to bone is excreted rapidly by the kidneys.
Potential adverse effects of bisphosphonates include upper gastrointestinal
disorders (eg, oesophagitis or oesophageal ulcer), influenza-like illness, renal
toxicity, and osteonecrosis of the jaw (Bounameaux et al, 1983; Cryer and Bauer,
2002; Chang et al, 2003). Symptoms of influenza-like illness such as fatigue,
fever, chills, myalgia, and arthralgia are transitory and mostly observed after
the first exposure to nitrogen-containing bisphosphonates (Adami and
Zamberlan, 1996; Reid et al, 2002). Osteonecrosis of the jaw can occur with
heavy doses of intravenous bisphosphonates in patients with malignancy
(Migliorati et al, 2005; Gimsing et al, 2010). Overall, the safety and tolerability of
the nitrogen-containing bisphosphonates seem good, and a long-term treatment
does not appear to carry a risk of serious adverse events (Strampel et al, 2007).
Hormone replacement
Oestrogen has important effects on bone. Oestrogen deficiency is considered to
be a major factor leading to bone loss in postmenopausal women. The
mechanism of oestrogen effect on bone is via oestrogen receptors that were
identified both on osteoclasts and especially on osteoblasts (Lindsay, 1993).
Oestrogen also has an indirect effect by increasing the production of insulin-like
growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), and transforming
growth factor-ß (TGF-ß) which also stimulates bone formation (Wren, 1997).
Oestrogen replacement reduces bone loss in postmenopausal osteoporosis by
inhibiting bone resorption and stimulating new bone formation (Chow et al,
1992; Riggs and Melton, 1993).
Oestrogen, with or without a progesterone, has beneficial effects on surrogate
markers of bone turnover and on fracture risk and has been used extensively for
the prevention of osteoporosis. There is evidence that hormone replacement
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increases bone mineral density in the hip, lumbar spine, and peripheral body
sites (Wells et al, 2002). A meta-analysis of randomised clinical trials has shown
that hormone replacement reduces the incidence of non-vertebral fractures in
women, but the benefit may decrease if it is started after age of 60 years
(Torgerson and Bell-Syer, 2001a). Hormone replacement was associated with
significant reduction in vertebral fracture as well (Torgerson and Bell-Syer,
2001b).
Hormone replacement generally includes either oestrogen alone or oestrogen
combined with progesterone or a chemical analogue, called a progestin. The
addition of a progestin reduces the risk of endometrial hyperplasia associated
with the use of oestrogen alone in women with a uterus (Lethaby et al, 2004).
Progestogens have adverse effects on blood lipids and may cause symptoms
such as headache, bloating, and breast tenderness (McKinney and Thompson,
1998). Hormone replacement is used in a variety of formulations which can be
taken orally, vaginally, transnasally, as an implant, skin patch, cream, or gel.
The transdermal route avoids first-pass metabolism, thus having less metabolic
effects on the liver and reducing the cholestatic potential of hormone
replacement. Hormone replacement administrated transdermally is potentially
safer in patients with chronic liver disease (Ribot et al, 1990; Stevenson et al,
1990). Doses often vary cyclically, with oestrogens taken daily and progesterone
or progestins taken for about two weeks every month or two. Clinical effects are
different according to the type of hormone replacement and its duration of use.
Hormone replacement has been used worldwide to treat symptoms of
menopause and to prevent chronic conditions such as osteoporosis. There is no
evidence that hormone replacement could prevent cardiovascular events in
postmenopausal women (with or without cardiovascular disease) (Gabriel et al,
2005). On the contrary, a Cochrane review assessing the long-term clinical
effects of using hormone replacement for perimenopausal and postmenopausal
women reports strong evidence that hormone replacement significantly
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increases the risk of venous thromboembolism, fatal or nonfatal heart attacks
(after one year's use), stroke (after three years use), breast cancer, gallbladder
disease, and in women over 65 years, the risk of dementia (Farquhar et al, 2009).
Prolonged use of unopposed oestrogen (that is without progesterone) may
carry an increased risk for ovarian and endometrial cancer (Rodriguez et al,
2001; Lacey et al, 2002; Riman et al, 2002; U.S. PSTF 2002).
Beneficial effects of hormone replacement on bone mineral density in primary
biliary cirrhosis have been reported (Olsson et al, 1999; Menon et al, 2003).
There is a theoretical concern of worsening cholestasis by application of
hormone replacement to patients with primary biliary cirrhosis (Schreiber and
Simon, 1983). However, in a small retrospective study, hormone replacement
resulted in a significant increase in bone mineral density compared to untreated
patients, and there was no evidence of worsening cholestasis (Crippin et al,
1994). Furthermore, hormone replacement could also be used to treat
postmenopausal symptoms in women with primary biliary cirrhosis, and such
trials might have examined the effects of hormone replacement on the bone.
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OBJECTIVES
The objective of this PhD thesis was to summarize the evidence from Cochrane
systematic reviews on treatment options for patients with primary biliary
cirrhosis and osteoporosis associated with primary biliary cirrhosis.
MATERIAL AND METHODS
Cochrane Reviews are systematic reviews of primary research in human health
care and health policy, and are internationally recognized as the highest
standard in evidence-based health care. They investigate the effects of
interventions for prevention and treatment. A Cochrane Review is a scientific
investigation in itself, with a pre-planned methods section and an assembly of
original studies (predominantly randomised controlled trials and clinical
controlled trials) as their ‘subjects’. The results of these multiple primary
investigations are synthesized by using strategies that limit bias and random
error. These strategies include a comprehensive search of all potentially
relevant studies and the use of explicit, reproducible criteria in the selection of
studies for review. Primary research designs and study characteristics are
appraised, data synthesized, and results interpreted.
Criteria for considering reviews for inclusion
Only Cochrane systematic reviews were considered for inclusion in this thesis.
We performed four Cochrane systematic reviews of all relevant randomised
clinical trials with meta-analyses and trial sequential analyses using The
Cochrane Collaboration methodology. Two systematic reviews assessed the
effects of ursodeoxycholic acid and bezafibrate in patients with primary biliary
cirrhosis, and the other two systematic reviews assessed the effects of
bisphosphonates and hormone replacement for osteoporosis in patients with
primary biliary cirrhosis. Three out of four systematic reviews were performed
according to published protocols following the recommendations of the
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Cochrane Handbook for systematic reviews of interventions, and the review
assessing the effects of ursodeoxycholic acid in patients with primary biliary
cirrhosis was updated according to the same recommendations.
Types of participants
Eligible participants were patients with primary biliary cirrhosis, i.e., patients
having at least two of the following: elevated serum activity of alkaline
phosphatases, a positive antimitochondrial antibody, and liver biopsy
compatible with primary biliary cirrhosis (EASL, 2009; Silveira et al, 2010).
Eligible participants were participants with primary biliary cirrhosis who
received bisphosphonates as primary and secondary prevention, and
postmenopausal women with primary biliary cirrhosis who received hormone
replacement as primary and secondary prevention. A trial was considered as
primary prevention if it included patients that had an average T-score of -1.0 or
above, or if the prevalence of vertebral fracture at baseline was less than 20%. A
trial was considered as secondary prevention if the inclusion criteria were
restricted to patients with T-score between -1 and -2.5 or below -2.5, or to
patients who had experienced previous fractures. Participants who were liver-
transplanted patients were excluded.
Types of interventions
Interventions for primary biliary cirrhosis
Ursodeoxycholic acid administered perorally at any dose versus placebo or no
intervention. Bezafibrate administered at any dose or regimen versus placebo or
no intervention, or any other drug that is being used for treatment of primary
biliary cirrhosis, eg, ursodeoxycholic acid, colchicine, glucocorticoids,
azathioprine, d-penicillamine, cyclosporine A, methotrexate, or any other drug
that is being compared.
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Interventions for osteoporosis in primary biliary cirrhosis
Bisphosphonates administered orally, such as alendronate, etidronate, or any
other bisphosphonate that could be identified versus placebo or no
intervention, or another bisphosphonate, or any other drug.
Any hormone replacement therapy administered by any route, or regimen, or
dose versus placebo or no intervention.
Types of outcomes measures
Ursodeoxycholic acid
Primary outcomes
1. All-cause mortality
2. All-cause mortality or liver transplantation
3. Adverse events: serious adverse events are defined as any untoward
medical occurrence that was life threatening, resulted in death, or was
persistent or led to significant disability; or any medical event, which had
jeopardized the patient or required intervention to prevent it (ICH-GCP,
1997). All other adverse events (that is, any medical occurrence not
necessarily having a causal relationship with the treatment) will be
considered as non-serious
4. Quality of life
Secondary outcomes
1. Liver transplantation
2. Pruritus: number of patients with pruritus or pruritus score
3. Fatigue: number of patients with fatigue
4. Liver-related morbidity (number of patients who developed jaundice,
portal hypertension, oesophageal varices, gastric varices, upper
gastrointestinal haemorrhage, ascites, hepatic encephalopathy, hepato-
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renal syndrome)
5. Biochemical markers: serum bilirubin, serum alkaline phosphatases,
serum gamma-glutamyltransferase, serum aspartate aminotransferase,
serum alanine aminotransferase, serum albumin, total cholesterol,
plasma immunoglobulins, prothrombin index
6. Liver biopsy findings: worsening of liver histological stage or score
7. Cost-effectiveness: the estimated costs connected with the interventions
were weighed against any possible health gains.
Bezafibrate
Primary outcomes
1. All-cause mortality
2. Liver-related morbidity
3. Adverse events
4. Quality of life
Secondary outcomes
1. Pruritus
2. Fatigue
3. Biochemical markers: serum alkaline phosphatases, serum gamma-
glutamyltransferase, serum aspartate aminotransferase, serum alanine
aminotransferase, plasma immunoglobulin M, total cholesterol,
triglyceride, platelet count, and serum bilirubin
4. Liver biopsy findings (histological stage)
5. Number of patients having bezafibrate withdrawn due to adverse events
Bisphosphonates or hormone replacement
Primary outcomes
1. All-cause mortality
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2. Fractures (number of participants with new fractures and number of
fractures at all sites)
3. Adverse advents
4. Quality of life
Secondary outcomes
1. Bone mineral density measured by dual-energy X-ray absorptiometry
(DXA) at the following sites: lumbar spine; proximal femur – hip; radius;
and total body
2. Liver-related mortality or liver transplantation
3. Liver-related morbidity
4. Biochemical indices (serum bilirubin, serum alkaline phosphatases,
serum alanine aminotransferase, serum aspartate aminotransferase, and
albumin) for hormone replacement
5. Biochemical markers of bone turnover (serum osteocalcin and the
procollagen type I N-terminal propeptide (PINP) - as indices of bone
formation, and urinary hydroxyproline, the amino (NTx), and ß-
carboxyterminal (CTx) telopeptides of collagen I - as indices of bone
resorption) for bisphosphonates and hormone replacement; and serum
alkaline phosphatases; 25-hydroxyvitamin D; and parathyroid hormone
(PTH) for bisphosphonates
6. Number of patients having bisphosphonate or hormone replacement
withdrawn due to adverse events
Search methods for identification of reviews
Included reviews were published in The Cochrane Library; there was no
additional searching.
Data collection and analysis
21
Selection of reviews
Cochrane systematic reviews addressing treatment of primary biliary cirrhosis
and osteoporosis associated with primary biliary cirrhosis were conducted by
the same authors and confirmed for inclusion in this analyses. Any
disagreement was resolved by discussion with a mentor and co-mentor.
Data extraction and management
One review author (JR) collated results from the four reviews, and another
checked them (MK). The following information was extracted from included
Cochrane systematic reviews: review objective, search methods for
identification of studies, inclusion criteria (study design, participants,
intervention, comparator and outcomes), source of funding, and stated conflicts
of interest of review authors. From each trial the following information was
extracted: first author, country of origin, trial design (parallel or cross-over),
inclusion and exclusion criteria, number of patients randomized, characteristics
of patients: age range (mean or median) and sex ratio, dose of interventions,
duration, frequency and mode of administration, type and dose of additional
interventions, and outcomes at the end of treatment. Two review authors (JR
and GP) extracted data independently using data extraction forms that were
developed for the purpose. If more than one publication of a trial existed, we
listed the publications under the publication with the most complete data and
marked it as primary. If information was not available in the published trial, in
order to obtain missing data and assess the trials correctly, we contacted
authors of the trial publications. We added information obtained through
correspondence with these authors to the data extraction form. In the ’Notes’
section of the respective trial (’Table of included studies’), we provided the date
when the information was requested and received. Disagreements were
resolved by discussion among the review authors.
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Assessment of methodological quality of included reviews
Quality of evidence from primary studies in included reviews
Assessment of risk of bias in primary studies
The confidence that the design and the report of the randomised clinical trial
would restrict bias in the comparison of the intervention defines
methodological quality, and hence risk of bias, which we assessed using the
following domains (Schulz et al, 1995; Moher et al, 1998; Kjaergard et al, 2001;
Gluud, 2006; Wood et al, 2008).
Allocation sequence generation
- Low risk of bias: sequence generation was achieved using computer random
number generation or a random number table. Drawing lots, tossing a coin,
shuffling cards, and throwing dice are adequate if performed by an
independent adjudicator.
- Uncertain risk of bias: the trial is described as randomised, but the method
of sequence generation was not specified.
- High risk of bias: the sequence generation method is not, or may not be,
random. Quasi-randomised trials, those using dates, names, or admittance
numbers in order to allocate patients are inadequate and will be excluded
for the assessment of benefits but not for harms.
Allocation concealment
-Low risk of bias: allocation was controlled by a central and inde-pendent
randomisation unit, sequentially numbered, opaque and sealed envelopes or
similar, so that intervention allocations could not have been foreseen in advance
of, or during, enrolment.
-Uncertain risk of bias: the trial was described as randomised but the method
used to conceal the allocation was not described, so that intervention allocations
may have been foreseen in advance of, or during, enrolment.
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-High risk of bias: if the allocation sequence was known to the investigators
who assigned participants or if the study was quasi-randomised. Quasi-
randomised trials will be excluded for the assessment of benefits but not for
harms.
Blinding
-Low risk of bias: the trial was described as blinded, the parties that were
blinded, and the method of blinding was described, so that knowledge of
allocation was adequately prevented during the trial.
-Uncertain risk of bias: the trial was described as blind, but the method of
blinding was not described, so that knowledge of allocation was possible
during the trial.
-High risk of bias, the trial was not blinded, so that the allocation was known
during the trial.
Incomplete outcome data
- Low risk of bias: the numbers and reasons for dropouts and withdrawals in all
intervention groups were described or if it was specified that there were no
dropouts or withdrawals.
-Uncertain risk of bias: the report gave the impression that there had been no
dropouts or withdrawals, but this was not specifically stated.
-High risk of bias: the number or reasons for dropouts and withdrawals were
not described.
Selective outcome reporting
- Low risk of bias: pre-defined, or clinically relevant and reasonably
expected outcomes are reported on.
-Uncertain risk of bias: not all pre-defined, or clinically relevant and reasonably
expected outcomes are reported on or are not re-ported fully, or it is unclear
whether data on these outcomes were recorded or not.
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-High risk of bias: one or more clinically relevant and reasonably expected
outcomes were not reported on; data on these outcomes were likely to have
been recorded.
Other bias
-Low risk of bias: the trial appears to be free of other domains that could put it
at risk of bias.
-Uncertain risk of bias: the trial may or may not be free of other domains that
could put it at risk of bias.
-High risk of bias: there are other factors in the trial that could put it at risk of
bias, eg, for-profit involvement, authors have conducted trials on the same topic
etc.
Trials assessed as having ’low risk of bias’ in all of the specified individual
domains were considered ’trials with low risk of bias’. Trials assessed as having
’uncertain risk of bias’ or ’high risk of bias’ in one or more of the specified
individual domains were considered trials with ’high risk of bias’ (Gluud et al,
2011).
We used the GRADE Pro 'Summary of findings' tables from each review to
indicate the quality of the evidence for the main comparisons. The following
criteria were taken into account: study limitations (that is risk of bias),
consistency of effect, imprecision, indirectness and publication bias.
Dealing with missing data and assessment of heterogeneity in included
reviews
We performed analyses according to the intention-to-treat method only for
dichotomous outcomes. For continuous outcomes we performed available
patient analysis and included data only on those whose results were known.
Regarding the primary outcome measures, we included patients with
incomplete or missing data in sensitivity analyses, by imputing the missing data
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following the scenarios below in case of available data (Hollis and Campbell,
1999; Gluud et al, 2011).
-Available patient analysis which simply excludes all patients with the missing
outcome from the analysis.
- Extreme-case analysis favoring the experimental intervention (’best-worse’
case scenario): none of the dropouts/patients lost from the experimental arm
but all of the dropouts/patients lost
We explored the presence of statistical heterogeneity by the chi-squared test
with significance less than or equal to P 0.10 and measured the quantity of
heterogeneity by I² (Higgins et al, 2003). When data were available from one
trial only, we used Fisher’s exact test (Fisher, 1922) for dichotomous data and
Student’s t-test (Student, 1908) for continuous data.
Between-trial heterogeneity was explored by meta-regression with STATA 8.2
(STATA Corp, College Station, Tex), depending on the available data. The
covariates were: risk of bias of the trials, disease severity of patients at entry,
intervention dosage, and trial duration (treatment and follow-up). Univariate
and multivariate analyses including all covariates were performed. The results
are presented with regression coefficients and 95% CI.
Data synthesis
We combined the reviews in a narrative summary, organised by interventions.
There was no pooling of data beyond what was reported in the individual
reviews. We performed all included reviews in the thesis according to the
recommendations of The Cochrane  Handbook for Systematic Reviews of
Interventions (Higgins and Green, 2011) and the Cochrane Hepato-Biliary
Group Module (Gluud et al, 2011). For the statistical analyses, we used Review
Manager 5.1 (RevMan 2011). We meta-analysed the data with both a random-
effects model (DerSimonian and Laird, 1986) and a fixed-effect model (DeMets,
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1987) to ensure robustness of the results. In case of significant differences of the
results that the two models produced, we presented the result with both
methods. We presented the results with the fixed-effect model if the results of
the two models did not differ (Higgins and Thompson, 2002).
Data synthesis from primary studies in included reviews
No de novo data analysis of trial level outcomes was conducted for this thesis.
For each included review, we extracted all results for the outcomes listed above,
and where outcomes were meta-analysed, we have reported pooled effect sizes.
Where no quantitative pooling of effect sizes has been reported, or where
outcomes are reported descriptively by single studies, we have reported these
results by using statistical significance. Dichotomous data were expressed as
relative risk (RR) and/or risk difference (RD) with 95% confidence intervals
(CI). When continuous scales of measurement were used to assess the treatment
effects, we used the mean difference (MD) (Thompson and Higgins, 2002).
Mean differences based on changes from baseline can usually be assumed to be
addressing exactly the same underlying intervention effects as analyses based
on final measurements (Higgins and Green, 2011). Therefore, we combined data
reported as change from baseline values with final measurement values in
meta-analysis when using the mean difference method in RevMan (RevMan
2011). We did not use standardised mean differences (SMD) when we combined
change scores and final measurements. For trials addressing the same outcome
but using different scales of measuring, SMD were used.
Trial sequential analysis
In order to control for the risks of random errors due to sparse data and
multiplicity, we performed trial sequential analysis (Brok et al, 2008; Wetterslev
et al, 2008; Thorlund et al, 2009). We calculated the required information size
(ie, the number of participants needed in a meta-analysis to detect or reject a
certain intervention effect) (Wetterslev et al, 2008). In our analysis, the required
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information size was based on the minimal relevant difference of a half
standard deviation of the meta-analysis, the variance of the meta-analysis, a
type I error of 5%, and a type II error of 20% (Wetterslev et al, 2008). As default,
diversity-adjusted required information size was used unless otherwise stated
(Wetterslev et al, 2008; Wetterslev et al, 2009). The underlying assumption of
trial sequential analysis is that testing for significance may be performed each
time a new trial is added to the meta-analysis. We added the trials according to
the year of publication, and if more than one trial was published in a year, trials
were added alphabetically according to the last name of the first author
(Wetterslev et al, 2008).
On the basis of the required information size, trial sequential monitoring
boundaries were constructed (Wetterslev et al, 2008). These boundaries
determine the statistical inference one may draw regarding the cumulative
meta-analysis that has not reached the required information size; if the trial
sequential monitoring boundary is crossed before the required information size
is reached, firm evidence may be established and further trials may turn out to
be superfluous. On the other hand, if the boundary is not surpassed, it is most
probably necessary to continue doing trials in order to detect or reject a certain
intervention effect.
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Results
Ursodeoxycholic acid (Paper I)
Results of the search
Our search strategy identified 1365 publications, out of which 637 were
duplicates. Of the remaining 728 publications, 623 were excluded because they
were reviews, because they did not relate to primary biliary cirrhosis, or
because they did not describe a randomised clinical trial investigating the effect
of ursodeoxycholic acid in patients with primary biliary cirrhosis. The
remaining 105 publications referred to 16 randomised clinical trials (Image 1).
Image 1. Flow chart
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Fourteen of the included trials consisted of more than one publication. Two out
of the 16 randomised clinical trials were published as abstracts only (De la Mora
et al, 1994; Goddard et al, 1994), and the De la Mora 1994 trial provided no
extractable data on the trial's characteristics and outcomes. Most of the primary
authors and manufacturers of the ursodeoxycholic acid were contacted for
further information and data relating to the trials while conducting the previous
up-date of this review. Dr. Albert Pares kindly provided data on the method of
sequence generation. Through a search for ongoing trials in Clinicaltrials.gov
(http://clinicaltrials.gov/) and WHO International Clinical Trials Registry
Platform (http://www.who.int/ictrp/en/) we have not identified any
registered ongoing or planned trials.
Included studies
A total of 1476 patients with primary biliary cirrhosis were randomised in the
16 randomised clinical trials. Ursodeoxycholic acid dose varied from 7.7 to 15.0
mg/kg/day with a median of 10 mg/kg/day. The duration of the trials varied
from 3 to 92 months with a median of 24 months. The percentage of
symptomatic patients and patients with advanced primary biliary cirrhosis at
baseline varied from 15% to 83% with a median of 51%. The details are
displayed in Table 1. From the publications which reported sex of the patients,
more than 89.5% were females. Three trials were conducted in United States
(Senior and O’Brian, 1991; Lindor et al, 1994; Combes et al, 1995) and two trials
were conducted in United Kingdom (Goddard et al, 1994; Turner et al, 1994).
Other trials were conducted each in different countries: Italy, Mexico, Sweden,
Canada, China, Germany, Japan, Greece, Spain, France, and Finland (Tables of
included studies). Fiftheen trials had the parallel group design and one trial had
the cross-over group design (Hwang et al, 1993).
Following the stipulated follow-up in the ursodeoxycholic acid-group and the
placebo-group, six trials (Poupon et al, 1991; Battezzati et al, 1993; Heathcote et
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al, 1994; Lindor et al, 1994; Combes et al, 1995; Eriksson et al, 1997) continued
ursodeoxycholic acid treated patients on open label ursodeoxycholic acid
(ursodeoxycholic acid→ursodeoxycholic acid) and offered open label
ursodeoxycholic acid to the patients originally given placebo
(placebo→ursodeoxycholic acid). The Papatheodoridis 2002 trial continued to
administer ursodeoxycholic acid to all patients randomised to the
ursodeoxycholic acid arm and switched 14/43 'no intervention' patients to
ursodeoxycholic acid after they had been followed for a mean duration of 3.5
years. It was not possible to separate the data of the original period
(ursodeoxycholic acid versus no intervention) from the total period
(ursodeoxycholic acid→ursodeoxycholic acid versus no
intervention→ursodeoxycholic acid), as only data from the total period were
given.
Table 1 Tables of the included trials
Trial Risk of
bias
Ursodeoxycholic acid
dose*
Trial duration
(months)
Severity of
PBC#¤
Papatheodoridis
2002
High 13.5 92.4 0.6400
Pares 2000 Low 15.0 40.8 0.2708
Combes 1995 High 11.0 24.0 0.6689
Leuschner 1989 High 10.0 9.0 0.1500
Eriksson 1997 High 7.7 24.0 0.3350
Vuoristo 1995 High 13.5 24.0 0.3333
Goddard 1994 High 10.0 15.0 0.3200
Lindor 1994 Low 14.0 48.0 0.6833
Battezzati  1993 Low 8.7 12.0 0.4950
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Senior 1991 High 10.0 6.0 0.6666
Turner 1994 Low 10.0 24.0 0.8261
Hwang 1993 High 9.2 3.0 0.5833
Oka 1990 High 9.2 6.0 0.3795
Heathcote 1994 Low 14.0 24.0 0.5270
Poupon 1991 High 14.0 24.0 0.4658
* ursodeoxycholic acid dose in mg/kg/day.
# PBC= primary biliary cirrhosis.
¤ proportion of patients with stage III or IV at entry;
or proportion of symptomatic patients at entry.
Excluded studies
The excluded studies are listed under 'Tables of excluded studies' and the
reasons for exclusion are given there.
Risk of bias in included studies
Risk of bias was assessed according to six domains: allocation sequence
generation; allocation concealment; blinding; handling of incomplete outcome
data; selective outcome reporting; and other potential sources of bias. One out
of 16 trials was considered as having low risk of bias (Lindor et al, 1994). Our
statistical analyses are, therefore, based mainly on trials with high risk of bias.
For details of the judgements made for the individual trials, please see Image 2
and Image 3.
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Image 2. Risk of bias summary: review authors' judgements about each risk of
bias item for each included trial
Image 3. Risk of bias graph: review authors' judgements about each risk of bias
item presented as percentages across all included studies
Allocation
The generation of the allocation sequence was adequately described in six trials
(Battezzati et al, 1993; Heathcote et al, 1994; Lindor et al, 1994; Eriksson et al,
1997; Pares et al, 2000; Papatheodoridis et al, 2002). The remaining ten trials
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were described as randomised, but the method for sequence generation was not
described (Leuschner et al, 1989; Oka et al, 1990; Poupon et al, 1991; Senior and
O’Brien, 1991; Hwang et al, 1993; De la Mora et al, 1994; Goddard et al, 1994;
Turner et al, 1994; Combes et al, 1995; Vuoristo et al, 1995).
The method used to conceal allocation was adequately described in six trials
(Oka et al, 1990; Battezzati et al, 1993; Heathcote et al, 1994; Lindor et al, 1994;
Pares et al, 2000; Papatheodoridis et al, 2002). The method for allocation
concealment was judged as unclear in 10 trials (Leuschner et al, 1989; Oka et al,
1990; Poupon et al, 1991; Heathcote et al, 1994; Lindor et al, 1994; Turner et al,
1994; Vuoristo et al, 1995; Eriksson et al, 1997; Pares et al, 2000; Papatheodoridis
et al, 2002).
Blinding
The method of blinding was adequately described in 11 trials (Leuschner et al,
1989; Oka et al, 1990; Poupon et al, 1991; Battezzati et al, 1993; Hwang et al,
1993; Heathcote et al, 1994; Lindor et al, 1994; Turner et al, 1994; Combes et al,
1995; Eriksson et al, 1997; Pares et al, 2000). The method of blinding was unclear
or not used in five trials (Senior and O’Brian, 1991; De la Mora et al, 1994;
Goddard et al, 1994; Vuoristo et al, 1995; Papatheodoridis et al, 2002).
Incomplete outcome data
Incomplete data were addressed adequately in the included trials except for
three trials (Senior and O’Brian, 1991; De la Mora et al, 1994; Goddard et al,
1994).
Selective reporting
Predefined primary and secondary outcomes were adequately assessed in all
included trials except three (Senior and O’Brian, 1991; De la Mora et al, 1994;
Goddard et al, 1994). Whenever less than 16 trials reported on an outcome,
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there was risk of outcome reporting bias as we had no access to any of the trial
protocols.
Other potential sources of bias
Following the information provided in the trial publication, one trial may be
free of other causes of bias (Lindor et al, 1994).
Effects of interventions
Primary outcomes
All-cause mortality
Fourteen trials provided information on all-cause mortality and could be
included in the analyses. The included trials reported a total of 91 (6.5%) deaths
in 1391 patients (Image 4). In the ursodeoxycholic acid group, 45 (6.4%) out of
699 patients died versus 46 (6.6%) out of 692 patients in the control group.
Meta-analyses with both the fixed-effect model and random-effects model
showed that ursodeoxycholic acid had no effect on all-cause mortality (RR 0.97;
95% CI 0.67 to 1.42, I² = 0%) (Image 4).
Image 4: UDCA vs placebo/no intervention; outcome: all-cause mortality
35
Inspection of the funnel plot did not indicate bias (Image 5).
Image 5. Funnel plot of comparison: ursodeoxycholic acid versus placebo or no
intervention, outcome: All-cause mortality
The subgroup analyses stratifying the trials according to risk of bias, risk of bias
including industry involvement, trial duration, and dose of ursodeoxycholic
acid did not reveal any differences in effect on all-cause mortality (Image 6, 7, 8,
9). Heterogeneity was absent (I² = 0%, P = 0.56).
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Image 6: UDCA vs placebo/no intervention; outcome: all-cause mortality
stratified after risk of bias
Image 7: UDCA vs placebo/no intervention; outcome: all-cause mortality
stratified after risk of bias including industry involvment
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Image 8: UDCA vs placebo/no intervention; outcome: all-cause mortality
stratified after trial duration
Image 9: UDCA vs placebo/no intervention; outcome: all-cause mortality
stratified after dose of ursodeoxycholic acid
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Trial sequential analysis with data from all included trials showed that only
1382 patients of the diversity-adjusted required information size of 8539 were
accrued (16%) and no firm evidence for benefit or harm was reached (Image 10).
The cumulative Z-curve did not cross the red trial sequential alpha-spending
monitoring boundaries for benefit or harm. Therefore, there is no evidence to
support or reject that ursodeoxycholic acid influences mortality.
Image 10. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on all-cause
mortality. The trial sequential analysis is performed with an assumed control
proportion of death of 7.7%, an anticipated relative risk reduction (RRR) of 20%,
a type 1 error risk of 5% (two-sided) (a), and a power of 80% (a type II error risk
of 20%) (b). The diversity-adjusted required information size (DARIS) to detect
or reject a RRR of 20% with a between trial heterogeneity of 0% is estimated to
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8539 patients. The actually accrued number of patients is 1382, which is only
16% of the required information size. The blue cumulative Z-curve does not
cross the red trial sequential alpha-spending monitoring boundaries for benefit
or harm. Therefore, there is no evidence to support or refute that
ursodeoxycholic acid influences mortality with a 20% RRR of mortality. The
cumulative Z curve does not reach the futility area delineated by the trial
sequential beta-spending monitoring boundaries (which are not even drawn by
the program), demonstrating that further randomised trials are needed.
Sensitivity analyses to assess intervention effects of 40% or 30% relative risk
reduction of mortality showed that we could exclude a very large intervention
effect of 40% relative risk reduction of deaths (Image 11). However, we were
unable to prove or disprove a relative risk reduction of 30% (Image 12), and
below (data not shown). For such smaller intervention effects, the number of
trial patients has to be increased substantially.
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Image 11. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on all-cause
mortality. The trial sequential analysis is performed with an assumed control
proportion of death of 7.7%, an anticipated relative risk reduction (RRR) of 40%,
a type 1 error risk of 5% (two-sided) (a), and a power of 80% (type 2 error risk of
20%) (b). The diversity-adjusted required information size to detect or reject a
RRR of 40% with a between trial heterogeneity of 0% is estimated to 1914
patients. The actually accrued number of patients is 1382, which is 72% of the
required information size. The blue cumulative Z-curve does not cross the red
trial sequential alpha-spending monitoring boundaries for benefit or harm.
However, the boundaries for futility (the red inner wedge boundaries showing
the trial sequential beta-spending monitoring boundaries) are crossed. The red
conventional boundaries (horizontal line at Z = 1.96 and Z = -1.96) for harm or
benefit are not crossed. Therefore, there is no evidence to support
ursodeoxycholic acid and we can refute that ursodeoxycholic acid influences
mortality by a 40% RRR of mortality with the chosen error risks.
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Image 12. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on all-cause
mortality. The trial sequential analysis is performed with an assumed control
proportion of death of 7.7%, an anticipated relative risk reduction (RRR) of 30%,
a type 1 error risk of 5% (two-sided) (a), and a power of 80% (a type 2 error risk
of 20%) (b). The diversity-adjusted required information size (DARIS) to detect
or reject a RRR of 30% with a between trial heterogeneity of 0% is estimated to
3599 patients. The actually accrued number of patients is 1382, which is only
38% of the required information size. The blue cumulative Z-curve does not
cross the red trial sequential monitoring boundaries for benefit or harm.
Therefore, there is no evidence to support that ursodeoxycholic acid influences
mortality. The cumulative Z-curve does not reach the futility area delineated by
the trial sequential beta-spending monitoring boundaries (which are not even
drawn by the program), demonstrating that further randomised trials are
needed.
Available patient analysis did not result in any changes of effect estimates (RR
0.98; 95% CI 0.67 to 1.43; I² = 0%; 1247 patients, 14 trials (Image 13). Analysing
the missing data in the best-case scenario (assuming that patients with
unknown vital status receiving ursodeoxycholic acid were alive and that all
patients from the control group with unknown vital status were dead) or in the
worst-case scenario (assuming that patients with unknown vital status receiving
ursodeoxycholic acid were dead and all patients with unknown vital status
from the control group were alive) showed statistical significant effects of
ursodeoxycholic acid ranging from a beneficial effect (best-case scenario: RR
0.35; 95% CI 0.26 to 0.48; 1 391 patients, 14 trials) to a harmful effect (worst-case
scenario: RR 2.16, 95% CI 1.57 to 2.97; 1391 patients, 14 trials) (Image 13).
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Image 13: Influence of missing data – UDCA vs placebo or no intervention;
outcome: mortality – completed patient’s course plus case scenarios
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Univariate meta-regression analyses revealed that none of examined covariates
(risk of bias of the trials, disease severity of patients at entry, ursodeoxycholic
acid dosage, and trial duration) were significantly associated with the estimated
intervention effect on mortality. In multivariate meta-regression analysis
including all covariates, none were significantly associated with the estimated
intervention effect on mortality (Table 2).
Table 2 UDCA* effects on mortality adjusted for trial-level covariates
Covariates Coefficient 95% CI P-value
Risk of bias (low versus high) 0.225 -1.153 to 1.630 0.749
UDCA* dose (mg/kg/day) -0.284 -1.004 to 0.437 0.440
Trial duration (year) 0.014 -0.012 to 0.040 0.296
Severity of PBC# -4.938 -10.459 to 0.582 0.080
* UDCA= ursodeoxycholic acid.
# PBC= primary biliary cirrhosis.
Analysis of data from the extended follow-up for ursodeoxycholic
acid→ursodeoxycholic acid versus placebo→ursodeoxycholic acid into the
analyses demonstrated a RR of 0.97 with 95% CI 0.73 to 1.30 (Image 14). It
compared 76 (10.9%) deaths in 699 patients originally randomised to
ursodeoxycholic acid with 78 (11.2%) deaths in 692 patients originally
randomised to placebo or no intervention.
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Image 14: extended follow-up for ursodeoxycholic acid→ursodeoxycholic acid
versus placebo/no intervention→ursodeoxycholic acid; outcome: mortality
All-cause mortality or liver transplantation
Fifthteen trials provided information on all-cause mortality or liver
transplantation and could be included in the analyses. The included trials
reported a total of 175 (12.3%) deaths or transplants in 1419 patients (Image 15).
In the ursodeoxycholic acid group, 86 (12.0%) out of 713 patients died or were
transplanted versus 89 (12.6%) out of 706 patients in the control group. Meta-
analyses with both the fixed-effect model and random-effects model showed no
significant difference in effect between the compared interventions (RR 0.96;
95% CI 0.74 to 1.25, I² = 15%) (Image 15).
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Image 15: UDCA vs placebo or no intervention; outcome: all-cause mortality
Inspection of the funnel plot did not indicate bias (Image 16)
Image 16. Funnel plot of comparison: UDCA versus placebo or no intervention,
outcome: All-cause mortality or liver transplantation stratified after risk of bias
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The subgroup analyses stratifying the trials according to risk of bias, risk of bias
including industry involvement, trial duration, and dose of ursodeoxycholic
acid did not reveal any differences in effect estimates in the risk of all-cause
mortality or liver transplantation (Image 17, 18, 19, 20). Heterogeneity might not
be important (I² = 15%, P = 0.31).
Image 17: UDCA vs placebo/no intervention; outcome: all-cause mortality
or liver transplantation stratified after risk of bias
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Image 18: UDCA vs placebo/no intervention; outcome: all-cause mortality
or liver transplantation stratified after risk of bias including industry
involvment
Image 19: UDCA vs placebo/no intervention; outcome: all-cause mortality
or liver transplantation stratified after trial duration
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Image 20: UDCA vs placebo/no intervention; outcome: all-cause mortality
or liver transplantation stratified after dose of ursodeoxycholic acid
Trial sequential analysis with data from all included trials showed that only 1
410 patients of the required diversity-adjusted information size of 4 043 were
accrued (35%) and no firm evidence for benefit or harm was therefore reached
(Image 21). The cumulative Z-curve did not cross the red trial sequential alpha-
spending monitoring boundaries for benefit or harm. Therefore, there is no
evidence to support or refute that ursodeoxycholic acid influences mortality or
transplantation. Sensitivity analyses showed that an intervention effect
corresponding to a 30% relative risk reduction of all-cause mortality or liver
transplantation can be excluded (Image 22).
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Image 21. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on all-cause
mortality or liver transplantation. The trial sequential analysis is performed
with an assumed control proportion of death of 15.1%, an anticipated relative
risk reduction (RRR) of 20%, a type 1 error risk of 5% (two-sided), and a power
of 80% (a type 2 error risk of 20%) (b). The diversity-adjusted required
information size (DARIS) to detect or reject a RRR of 20% with a between trial
heterogeneity of 37% is estimated to 4043 patients. The actually accrued number
of patients is 1410, which is only 35% of the required information size. The blue
cumulative Z-curve does not cross the red trial sequential monitoring
boundaries for benefit or harm. Therefore, there is no evidence to support or
refute that ursodeoxycholic acid influences mortality or transplantation. The
cumulative Z curve does not reach the futility area delineated by the trial
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sequential beta-spending monitoring boundaries (which are not even drawn by
the program), demonstrating that further randomized trials are needed.
Image 22. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on all-cause
mortality or liver transplantation. The trial sequential analysis is performed
with an assumed control proportion of death of 15.1%, an anticipated relative
risk reduction (RRR) of 30%, a type 1 error risk of 5% (two-sided), and a power
of 80% (a type 2 error risk of 20%) (b). The diversity-adjusted required
information size (DARIS) to detect or reject a RRR of 30% with a between trial
heterogeneity of 37% is estimated to 1712 patients. The actually accrued number
of patients is 1410, which is 82% of the required information size. The blue
cumulative Z-curve does not cross the red trial sequential alpha-spending
monitoring boundaries for benefit or harm. However, the boundaries for futility
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delineated by the trial sequential beta-spending monitoring boundaries (the red
inner wedge boundaries) are crossed. Accordingly, the red conventional
boundaries (horizontal line at z =1.96 and z =-1.96) for harm or benefit are not
crossed. Therefore, there is no evidence to support that ursodeoxycholic acid
influences mortality or transplantation. Moreover, a 30% RRR of mortality or
transplantation can be rejected with the chosen error risks.
Available patient analysis did not result in any significant changes of effect
estimates (RR 0.93; 95% CI 0.64 to 1.34; I² = 23%; 1 275 patients, 15 trials) (Image
23). The best-case scenario and worst-case scenario analyses on missing data
showed statistical significant effects of ursodeoxycholic acid ranging from a
beneficial effects (best-case scenario: RR 0.49; 95% CI 0.30 to 0.80; 1419 patients,
15 trials) to a harmful effects (worst-case scenario: RR 1.60; 95% CI 1.21 to 2.10;
1419 patients, 15 trials) (Image 23). These data show that we have too little
knowledge about the true effect of ursodeoxycholic acid on all-cause mortality
or liver transplantation, also due to poor outcome reporting of the included
trials on mortality and liver transplantation.
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Image 23: Influence of missing data – UDCA vs placebo or no intervention;
outcome: mortality or liver transplantation – completed patient’s course plus
case scenarios
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Univariate meta-regression analyses revealed that none of the examined
covariates (risk of bias, disease severity of patients at entry; ursodeoxycholic
acid dosage, and trial duration) were significantly associated with the estimated
intervention effect on mortality or liver transplantation. In multivariate meta-
regression analysis including all covariates, none were significantly associated
with the estimated intervention effect on mortality or liver transplantation
(Table 3).
Table 3 UDCA* effects on mortality or transplantation adjusted for trial-
level covariates
Covariate Coefficient 95% CI P-value
Risk of bias (low vs. high) -0.487 -1.484 to 0.510 0.338
UDCA* (mg/kg/day) 0.039 -0.244 to 0.322 0.787
Trial duration (year) 0.008 -0.011 to 0.027 0.408
Severity of PBC# -1.282 -3.637 to 1.073 0.286
* UDCA= ursodeoxycholic acid.
# PBC= primary biliary cirrhosis.
Including data from the extended follow-up for ursodeoxycholic
acid→ursodeoxycholic acid versus placebo/no intervention→ursodeoxycholic
acid demonstrated a RR of 0.88 with 95% CI from 0.73 to 1.06 (Image 24). The
meta-analysis showed 147 (20.6%) deaths or liver transplantations out of 713
patients originally randomised to ursodeoxycholic acid, and 165 (23.3%) deaths
or liver transplantations out of 706 patients originally randomised to placebo or
'no intervention'.
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Image 24: extended follow-up for ursodeoxycholic acid→ursodeoxycholic acid
versus placebo/no intervention→ursodeoxycholic acid; outcome: mortality or
liver transplantation
Adverse events
We divided the reporting of adverse events into the following types: serious
adverse events and non-serious adverse events (ICH-GCP 1997).
There was no significant difference in the risk ratio for overall proportion of
serious adverse events when comparing ursodeoxycholic acid with placebo or
no intervention (RR 0.87; 95% CI 0.68 to 1.12; I² = 23%; 1382 patients, 14 trials)
(Image 25). In the ursodeoxycholic group 94 serious adverse events were
reported versus 107 serious adverse events in the control group of the included
trials.
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Image 25: UDCA vs placebo or no intervention; outcome: serious adverse
advents
There was also no significant difference in the risk ratio for overall incidence of
non-serious adverse events when comparing ursodeoxycholic acid with placebo
or 'no intervention' (RR 1.46; 95% CI 0.83 to 2.56; I² = 0%; 1 277 patients, 12
trials) (Image 26).
Image 26: UDCA vs placebo or no intervention; outcome: non-serious adverse
advents
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For assessment of harm, besides the data provided by randomised clinical trials
which are included in our analyses (Image 25, 26) we also included data from
eleven non-randomised studies which reported on harm (Podda et al, 1989;
Lotterer 1990; Kneppelhout 1992; Peridigoto 1992; Shibata 1992; Ikeda 1996;
Poupon et al, 1996; Schonfeld 1997; Van Hoogstraten 1998; Angulo et al, 1999a;
Verma 1999). For details regarding description of these non-randomised studies
see Tables of excluded studies. In Lotterer 1990, there were 7 patients out of 12
who experienced adverse events. One patient died, two patients had acute
upper gastrointestinal bleeding, one patient developed ascites, one patient had
transient diarrhoea, and one patient had transient exacerbation of pruritus
(Table 4).
Table 4 Adverse events (Lotterer 1990)
Adverse event UDCA*
Death 1/12
Transient exacerbation of pruritus 1/12
Transient diarrhoea 2/12
Ascites 1/12
Acute upper GI bleeding 2/12
* UDCA = ursodeoxycholic acid.
In Ikeda 1996, in the colchicine-ursodeoxycholic acid group, there were 2
patients out of 10 who experienced diarrhoea versus 0 patients out of 12 in the
ursodeoxycholic acid group. In Poupon et al, 1996, in the colchicine-
ursodeoxycholic acid group, there were 4 patients out of 37 who experienced an
57
adverse event such as death (2 patients), variceal bleeding (1 patient) and
peripheral polyneuropathy (1 patient) versus 2 patients out of 37 in the
ursodeoxycholic acid-placebo group (Table 5).
Table 5 Adverse events (Poupon 1996)
Adverse event Colchicin-UDCA UDCA-placebo
Variceal bleeding 1/37 2/37
Death 2/37 0/37
Peripheral polyneuropathy 1/37 0/37
The two former studies may say more about adverse events associated with
colchicine than with ursodeoxycholic acid. In Angulo et al, 1999a, 155 patients
with primary biliary cirrhosis were treated with three different doses of
ursodeoxycholic acid, there were 21 patients out of 155 who experienced
adverse events such as hypertension (2 patients), creatinine elevation (2
patients), thrombocytopenia (3 patients), leukopenia (1 patient), nausea and
vomiting (6 patients), diarrhoea (3 patients), fever (1 patient), and rash (3
patients) (Table 6).
Table 6 Adverse events (Angulo et al, 1999a)
Adverse event UDCA
Hypertension 2/155
Creatinine elevation 2/155
Thrombocytopenia 3/155
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Leukopenia 1/155
Nausea and vomiting 6/155
Diarrhoea 3/155
Fever 1/155
Rash 3/155
In Van Hoogstraten 1998, 61 patients with primary biliary cirrhosis were treated
with two different doses of ursodeoxycholic acid, there were 2 patients out of 61
who experienced adverse events such as liver failure (1 patient) and diarrhoea
(1 patient) (Table 7).
Table 7 Adverse events (Van Hoogstraten 1998)
Adverse event UDCA
Liver failure 1/61
Diarrhoea 1/61
In Peridigoto 1992, there were 3 patients who experienced adverse events such
as variceal bleeding and ascites and more than one event occurred in some
patient (Table 8).
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Table 8 Adverse events (Peridigoto 1992)
Adverse event UDCA
Variceal bleeding 3/3
Ascites 2/3
In Podda 1989, there were 2 patients out of 30 who experienced pruritus. In
Kneppelhout 1992, there were 9 patients out of 17 who experienced adverse
events such as liver transplantation, ascites, nausea, increased pruritus, increase
in pre-existent hyperbilirubinaemia, fever, weakness, and more than one event
occurred in some patient (Table 9).
Table 9 Adverse events (Kneppelhout 1992)
Adverse event UDCA
Nausea 2/17
Increased pruritus 4/17
Increase in pre-existent hyperbilirubinaemia 3/17
Ascites 1/17
Liver transplantation 1/17
Fever 1/17
Weakness 1/17
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In Schonfeld 1997, there was one patient out of 15 who experienced severe and
progressive fatigue, weight loss, ascites, an increase in serum bilirubin
concentration and was liver transplanted. In Shibata 1992, there were 3 patients
out of 12 who experienced adverse events such as death, bleeding varices,
hepatocellular carcinoma, diarrhoea, gallstones, and more than one event
occurred in some patient (Table 10).
Table 10 Adverse events (Shibata 1992)
Adverse event Colchicin-UDCA
Diarrhoea 1/12
Gallstones 1/12
Bleeding varices 1/12
Death 1/12
Hepatocellular carcinoma 1/12
In Verma 1999, there was one patient out of 24 who experienced severe
migraine.
Quality of life
None of the trials used specific quality-of-life scales. Two trials (Turner et al,
1994; Eriksson et al, 1997) evaluated symptoms using visual analogue scales.
None of these showed any significant difference between the ursodeoxycholic
acid group and placebo group. However, significantly (P < 0.01) more patients
felt better or much better following ursodeoxycholic acid intervention than after
placebo in the Eriksson 1997 trial.
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Secondary outcomes
Liver transplantation
Fourteen trials provided information on liver transplantation and could be
included in the analyses. The included trials reported 78 (5.6%) transplants in
1391 patients (Image 27). In the ursodeoxycholic acid group, 37 (5.3%) out of 699
patients were transplanted versus 41 (5.9%) out of 692 patients in the control
group. Meta-analyses with both the fixed-effect model and random-effects
model showed no significant difference in effect of ursodeoxycholic acid on
liver transplantation (RR 0.89; 95% CI 0.59 to 1.36, I² = 0%) (Image 27).
Image 27: UDCA vs placebo or no intervention; outcome: liver transplantation
Including data from the extended follow-up for ursodeoxycholic
acid→ursodeoxycholic acid versus placebo/'no intervention'→ursodeoxycholic
acid (now comprising 65 (9.3%) liver transplantations in 699 patients originally
randomised to ursodeoxycholic acid versus 85 (12.3%) liver transplantations in
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692 patients originally randomised to placebo/no intervention) demonstrated
an RR of 0.76 with 95% CI from 0.57 to 1.03 (Image 28).
Image 28: extended follow-up for ursodeoxycholic acid→ursodeoxycholic acid
versus placebo/'no intervention'→ursodeoxycholic acid; outcome: liver
transplantation
Pruritus and fatigue
Ursodeoxycholic acid did not significantly influence neither the number of
patients with pruritus (RR 0.96; 95% CI 0.84 to 1.09; I² = 0%; 630 patients, 6
trials) (Image 29) nor the pruritus score (SMD -0.10; 95% CI -0.33 to 0.12; I² = 0%;
314 patients, 3 trials) (Image 30).
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Image 29: UDCA vs placebo or no intervention; outcome: pruritus
Image 30: UDCA vs placebo or no intervention; outcome: pruritus score
Trial sequential analysis of these data supports the finding in the meta-analysis
(Image 31).
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Image 31. Trial sequential analysis of the random-effects meta-analysis of the
effect of ursodeoxycholic acid versus placebo or no intervention on pruritus.
The trial sequential analysis is performed with an assumed control proportion
of pruritus of 54%, an anticipated relative risk reduction (RRR) of 20%, a type 1
error risk of 5% (two-sided), and a power of 80% (a type 2 error risk of 20%) (b).
The heterogeneity-adjusted required information size (DARIS) to detect or
reject a RRR of 20% with a between trial heterogeneity of 0% is estimated to 673
patients. The actually accrued number of patients is 621, which is 92% of the
required information size. The blue cumulative Z-curve does not cross the red
trial sequential monitoring boundaries for benefit or harm. However, the
boundaries for futility delineated by the trial sequential beta-spending
monitoring boundaries (the red inner wedge boundaries) are crossed.
Therefore, there is no evidence to support that ursodeoxycholic acid influences
pruritus and a 20% RRR of pruritus can be rejected with the chosen error risks.
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Fatigue was not significantly improved by ursodeoxycholic acid (RR 0.90; 95%
CI 0.81 to 1.00; I² = 62%; 506 patients, 4 trials) (Image 32).
Image 32: UDCA vs placebo or no intervention; outcome: fatigue
Liver-related morbidity
In fixed-effect meta-analysis, two trials in which the number of patients with
jaundice was reported led to a significant effect of ursodeoxycholic acid versus
placebo or no intervention (RR 0.35; 95% CI 0.14 to 0.90; I² = 51%; 198 patients, 2
trials). However, in random-effects meta-analysis, two trials in which the
number of patients with jaundice was reported showed no significant effect of
ursodeoxycholic acid versus placebo or no intervention (RR 0.56; 95% CI 0.06 to
4.95; I² = 51%; 198 patients, 2 trials) (Image 33).
Image 33: UDCA vs placebo or no intervention; outcome: jaundice
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Neither portal pressure (MD 0.60 mmHg; 95% CI -2.78 to 3.98; 28 patients, 1
trial) (Image 34), varices (RR 1.16; 95% CI 0.64 to 2.09; I² = 0%; 341 patients, 3
trials) (Image 35), bleeding varices (RR 1.05; 95% CI 0.52 to 2.15; I² = 0%; 767
patients, 7 trials) (Image 36), ascites (RR 0.55; 95% CI 0.24 to 1.26; I² = 0%; 547
patients, 5 trials) (Image 37) nor hepatic encephalopathy (RR 0.47; 95% CI 0.04
to 5.09; 212 patients, 2 trials) (Image 38) were significantly affected by
ursodeoxycholic acid treatment.
Image 34: UDCA vs placebo or no intervention; outcome: portal pressure
Image 35: UDCA vs placebo or no intervention; outcome: development of
varices
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Image 36: UDCA vs placebo or no intervention; outcome: variceal bleeding
Image 37: UDCA vs placebo or no intervention; outcome: ascites
Image 38: UDCA vs placebo or no intervention; outcome: hepatic
encephalopathy
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Biochemical markers
Ursodeoxycholic acid significantly decreased serum bilirubin concentration
(MD -8.69 µmol/l; 95% CI -13.90 to -3.48; I² = 0%; 881 patients, 9 trials) (Image
39).
Image 39: UDCA vs placebo or no intervention; outcome: serum bilirubin
Trial sequential analysis of these data supports the finding in the meta-analysis
(Image 40).
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Image 40. Trial sequential analysis of the cumulative meta-analysis of the effect
of ursodeoxycholic acid versus placebo or no intervention on serum bilirubin
concentration in patients with primary biliary cirrhosis. The diversity-adjusted
required information size (DARIS) of 1296 patients is calculated based on a
minimal relevant intervention effect (MIREDIF) of 7 µmol/l, a standard
deviation of 56 µmol/l (variance 3116), a risk of type I error of 5%, a power of
80% (a type 2 error risk of 20%) (b), and a diversity of 0%. The cumulated Z-
curve (blue curve) crosses the trial sequential monitoring boundary (red curve)
implying that there is evidence for a beneficial effect of 7 µmol/l decrease in the
serum bilirubin concentration when the cumulative meta-analysis is adjusted
for sparse data and multiple testing on accumulating data.
Ursodeoxycholic acid significantly decreased the activity of serum alkaline
phosphatases (MD -257.09 U/l; 95% CI -306.25 to -207.92; I² = 0%; 754 patients, 9
trials) (Image 41).
Image 41: UDCA vs placebo or no intervention; outcome: serum alkaline
phosphatases
Trial sequential analysis of these data supports the finding in the meta-analysis
(Image 42).
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Image 42. Trial sequential analysis of the cumulative meta-analysis of the effect
of ursodeoxycholic acid versus placebo or no intervention on the activity of
serum alkaline phosphatases in patients with primary biliary cirrhosis. The
diversity-adjusted required information size (DARIS) of 920 patients is
calculated based on a minimal relevant intervention effect (MIREDIF) of 90
IU/L, a standard deviation of 487 IU/L (variance 237214), a risk of type I error
of 5%, a power of 80% (a type 2 error risk of 20%) (b), and a diversity of 0%. The
cumulated Z-curve (blue curve) crosses the trial sequential monitoring
boundary (red curve) implying that there is evidence for a beneficial effect of 90
IU/L decrease in the activity of serum alkaline phosphatases when the
cumulative meta-analysis is adjusted for sparse data and multiple testing on
accumulating data.
Ursodeoxycholic acid significantly decreased the activity of serum gamma-
glutamyltransferase (MD -277.57 U/l; 95% CI -337.84 to -217.30; I² = 52%; 426
patients, 5 trials) (Image 43), serum aspartate aminotransferase (MD -35.59 U/l;
95% CI -42.88 to -28.30; I² = 0%; 782 patients, 8 trials) (Image 44), serum alanine
aminotransferase (MD -34.68 U/l; 95% CI -43.04 to -26.33; I² = 32%; 712 patients,
8 trials) (Image 45), total cholesterol (MD -0.78 mmol/l; 95% CI -1.04 to -0.52; I²
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= 19%; 712 patients, 9 trials) (Image 46), and plasma immunoglobulin M
concentration (MD -1.33 g/l; 95% CI -1.81 to -0.86; I² = 0%; 704 patients, 7 trials)
(Image 47).
Image 43: UDCA vs placebo or no intervention; outcome: serum gamma-
glutamyltransferase
Image 44: UDCA vs placebo or no intervention; outcome: serum aspartate
aminotransferase
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Image 45: UDCA vs placebo or no intervention; outcome: serum alanin
aminotransferase
Image 46: UDCA vs placebo or no intervention; outcome: total choletserol
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Image 47: UDCA vs placebo or no intervention; outcome: plasma
immunoglobulin M
Ursodeoxycholic acid had no significant effect on serum albumin concentration
(MD 0.34 mmol/l; 95% CI -0.45 to 1.13; I² = 0%; 457 patients, 4 trials) (Image 48)
and on prothrombin index (MD 2.05 %; 95% CI -0.62 to 4.71; I² = 0%; 308
patients, 2 trials) (Image 49).
Image 48: UDCA vs placebo or no intervention; outcome: serum albumin
74
Image 44: UDCA vs placebo or no intervention; outcome: prothrombin time
Liver histology
Liver biopsies at the end of treatment were performed and reported in seven
(Leuschner et al, 1989; Poupon et al, 1991; Lindor et al, 1994; Turner et al, 1994;
Combes et al, 1995; Pares et al, 2000; Papatheodoridis et al, 2002) out of 16 trials.
Ursodeoxycholic acid had statistically significant effect on histological stage
(random, RR 0.62; 95% CI 0.44 to 0.88; I² = 35%; 551 patients, 7 trials) (Image 50).
There was no effect of ursodeoxycholic acid on fibrosis (RR 0.88, 95% CI 0.57 to
1.38; 139 patients, 1 trial) or on florid duct lesions (RR 0.84, 95% CI 0.40 to 1.76;
115 patients, 1 trial). About half of the patients in the Pares et al, 2000 trial
observed statistically significant improvements in histological stage, portal
inflammation, and piecemeal necrosis in the ursodeoxycholic acid group, but
not regarding ductular proliferation or cholestasis. The placebo group had
significantly fewer bile ducts per portal tract. Our analyses were based on
presented available patient data at the end of treatment.
75
Image 50: UDCA vs placebo or no intervention; outcome: liver biopsy findings
Publication bias and other biases
Neither the Egger's nor the Begg's graphs and their corresponding tests on
mortality provided evidence for asymmetry (Egger's test, P = 0.47; Begg's test, P
= 0.83).
Description of studies: tables of included studies (Table 11) and tables of
excluded studies (Table 12).
Table 11. Tables of included studies
76
Battezzati 1993
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design (two interventions
groups).
Trial duration 1 year (six months treatment and six months
follow-up).
Follow-up: 5 patients receiving ursodeoxycholic acid and 1
placebo dropped out.
Participants Country: Italy.
Number of patients randomised: 88, mean age 54.5 years
(88.5% females), histological stage IV 49%.
Inclusion criteria:
Primary biliary cirrhosis (PBC) defined as:
- positive AMA ≥ 1:40 and liver biopsy compatible with
PBC.
If one of these were missing, patients could enter provided
they had three of the following:
- serum alkaline phosphatase > 2.0 times upper normal
limit;
- immunoglobulin M ≥ 280 mg/l;
- pruritus;
- serum bilirubin > 2 mg/l;
- a positive Schyrimer's test plus absence of extrahepatic
obstruction.
Exclusion criteria:
- serum bilirubin levels > 10 mg/dl;
- ascites;
- previous episodes of variceal bleeding or encephalopathy;
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- evidence of malignant conditions;
- alcohol abuse.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 500 mg daily in
two dived doses at mealtime ( ˜8.7 mg/kg/day; range 5.4-
11.6 mg/kg/day), n = 44;
Intervention group 2: placebo, n = 44.
No patient was taking any medication known to be
hepatotoxic nor had been treated with corticosteroids,
immunosuppressant agents, colchicine, penicillamine or
ursodeoxycholic acid in the previous six months.
Outcomes Symptoms.
Liver biochemistry.
Serum bile acids.
Serum cholesterol.
Notes Patients switched onto ursodeoxycholic acid at the end of
the trial.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence
generation
Low risk Sequence generation was achieved using
computer random number generation.
Allocation
concealment
Low risk Allocation was controlled by a central
pharmacy.
Blinding Low risk It was reported that the trial was double-
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All outcomes blinded, that placebo was 'identical in
appearance', and outcome assessment was
performed centrally.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention
groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are
reported on.
Other bias Unclear risk It was reported that ursodeoxycholic acid
and placebo were obtained through the
courtesy of ABC Farmaceutici, Torino,
Italy.
Combes 1995
Methods Multicenter double-blind, placebo controlled
randomised clinical trial with parallel group design
(two interventions groups).
Trial duration 2 years.
Follow-up: 2 patients from the ursodeoxycholic acid
and 3 patients from the placebo groups withdrew from
the trial during the placebo controlled period (0 to 2
year).
Participants Country: USA
Number of patients randomised: 151, from six centres,
mean age 49.2 years (89% females), histological stage I-
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II 32.5%, III-IV 67.5%.
Inclusion criteria:
- cholestatic liver disease for at least six months;
- serum alkaline phosphatase > 1.5 times upper normal
limit;
- positive AMA;
- no biliary obstruction;
- liver biopsy compatible with PBC.
Exclusion criteria:
- PBC treatment during the last three months;
- recurrent bleeds from varices;
- spontaneous encephalopathy;
- diuretic-resistant ascites;
- serum bilirubin ≥ 20 mg/dl;
- pregnancy;
- age < 19 years;
- other cause of liver disease.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 10 to 12
mg/kg/day once at bedtime (Ciba-Geigy Corporation),
n = 77;
Intervention group 2: placebo (2 years) and open-label
ursodeoxycholic acid (4 years), n = 74.
Outcomes Mortality free of liver transplantation.
Liver transplantation.
Symptoms.
Liver biochemistry.
Liver histology.
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ursodeoxycholic acid enrichment in bile.
Notes Three patients randomised to receive placebo had high
bile-ursodeoxycholic acid concentrations, suggesting
ursodeoxycholic acid intake.
All patients were offered open label ursodeoxycholic
acid following completion of the first 2-year of the trial.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was
not specified.
Allocation
concealment
Unclear risk The trial was described as randomised
but the method used to conceal the
allocation was not described, so that
intervention allocations may have been
foreseen in advance of, or during
enrolment.
Blinding
All outcomes
Low risk Described as double-blind, placebo
described as 'comparable-appearing'
and it was reported that 'coded
medications were provided'. All
investigators remained blinded
throughout the trial to the treatment
allocation for each patient.
Incomplete
outcome data
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention
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All outcomes groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are
reported on.
Other bias Low risk The trial appears to be free of
information that could put it at risk of
bias.
De la Mora 1994
Methods Randomised trial.
Follow-up: information not provided.
Participants Patients with PBC (n = 28) from one centre in Mexico.
Interventions Experimental: ursodeoxycholic acid
(details were not given).
Control: placebo.
Outcomes Serum cholesterol.
Notes
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised,
but the method of sequence generation was
not specified.
Allocation
concealment
Unclear risk The trial was described as randomised
but the method used to conceal
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the allocation was not described, so that
intervention allocations may have been
foreseen in advance of, or during,
enrolment.
Blinding
All outcomes
Unclear risk 'Placebo' employed, but it is not known if
it was indeed double blind.
Incomplete
outcome data
All outcomes
Unclear risk The report gave the impression that there
had been no dropouts or withdrawals,
but this was not specifically stated.
Selective
reporting
Unclear risk Not all pre-defined, or clinically relevant
and reasonably expected outcomes are
reported on or are not reported fully,
or it is unclear whether data on these
outcomes were recorded or not.
Other bias Unclear risk The trial may or may not be free of
information that could put it at risk of bias.
Eriksson 1997
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design (two interventions
groups).
Trial duration 2 years.
Follow-up: 8 patients from the ursodeoxycholic acid
and 7 patients from the placebo withdrew.
Patients were stratified into symptomatic and
asymptomatic.
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Participants Country: Sweden.
Number of patients randomised: 116, from six centres in
Sweeden, mean age 57 years (85.5% females).
Inclusion criteria:
PBC defined as chronic cholestatic liver disease of
more than six months duration with histology typical of or
compatible with PBC plus at least two of the following:
- positive anti-mitochondrial antibodies;
- alkaline phosphatases > 1.5 times the upper reference
value;
- IgM > 1.5 times the upper reference value during
the year preceding the entry into the trial.
Exclusion criteria:
- patients with severe end-stage liver disease;
- diuretic-resistant ascites;
- repeated variceal bleeding in spite of sclerosing
treatment;
- patients waiting for liver transplantation;
- pregnancy;
- alcohol or drug abuse.
Interventions Patients were randomly assigned to receive:
Intervention group 1: 500 mg ursodeoxycholic acid (˜7.7
mg/kg/day) as two capsules in the evening, n = 60;
Intervention group 2: placebo, n = 56.
Outcomes Mortality.
Liver transplantation.
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Symptoms - pruritus, fatigue, ascites, jaundice.
Liver biochemistry and bile acids.
Histology - portal inflammation, spill-over, interface
hepatitis, bile duct proliferation, portal fibrosis.
Quality of life.
Notes At 24 months, 32 of 49 patients allocated to placebo and
still remaining in the trial were switched to
ursodeoxycholic acid and 42 of 52 patients allocated to
ursodeoxycholic acid and still remaining in the trial
continued with ursodeoxycholic acid.
Anti-hepatitis C virus tests not performed.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Sequence generation was achieved using a
randomisation list which was produced for
every clinic.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation
was
not described, so that intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Low risk Described as 'double-blind', and placebo
looked identical to ursodeoxycholic acid,
but details on taste and smell not given.
However outcome assessment was blinded
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and the possible non-blinding of others
unlikely to introduce bias.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias Low risk Trial appears to be free of information that
could put it at risk of bias.
Goddard 1994
Methods Double-blind, placebo controlled randomised clinical trial
with parallel group design (three interventions groups and
one control group).
Mean follow-up: 15 months (range: 0 to 30 months).
Participants Country: UK.
Number of patients randomised: 57, mean age and sex ratio
not provided.
Inclusion criteria:patients with PBC.
Exclusion criteria: none listed.
Diagnostic criteria (data being sought).
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 10mg/kg/day.
Intervention group 2: colchicine 1 mg/day.
Intervention group 3: ursodeoxycholic acid plus colchicine.
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Control: placebo.
Outcomes Mortality (being sought).
Liver transplantation (being sought).
Liver biochemistry.
Notes No exact data on number of patients randomised to each arm.
Data on mortality and liver transplantation are not given
separately.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but the
method used to conceal the allocation was not
described, so that intervention allocations may
have been foreseen in advance of, or during,
enrolment.
Blinding
All outcomes
Unclear risk 'Placebo' employed, but it is not known if it was
indeed double blind.
Incomplete
outcome data
All outcomes
Unclear risk Treatment failures were reported but the exact
numbers and reasons for dropouts and
withdrawals were not described in all
intervention groups.
Selective
reporting
Unclear risk One or more clinically relevant and reasonably
expected outcomes were not reported fully, or
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it is unclear whether data on these outcomes
were recorded or not.
Other bias Unclear risk The trial may or may not be free of information
that could put it at risk of bias.
Heathcote 1994
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design (two interventions
groups).
Trial duration 2 years.
Follow-up: 13 patients receiving ursodeoxycholic acid and 19
placebo withdrew.
Participants Country: Canada.
Number of patients randomised: of 408 patients assessed, 222
patients were randomised (1:1) during a 26 months period,
mean age 56.3 years (93% females), histological stage I 18.5%, II
27%, III 29%, IV 25.5%.
Inclusion criteria:
- positive AMA;
- serum alkaline phosphatase > 1.0 times upper normal limit;
- liver biopsy compatible with PBC;
- age > 18 years.
Exclusion criteria:
- patients on liver transplant list;
- patients needed to take enzyme-inducing drugs;
- pregnancy;
- severe coexisting condition that was likely to affect survival
within five years of trial entry.
88
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 14mg/kg/day
swallowed with the evening meal, n = 111;
Intervention group 2: placebo, n = 111.
Outcomes Mortality.
Liver transplantation.
Symptoms - pruritus, fatigue.
Liver biochemistry and bile acids.
Histology.
Notes Patients offered ursodeoxycholic acid at the end of the trial for
6 to 24 months.
Data for serum cholesterol were extracted from Heathcote 1993
(Heathcote 1994).
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk The method of sequence generation was
generated using consecutive identification
numbers.
Allocation
concealment
Low risk Allocation was controlled separately at each
centre by the trial pharmacist stratified for
symptomatic/asymptomatic.
Blinding
All outcomes
Low risk Described as double-blind, and the placebo
tablets were identical and 'equally bitter tasting',
this was confirmed by the research coordinator.
Also, outcome assessment was blinded.
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Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and reasonably
expected outcomes are reported on.
Other bias Unclear
risk
It was reported that trial medications were kindly
provided by Interfalk and Jouveinal Inc., Canada.
Hwang 1993
Methods Double-blind, placebo controlled randomised clinical
trial with cross-over group design
(two interventions groups).
Trial duration: 3 months.
Follow-up: no patients withdrew.
Participants Country: China.
Number of patients randomised: 12, mean age 58 years
(100% females).
Inclusion criteria:
- elevated serum alkaline phosphatase and
gamma-glutamyl transferase with lack of large bile duct
abnormalities;
- positive AMA with elevated immunoglobulin M, G or A;
- liver biopsy compatible with PBC.
Exclusion criteria:
- previous PBC treatment.
Interventions Patients were randomly assigned to receive:
90
Intervention group 1: ursodeoxycholic acid 600 mg/day.
Intervention group 2: placebo.
Outcomes Mortality.
Symptoms.
Liver biochemistry.
Notes All patients switched to ursodeoxycholic acid on
completion of the six months cross-over trial.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Low risk It was reported that placebo was 'identical
tablet form containing starch'.
Incomplete
outcome data
All outcomes
Low risk It was specified that there were no
dropouts or withdrawals, and that all 12
patients completed a six month course of
treatment.
Selective
reporting
Low risk All expected outcomes are reported.
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Other bias Low risk The trial appears to be free of information
that could put it at risk of bias.
Leuschner 1989
Methods Double-blind, placebo controlled randomised clinical
trial with parallel group design (two interventions
groups).
Trial duration: 9 months.
Follow-up: 2 patients from placebo arm left the trial.
Participants Country: Germany.
Number of patients randomised: 20, mean age not
provided (90% females).
Inclusion criteria: PBC defined as at least three of the
following:
- alkaline phosphatase > 1.7 times upper normal limit;
- gamma-glutamyl transferase > 5.0 times upper normal
limit;
- immunoglobulin M > 2.0 times upper normal limit;
- positive AMA plus no obstruction of the extrahepatic
biliary tract.
Exclusion criteria:
- oesophageal varices;
- ascites;
- pancreatitis;
- cardiac failure or renal failure;
- pregnancy;
- age < 30 years;
- any previous PBC treatment within the four weeks;
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- alcohol or drug abuse.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 10 mg/kg/
day, divided into two doses, n = 10.
Intervention group 2: placebo, n = 10.
Outcomes Outcome measure(s):
- mortality;
- symptoms;
- liver biochemistry;
- liver histology.
Notes Two patients from the placebo arm left the trial for
reasons unrelated to the trial and are not considered in
the analysis of the results.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Low risk It was reported that placebo was 'identical
tablet'.
93
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk All expected outcomes are reported.
Other bias Low risk The trial appears to be free of information
that could put it at risk of bias.
Lindor 1994
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design
(two interventions groups).
Trial duration: 4 years.
Follow-up: five voluntary withdrawals in
ursodeoxycholic acid arm and 13 voluntary withdrawals
in the placebo arm.
Participants Country: USA.
Number of patients randomised: 180, enrolled from four
USA centres, mean age 53 years (89% females). However,
162 patients (90%) came from one centre.
Inclusion criteria:
PBC defined as:
- chronic cholestatic liver disease for at least six months;
- serum alkaline phosphatase level > 1.5 times upper
normal limit;
- antimitochondrial antibody positivity;
- absence of biliary obstruction;
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- liver biopsy compatible with PBC.
Exclusion criteria:
- previous PBC treatment in preceding 3 months;
- anticipated need for liver transplantation within one
year;
- recurrent variceal haemorrhage;
- spontaneous encephalopathy, or diuretic resistant
ascites;
- pregnancy;
- age less than 18 or more than 70 years;
- other co-existent liver disease.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid in the form
of 250 mg tablets at a dose of 13 to 15mg/kg/day in four
divided doses, n = 89;
Intervention group 2: placebo, n = 91.
Outcomes Outcome measure(s):
- mortality;
- liver transplantation;
- symptoms;
- autoimmune conditions;
- liver biochemistry;
- liver histology;
- adverse events.
Notes Patients originally receiving placebo switched to
ursodeoxycholic acid after four years and were followed
for an additional eight years.
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Data for the following outcomes were extracted from
(Lindor 1994):
- development of varices (Angulo et al, 1999);
- bleeding varices (Lindor et al, 1997);
- ascites (Lindor et al, 1997);
- cholesterol (Balan et al, 1994).
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Randomisation was performed separately
for each strata using 'a blocked,
randomised assignment schedule'.
Allocation
concealment
Low risk Allocation was controlled so that
intervention allocations could not have
been foreseen in advance of, or during
enrolment.
Blinding
All outcomes
Low risk The trial was described as blinded,
the parties that were blinded, and
the method of blinding was described,
so that knowledge of allocation was
adequately prevented during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention
groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported on.
Other bias Low risk The trial appears to be free of other
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information that could put it at risk of bias.
Oka 1990
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design (two interventions
groups).
Trial duration: 24 weeks.
Follow-up: 4 patients receiving ursodeoxycholic acid and
3 placebo dropped out.
Participants Country: Japan.
Number of patients randomised: 52, from 13 departments
in Japan, mean age 59 years (91% females).
Inclusion criteria:
- PBC was diagnosed clinically and histologically.
Exclusion criteria:
- patients with severe symptoms or having received other
medications for their PBC within the last three months.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 600 mg/day in
three divided doses, n = 26;
Intervention group 2: placebo, n = 26.
Outcomes Symptoms (itching).
Complications (oesophageal varices).
Liver biochemistry.
Serum cholesterol.
Serum bile acids.
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Notes
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised,
but the method of sequence generation
was not specified.
Allocation
concealment
Low risk Allocation was controlled by a single
monitor according to a randomisation
scheme (1:1), so that intervention
allocations could not have been foreseen
in advance of, or during, enrolment.
Blinding
All outcomes
Low risk "Placebo tablets could not be distinguished
from ursodeoxycholic acid tablets".
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias Low risk The trial appears to be free of information
that could put it at risk of bias.
Papatheodoridis 2002
Methods Randomised clinical trial with parallel group design (two
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interventions groups).
Trial duration: 92 months.
Follow-up: no patients lost to follow-up.
Participants Country: Greece.
Number of patients randomised: 86, mean age 54 years
(89% females).
Inclusion criteria:
- liver histology compatible with PBC;
- positive antimitochondrial antibodies;
- alkaline phosphatase levels more than twice the upper
limit of normal.
Exclusion criteria:
- extrahepatic biliary obstruction or other cause of liver
disease;
- patients aged > 70 years;
- patients treated with any immunosuppressive agent
within the 12 months before entry;
- patients with decompensated cirrhosis (Child class B or
C);
- baseline bilirubin levels ≥ 3 mg/dl.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 12 to 15
mg/kg/day, n = 43;
Intervention group 2: no intervention, n = 43.
Outcomes Liver decompensation.
Mortality or liver transplantation.
Symptoms.
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Liver biochemistry.
Liver histology.
Notes 14/43 control patients were crossed-over to
ursodeoxycholic acid at their own request at a median of
3.5 years (range 2 to 8 years) after entry in the trial. Mean
follow-up was 7.3 ± 3.0 years in the ursodeoxycholic acid
group and 8.1 ± 3.1 years in the control group. The authors
did both intention-to-treat analysis and treatment-as-
received analysis.
Data for the following outcomes were extracted from
graphs from Hadziyannis 1990 (Papatheodoridis et al,
2002):
- serum bilirubin;
- serum alanine aminotransferase.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence
generation
Low risk Sequence generation was achieved using
random number table.
Allocation
concealment
Low risk Allocation was controlled by serially
numbered sealed envelopes.
Blinding
All outcomes
Unclear risk The trial did not address this component
and it was likely unblinded.
Incomplete
outcome data
All outcomes
Low risk It was specified that there were no
dropouts or withdrawals.
Selective reporting Low risk Pre-defined, or clinically relevant and
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reasonably expected outcomes are
reported on.
Other bias Unclear risk The trial reported a grant from the
pharmaceutical company Galenica Hellas.
Pares 2000
Methods Double-blind, placebo controlled randomised clinical trial
with parallel group design (two interventions groups).
Trial duration: at least 2 years (median follow-up was 3.4
years).
Follow-up: 10 ursodeoxycholic acid treated patients and 21
placebo treated patients discontinued.
Participants Country: Spain.
Number of patients randomised: 192, from 16 hospitals in
Spain, mean age 54 years (93% females).
Inclusion criteria:
- compatible liver biopsy;
- alkaline phosphatase > 2 upper normal limit;
- positive antimitochondrial antibodies;
- patients with negative antimitochondrial antibodies were
accepted if there was no evidence of extrahepatic biliary
obstruction.
Exclusion criteria:
- age > 72 years;
- previous PBC treatment in the 6 months before entry;
- life expectancy less than 6 months;
- drug addiction;
- pregnancy;
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- other cause of liver disease.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 14 to 16
mg/kg/day in three divided doses, n = 99;
Intervention group 2: no intervention, n = 93.
Outcomes Mortality.
Liver transplantation.
Symptoms.
Complications.
Liver biochemistry.
Liver histology.
Adverse events.
Notes Data for liver biopsy findings - dichotomous variables
outcome were extracted from Pares 2001 (Pares et al, 2000).
Additional information requested on 26th January 2012 and
reply received on 31st January 2012 through personal
communication with the principal author Dr. Albert Pares
who provided data on the method of sequence generation.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Patients were randomised to take
ursodeoxycholic acid or placebo (ratio 1: 1),
using a randomisation code generated by
computer.
Allocation Low risk Allocation was controlled by serially
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concealment numbered sealed and opaque envelopes.
Blinding
All outcomes
Low risk The trial was described as blinded, the
parties that were blinded, and the method
of blinding was described ('placebo was
identical in appearance, smell, and taste'),
so that knowledge of allocation was
adequately prevented during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias Unclear risk It was reported that trial medications were
provided by Zambon S. A., Laboratorio
Farmaceutico.
Poupon 1991
Methods Multicenter double-blind, placebo controlled randomised
clinical trial with parallel group design (two interventions
groups).
Trial duration: 2 years.
Follow-up: 5 patients receiving ursodeoxycholic acid and 6
placebo withdrew.
Participants Country: France and Canada.
Number of patients randomised: 146, from 22 centres in
France and Canada, mean age 56 years (92% females).
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Inclusion criteria:
- liver biopsy compatible with PBC;
- serum alkaline phosphatase > 2.0 upper normal limit;
- positive AMA.
Exclusion criteria:
- PBC treatment within last six months;
- serum bilirubin > 150 µmol/l;
- serum albumin < 25 g/l;
- past or active bleeding oesophageal varices;
- presence of extrahepatic obstruction;
- excessive alcohol consumption;
- positive hepatitis B surface antigen.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 13 to 15
mg/kg/day, n = 73;
Intervention group 2: placebo, n = 73.
Outcomes Mortality.
Liver transplantation.
Symptoms.
Liver biochemistry.
Liver histology.
Notes All patients treated for two years with placebo were offered
ursodeoxycholic acid and further followed-up for another
two years together with patients continuing on
ursodeoxycholic acid.
One patient, included in the publications of the study up to
1993, was excluded from the 1994 publication due to a raised
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serum bilirubin at entry, which violated the entry criteria.
Data were extracted at the maximum follow-up where
applicable, if not the end of treatment was used for data
extraction.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but the
method used to conceal the allocation was not
described, so that intervention allocations may
have been foreseen in advance of, or during,
enrolment.
Blinding
All outcomes
Low risk The trial was described as blinded, the parties
that were blinded, and the method of blinding
was described - placebo was 'identical capsule',
so that knowledge of allocation was adequately
prevented during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported on.
Other bias Low risk The trial appears to be free of information that
could put it at risk of bias.
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Senior 1991
Methods Double-blind randomised clinical trial with parallel
group design (two interventions groups).
Trial duration: six months.
Follow-up: no patients withdrew.
Participants Country: USA.
Number of patients randomised: 19, mean age 53 years
(75% females).
Inclusion criteria:
- PBC confirmed by liver biopsy and supporting clinical
ests within six months of entry into the trial.
Exclusion criteria
- none listed.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 10 mg/kg/
day, n = 9;
Intervention group 2: placebo, n = 10.
Outcomes Mortality.
Symptoms.
Liver biochemistry.
Notes Data for the following outcomes were extracted from
O'Brian 1990 (Senior and O’Brian, 1991):
- mortality;
- liver transplantation.
Risk of bias
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Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Unclear risk The trial was described as double-blind,
but the method of blinding was not
described, so that knowledge of allocation
was possible during the trial.
Incomplete
outcome data
All outcomes
Unclear risk The report gave the impression that there
had been no dropouts or withdrawals,
but this was not specifically stated.
Selective
reporting
Unclear risk Not all pre-defined, or clinically relevant
and reasonably expected outcomes are not
reported fully and properly.
Other bias Unclear risk The trial reported partial support for
ursodiol supplies by Ciba-Geigy Corporation.
Turner 1994
Methods Double-blind, placebo controlled randomised clinical
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trial with parallel group design
(two interventions groups).
Trial duration: 2 years.
Follow-up: 5 patients receiving ursodeoxycholic acid and
4 placebo withdrew.
Participants Country: UK.
Number of patients randomised: 46, mean age 57 years
(96% females).
Inclusion criteria:
- liver biopsy compatible with PBC;
- positive AMA;
- abnormal liver function tests;
- no medication within six months of trial entry.
Exclusion criteria:
- none listed.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid
10mg/kg/day (mean actual dose (+/-SD): 11.4+/-0.9
mg/kg/day), n = 22;
Intervention group 2: placebo, n = 24.
Outcomes Mortality.
Liver transplantation.
Symptoms.
Liver biochemistry.
Liver histology.
Quality of life.
Notes Data for the following outcomes were extracted from the
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preliminary report of the included trial (Myszor 1990):
- pruritus score;
- serum bilirubin;
- serum alkaline phosphatases;
- serum aspartate aminotransferase.
Number of patients randomised 34, follow-up 1 year.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Low risk The trial was described as blinded,
the parties that were blinded, and
the method of blinding was described,
so that knowledge of allocation was
adequately prevented during the trial.
Incomplete
outcome data
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention groups
were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported on.
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Other bias Unclear risk It was reported that trial medications were
generously donated by Thames
Laboratories, Wrex-ham, Wales.
Vuoristo 1995
Methods Double-blind, placebo controlled randomised clinical trial
with parallel group design (two interventions groups and
one control group).
Trial duration: 2 years.
Follow-up: 0 patients receiving ursodeoxycholic acid and 8
placebo withdrew.
Participants Country: Finland.
Number of patients randomised: 90, from four centres in
Finland, mean age 55 years (82% females).
Inclusion criteria:
- elevated serum alkaline phosphatases activity;
- liver biopsy compatible with PBC;
- positive AMA.
Exclusion criteria:
- other cause of liver disease;
- positive hepatitis B surface antigen and hepatitis C
antibodies;
- end-stage PBC;
- patients treated with drugs that might affect prognosis;
- serum bilirubin level > 150 µmol/L;
- serum albumin level < 25 g/L;
- drug-resistant ascites;
- patients in whom liver transplantation was indicated;
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- previous PBC treatment for 6 months before the trial.
Interventions Patients were randomly assigned to receive:
Intervention group 1: ursodeoxycholic acid 12 to 15
mg/kg/day in two doses, n = 30;
Intervention group 2: colchicine 1 mg/day, n = 29;
Control: placebo, n = 31.
Outcomes Mortality.
Liver transplantation.
Symptoms.
Liver biochemistry.
Liver histology.
Adverse events.
Notes
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised but
the method used to conceal the allocation was
not described, so that intervention allocations
may have been foreseen in advance of, or
during, enrolment.
Blinding
All outcomes
Unclear risk The trial was described as blind, but the
method of blinding was not described fully
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(it was only reported that placebo was used,
but no mention on appearance), so
knowledge of allocation was possible during
the trial. The outcome assessment was
blinded.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias Unclear risk It was reported that ursodeoxycholic acid
tablets were donated by Leiras Oy, Helsinki,
Finland.
Table 12. Tables of excluded studies
Study Reason for exclusion
Angulo 1999 This is not a randomised trial, but a comparison of liver
histology of 16 ursodeoxycholic acid treated patients
from one randomised trial to the liver histology of 51
patients from another randomised trial.
Angulo 1999a There is no placebo or no intervention group in this
randomised trial, which compares low (5 to 7
mg/kg/day), standard (13 to 15 mg/kg/day), and high
(23 to 25 mg/kg/day) doses of ursodeoxycholic acid in
155 patients with PBC. The improvements in alkaline
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phosphatase, aspartate aminotransferase, Mayo risk
score, and biliary ursodeoxycholic acid enrichment were
significantly greater in the standard- and high-dose
groups compared to the low-dose group, but not
between the standard- and high-dose group. No
significant effects were noted on symptoms with any
dose.
Bateson 1998 This is a case series of 40 PBC patients with
symptomatic disease treated with ursodeoxycholic acid.
The results were compared to 12 historic
ursodeoxycholic acid-untreated PBC patients.
Brodanova1997 This is a case series of 13 PBC patients treated with
ursodeoxycholic acid.
Cauch-Dudek
1998
This is a case series of 88 patients with PBC evaluating
fatigue. A self-rated fatigue. Severity score did not
correlate with ursodeoxycholic acid use.
Crippa 1995 The trial is not randomised, but compares 18
ursodeoxycholic acid treated PBC patients to eight
untreated PBC patients.
Crosignani 1996 This is a dose-response study examining the effects of
three doses of tauro-ursodeoxycholic acid in 24 patients
with PBC.
Eisenburg 1988 This is a case series of 21 PBC patients during
ursodeoxycholic acid administration.
Ferri 1993 This is a controlled comparison of ursodeoxycholic acid
with tauro-ursodeoxycholic acid for PBC.
Grippa 1995 This is a non-randomised study comparing 18
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ursodeoxycholic acid treated PBC patients to eight
ursodeoxycholic acid-untreated PBC patients.
Ideo 1990 Out of three PBC patients treated with ursodeoxycholic
acid (600 mg/day), ursodeoxycholic acid was stopped
in one of these patiens 'randomly selected'.
Ikeda 1996 This is a randomised trial comparing ursodeoxycholic
acid plus colchicine versus ursodeoxycholic acid alone
in 22 patients with PBC.
Kehagioglou1991 The study is not described as randomised, but compares
16 PBC patients treated with ursodeoxycholic acid (14
mg/kg/day for a mean period of 22 months (range 3
months to 35 months) to a control group consisting of 10
PBC patients treated with placebo.
Kim 1997 This is a case series of eight ursodeoxycholic acid-
treated PBC patiens who lacked antimitochondrial
antibodies.
Kneppelhout1992 This is a case series of 19 patients with PBC during
ursodeoxycholic acid administration.
Krzeski 1999 This is a case series of 60 PBC patients treated with
ursodeoxycholic acid.
Larghi 1997 This is a randomised trial with crossover design
comparing ursodeoxycholic acid versus tauro-
ursodeoxycholic acid.
Leuschner 1996 This randomised trial compared ursodeoxycholic acid
plus prednisolone versus ursodeoxycholic acid plus
placebo for PBC.
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LONDON 1998 This trial compared placebo to different doses of URSO
(300 mg/day, 600 mg/day, 900 mg/day and 1200
mg/day) in 23 biopsy proven early stage PBC patients.
There is no mention of randomisation. Patients were
followed for eight weeks with a four week washout
period between doses. A significant trend toward
normalising of abnormal liver function tests was
observed together with a significant increase in
lethargy, irrespective of ursodeoxycholic acid dose,
compared to placebo.
Lotterer 1990 This is a case series of twelve PBC patients during
ursodeoxycholic acid administration.
Matsuzaka 1994 This is a case series of three PBC patients during
ursodeoxycholic acid administration.
Matsuzaki 1990 This is a case series of ten PBC patients during
ursodeoxycholic acid administration.
MAYO-II 1997 This trial randomised 150 PBC patients to three doses of
ursodeoxycholic acid (5 to 7 mg/kg/day; 13 to 15
mg/kg/day; 22 to 25 mg/kg/day) and followed the
patients for one year. No differences were observed
between the medium and the high dose with respect to
liver biochemistry changes, but both these dose groups
had significantly greater improvement of liver
biochemistry compared to the low dose group. Clinical
events such as death, transplantation, or complications
of liver disease were rare and were not different
between the three dose groups.
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NEWARK-I The study is not randomised. The study included only
four patients with PBC and apparently these were
treated first with placebo for three months and then
with ursodeoxycholic acid (10-15 mg/kg/day) for three-
six months. No major outcome variables are reported.
NEWARK-III This study investigated biochemical features, including
biliary bile acids, in 14 patients with PBC using a paired
design. First, all patients received placebo for three
months. Then, the patients were treated with 900 mg
ursodeoxycholic acid (10-12 mg/kg/day) for six months
(n = 11) to 12 months (n = 8). The latter patients were
then treated with placebo for three months and
restarted on ursodeoxycholic acid for another 12
months. Due to the paired design, the observed
improvements may be due to the fluctuating course of
PBC.
Ogino 1993 This is a case series of 28 PBC patients treated with
ursodeoxycholic acid and compared to seven PBC
patiens not treated with ursodeoxycholic acid.
Okuyama 1988 This is a study of a single PBC patient during
ursodeoxycholic acid administration.
Osuga 1989 This is a case series of eight PBC patients during
ursodeoxycholic acid administration.
Peridigoto 1992 This is a study of three PBC patiens during
ursodeoxycholic acid administration.
Podda 1989 This is a randomised trial examining three doses of
ursodeoxycholic acid in PBC patients and patients with
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primary sclerosing cholangitis and chronic hepatitis.
Poupon 1987 This is a case series of 15 PBC patients during
ursodeoxycholic acid administration.
Poupon 1989 This study is not randomised.
Poupon 1996 This is a randomised trial comparing ursodeoxycholic
acid plus colchicine versus ursodeoxycholic acid in 74
patients with PBC.
Schonfeld 1997 This is a case series of 15 PBC patients during
ursodeoxycholic acid administration.
Shibata 1992 This is a case series of 12 PBC patients during
ursodeoxycholic acid administration.
Stiehl 1990 This is a case series of 29 patients with PBC during
ursodeoxycholic acid administration.
Taha 1994 This is a case series of patients with PBC during
different drug administrations (cholestyramine, wash
out, ursodeoxycholic acid, and ursodeoxycholic acid
plus cholestyramine).
Takezaki 1991 This is a study of a single PBC patient during
ursodeoxycholic acid administration.
Toda 1998 No placebo or no intervention group are included. The
trial compares the efficacy of three doses of
ursodeoxycholic acid (150 mg/day; 600 mg/day; 900
mg/day) in 82 PBC patients for 24 months.
Unoura 1990 Not a randomised trial, but compares 16
ursodeoxycholic acid treated PBC-patients to eight
patients without ursodeoxycholic acid treatment.
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Van de Meeberg
1996
No placebo or no intervention group. Five patients
treated 'in random order' with 10 mg ursodeoxycholic
acid/kg/day in either a single or in three divided doses
- no difference in liver biochemistry improvement.
Van Hoogstraten
1998
This RCT compares 10 versus 20 mg ursodeoxycholic
acid/kg/day during six months in 61 PBC patients.
Liver biochemistry improved in PBC patients receiving
20 mg/kg/day compared to a dose of 10 mg/kg/day.
Verma 1999 This cross-over RCT compares different doses of
ursodeoxycholic acid in twenty-four biopsy-proven
early-stage PBC patients (one male, 23 female) who
received five doses of ursodeoxycholic acid (0, 300, 600,
900, 1200 mg/day) each for eight weeks with four-week
washout periods between doses. Symptoms (pruritus,
fatigue, diarrhoea) were assessed on a four-point scale
(none, mild, moderate, severe). Liver function tests were
performed using conventional methods, and serum bile
acids were measured using gas liquid chromatography.
There was a trend towards normalization of the
abnormal LFTs in a dose-dependent manner (for Y-
glutamyl transferase (yGT), alkaline phosphatase (ALP),
alanine transaminase (ALT) and IgM). Multi-factorial
analysis showed that ursodeoxycholic acid treatment,
irrespective of dose, was significantly better than
placebo for all the variables. The 900 mg and 1200 mg
doses were better than both 300 mg and 600 mg using
gamma-glutamyl transpeptidase and total bilirubin as
variables, better than 300 mg using alkaline phosphatase
118
and IgM as variables, and better than 600 mg using
albumin as a variable. No variables showed a significant
difference between 900 and 1200 mg. The study
concluded that the optimum dose of ursodeoxycholic
acid is 900 mg/day (equivalent to 13.5 mg/kg/day).
This trial is excluded due to the cross-over design and
due to the fact that it did not provide any data on the
primary outcome variables.
Wirth 1994 This is a case series of 14 patients with PBC examined
before and during ursodeoxycholic acid administration.
Wirth 1995 This is a case series of 22 patients with PBC, who have
their subtypes of antimitochondrial antibodies
examined and related to response to ursodeoxycholic
acid administration.
Wolfhagen 1994 No randomisation, combination therapy with
ursodeoxycholic acid and prednisone in seven patients.
Yamazaki 1992 This is a study of a single PBC patient with eosinophilic
infiltration.
Yamazaki 1996 This is a case series of 38 PBC patients, of which 55 per
cent exhibited eosinophilia. The eosinophilia was
reduced during ursodeoxycholic acid treatment.
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Bezafibrate (Paper II)
Results of the search
Our search strategy identified 95 publications, out of which 26 were duplicates.
Of the remaining 69 publications, 57 were excluded, either because they were
reviews or because they did not relate to primary biliary cirrhosis or because
they did not describe a randomised clinical trial investigating the effect of
bezafibrate in patients with primary biliary cirrhosis. Twelve full text articles
were assessed for eligibility, out of which five were excluded with listed
reasons (Image 51).
Image 51. Flow chart
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We identified a total of seven publications referring to six randomised clinical
trials (Table 13). Four trials were published as full text articles (Kanda et al,
2003; Itakura et al, 2004; Iwasaki et al, 2008a; Iwasaki et al, 2008b). One trial was
published as an abstract and as a letter to the editor (Nakai et al, 1999). Another
trial was published only as a letter to the editor (Kurihara et al, 2000). The
primary authors were contacted for further information and data relating to the
trials. Dr. Shinji Iwasaki, kindly provided data on the method of sequence
generation, the number of patients in each intervention group at the end of
treatment, adverse events, and outcome measures (Iwasaki et al, 2008a; Iwasaki
et al, 2008b). No other responses have so far been received. We contacted
manufacturers of bezafibrate and asked for any information about unpublished
or on-going trials using bezafibrate involving patients with primary biliary
cirrhosis. No responses have so far been received. Through a search for ongoing
trials in Clinicaltrials.gov (http://clinicaltrials.gov/) we have not identified any
registered ongoing or planned trials. However, through a search for ongoing
trials in the WHO International Clinical Trials Registry Platform
(http://www.who.int/ictrp/en/), we identified one ongoing trial. This trial has
been classified as an ongoing trial (Table 15).
Included studies
A total of 151 patients with primary biliary cirrhosis were randomised in the six
randomised clinical trials. All trials were conducted in Japan. From the
publications which reported sex of the patients, more than 86% were females. In
four trials, all patients had non-advanced primary biliary cirrhosis according to
inclusion and exclusion criteria (Kanda et al, 2003; Itakura et al, 2004; Iwasaki et
al, 2008a; Iwasaki et al, 2008b). In two trials, no data about severity of primary
biliary cirrhosis among the patients and the exclusion criteria were provided
(Nakai et al, 1999; Kurihara et al, 2000). Five trials had the parallel group design
(Nakai et al, 1999; Kurihara et al, 2000; Kanda et al, 2003; Iwasaki et al, 2008a;
Iwasaki et al, 2008b), and one trial had the cross-over group design (Itakura et
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al, 2004). Four trials assessed bezafibrate plus ursodeoxycholic acid versus no
intervention plus ursodeoxycholic acid (referenced as bezafibrate versus no
intervention in the following) (Nakai et al, 1999; Kanda et al, 2003; Itakura et al,
2004; Iwasaki et al, 2008b), and two trials assessed bezafibrate versus
ursodeoxycholic acid (Kurihara et al, 2000; Iwasaki et al, 2008a). Bezafibrate was
given in a dose of 400 mg daily and ursodeoxycholic acid in a dose of 600 mg
daily in all trials. In two trials duration of administration of bezafibrate was six
months (Kanda et al, 2003; Itakura et al, 2004), and in four trials duration of
administration of bezafibrate was 12 to 13 months (Nakai et al, 1999; Kurihara
et al, 2000; Iwasaki et al, 2008a; Iwasaki et al, 2008b). All the trials reported
similar outcome measures: clinical events, changes in biochemical and
immunological variables, and adverse events. None of the trials reported on
quality of life or fatigue.
Excluded studies
Five studies were excluded; four studies were not randomised clinical trials
(Iwasaki et al, 1999; Miyaguchi et al, 2000; Ohmoto et al, 2001; Hazzan and Tur-
Kaspa, 2010), and in one study patients had hyperlipidaemia, not primary
biliary cirrhosis (Fukuo et al, 1996) (Table 14).
Risk of bias in included studies
Risk of bias was assessed according to six components: allocation sequence
generation; allocation concealment; blinding; handling of incomplete outcome
data; selective outcome reporting; and other potential sources of bias. Of the six
included trials, all trials were assessed as having high risk of bias (Nakai et al,
1999; Kurihara et al, 2000; Kanda et al, 2003; Itakura et al, 2004; Iwasaki et al,
2008a; Iwasaki et al, 2008b) (Image 52). Our statistical analyses are, therefore,
based only on trials with high risk of bias (Image 53).
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Image 52. Risk of bias summary: review authors' judgements about each risk of
bias item for each included study
Image 53. Risk of bias graph: review authors' judgements about each risk of bias
item presented as percentages across all included studies
Allocation
Two trials described a "computer-generated random digits" block method for
the generation of the randomisation allocation sequence (Iwasaki et al, 2008a;
Iwasaki et al, 2008b). We judged the risk of bias due to the generation of the
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randomisation sequence as unclear in the remaining four trials (Nakai et al,
1999; Kurihara et al, 2000; Kanda et al, 2003; Itakura et al, 2004). In two trials
allocation concealment was controlled by a central and independent
randomisation unit (Iwasaki et al, 2008a; Iwasaki et al, 2008b). Concealment of
allocation and hence risk of bias was unclear in the other four trials (Nakai et al,
1999; Kurihara et al, 2000; Kanda et al, 2003; Itakura et al, 2004).
Blinding
Four trials did not address this component and likely have not been blinded
(Nakai et al, 1999; Kurihara et al, 2000; Kanda et al, 2003; Itakura et al, 2004).
Two trials reported that there was no suitable placebo for bezafibrate available,
so the allocation was known during the trial (Iwasaki et al, 2008a; Iwasaki et al,
2008b). Accordingly, all six trials were considered of high risk of bias regarding
this domain.
Incomplete outcome data
Four trials described withdrawals or dropouts from treatment (Kanda et al,
2003; Itakura et al, 2004; Iwasaki et al, 2008a; Iwasaki et al, 2008b). In two trials
it was not specifically stated if there had been no dropouts or withdrawals
(Nakai et al, 1999; Kurihara et al, 2000).
Selective reporting
The trial protocols were not available for any of the trials. However, five trials
included expected outcomes (Kurihara et al, 2000; Kanda et al, 2003; Itakura et
al, 2004; Iwasaki et al, 2008a; Iwasaki et al, 2008b). In one trial we considered
positively their reporting equalizing the term ‘’no adverse reaction’’ with ‘’no
adverse event’’ (Kurihara et al, 2000). Also, in three trials (Kurihara et al, 2000;
Kanda et al, 2003; Itakura et al, 2004), in their reporting about adverse events,
we considered positively that no one died or developed liver-related
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complications when they reported ''no other adverse event was noted''. Only in
one trial, it was reported that no side effects of bezafibrate had been noted, so
we could not consider positively their reporting equalizing the term ‘’side
effects’’ with ‘’adverse events’’ (Nakai et al, 1999).
Other potential sources of bias
Three trials reported the following support: Grant-in-Aid for Scientific Research
from the Ministry of Education, Science and Culture of Japan (Nakai et al, 1999),
The Ministry of Health, Labour and Welfare of Japan with a Health Science
Research Grant on a Specific Disease (Study of Intractable Liver Diseases) to
chief scientist Gotaro Toda (Iwasaki et al, 2008a; Iwasaki et al, 2008b). In one
trial it was reported that Kissei Pharmaceutical, Matsumoto, Japan provided
bezafibrate, and Mitsubishi-Tokyo Pharmaceuticals, Tokyo, Japan supplied
with ursodeoxycholic acid (Kanda et al, 2003). Industrial sponsorship was not
addressed in two trials (Kurihara et al, 2000; Itakura et al, 2004).
Bezafibrate versus no intervention (Table 16)
Three trials provided data on all-cause mortality, liver morbidity, adverse
events, and number of patients having bezafibrate withdrawn due to adverse
events (Kanda et al, 2003; Itakura et al, 2004; Iwasaki et al, 2008b). Two trials
provided data on the number of patients with pruritus (Kanda et al, 2003;
Itakura et al, 2004). Four trials reported on the activity of serum alkaline
phosphatases and serum gamma-glutamyltransferase (Nakai et al, 1999; Kanda
et al, 2003; Itakura et al, 2004; Iwasaki et al, 2008b). Three trials reported on
plasma immunoglobulin M concentration (Nakai et al, 1999; Itakura et al, 2004;
Iwasaki et al, 2008b). Two trials provided data on the activity of serum alanine
aminotransferase, total cholesterol, triglycerides, and serum bilirubin
concentration (Itakura et al, 2004; Iwasaki et al, 2008b).
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Primary outcomes
All-cause mortality
Bezafibrate did not demonstrate any significant effect on all-cause mortality
(RD 0.00, 95% CI -0.11 to 0.11, I² = 0%) (Image 54). No deaths were reported in
any of the two groups (0/32 versus 0/28 patients).
Image 54: bezafibrate vs placebo or no intervention; outcome: all-cause
mortality
Liver-related morbidity
Bezafibrate had no significant effect on liver-related morbidity (RD 0.00, 95% CI
-0.11 to 0.11, I² = 0%) (Image 55). Jaundice, upper gastrointestinal haemorrhage,
ascites, hepatic encephalopathy, or hepato-renal syndrome occurred in 0/32
versus 0/28 patients in the bezafibrate and control groups.
Image 55: bezafibrate vs placebo or no intervention; outcome: liver morbidity
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Adverse events
Several adverse events were reported in the bezafibrate group of the included
trials (polydipsia (Kanda et al, 2003), serum creatine phosphokinase elevation,
and myalgia (Iwasaki et al, 2008b). However, there was no statistically
significant difference in the occurrence of adverse events in patients in the
bezafibrate group versus the control group (5/32 versus 0/28 patients) (RR 5.40,
95% CI 0.69 to 42.32, I² = 0%) (Image 56).
Image 56: bezafibrate vs placebo or no intervention; outcome: adverse events
For assessment of harm, besides the data provided by the three randomised
trials (Kanda et al, 2003; Itakura et al, 2004; Iwasaki et al, 2008b), we also
considered the data from four non-randomised studies which reported on harm
(Iwasaki et al, 1999; Miyaguchi et al, 2000; Ohmoto et al, 2001; Hazzan and Tur-
Kaspa, 2010). In each of four studies it was reported that there were no adverse
effects or side effects attributable to treatment.
Quality of life
No quality of life measurements were reported.
Secondary outcomes
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Pruritus
Bezafibrate did not significantly influence the number of patients with pruritus
(RR 1.12, 95% CI 0.50 to 2.53, I² = 0%) (Image 57).
Image 57: bezafibrate vs placebo or no intervention; outcome: pruritus
Fatigue
None of the trials reported data regarding fatigue.
Biochemical indices
These data were reported either as change from baseline (Itakura et al, 2004) or
final values (Nakai et al, 1999; Kanda et al, 2003; Iwasaki et al, 2008b). The data
were reported either as means with standard deviations (Kanda et al, 2003;
Iwasaki et al, 2008b) or as standard error of the mean; therefore, we converted
them to standard deviation (Itakura et al, 2004). In one trial we have judged
whether standard error of the mean or standard deviation is reported in a data
table in the trial report, based on the standard deviations for laboratory values
at randomisation given in a data table from the other trial reports we included
(Nakai et al, 1999). The results reported in one trial were depicted graphically,
and we extracted data from the graphs (Kanda et al, 2003).
In fixed-effect meta-analysis, bezafibrate significantly decreased the activity of
serum alkaline phosphatases (MD -186.04 U/L, 95% CI -249.03 to -123.04, I² =
34%) (Image 58).
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Image 58: bezafibrate vs placebo or no intervention; outcome: serum alkaline
phosphatases
Trial sequential analysis of these data supports the finding in the meta-analysis
(Image 59). The result of the trial sequential analysis is shown by the cumulated
Z-curve (blue curve) which crosses the trial sequential monitoring boundary
(red curve) implying that there is firm evidence for a beneficial effect of 100
U/L decrease in the activity of serum alkaline phosphatases in the bezafibrate
group (Image 59).
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Image 59 . Trial sequential analysis of the cumulative meta-analysis of the effect
of bezafibrate versus no intervention on the activity of serum alkaline
phosphatases in patients with primary biliary cirrhosis. The diversity-adjusted
required information size (DARIS) of 216 patients is calculated based on a
minimal relevant intervention effect (MIREDIF) of 100 U/L, a standard
deviation of 200 U/L, a risk of type I error of 5%, a power of 80%, and a
diversity of 41%. The cumulated Z-curve (blue curve) crosses the trial
sequential monitoring boundary (red curve) implying that there is firm
evidence for a beneficial effect of 100 U/L decrease in the activity of serum
alkaline phosphatases when the cumulative meta-analysis is adjusted for sparse
data and multiple testing on accumulating data.
In fixed-effect meta-analyses, bezafibrate significantly decreased plasma
immunoglobulin M (MD -164.00 mg/dl, 95% CI -259.47 to -68.53, I² = 46%)
(Image 60) and serum bilirubin concentration (MD -0.19 mg/dl, 95% CI -0.38 to
-0.00, I² = 0%) (Image 61).
Image 60: bezafibrate vs placebo/no intervention; outcome: immunoglobulin M
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Image 61: bezafibrate vs placebo or no intervention; outcome: serum bilirubin
Trial sequential analyses on these data do not support the findings in Analysis
1.8 and Analysis 1.11. Even though the Z-curve (blue curve) lies in the direction
of a decrease in plasma immunoglobulin M and serum bilirubin concentration
in the bezafibrate group, it does not cross the trial sequential monitoring
boundary, implying that there is no firm evidence for a beneficial effect of 121.5
mg/dl decrease in plasma immunoglobulin M concentration (Image 62) and of
0.20 mg/dl decrease in serum bilirubin concentration (Image 63).
Image 62. Trial sequential analysis of the cumulative meta-analysis of the effect
of bezafibrate versus no intervention on concentration of plasma
immunoglobulin M in patients with primary biliary cirrhosis. The diversity-
adjusted required information size (DARIS) of 239 patients is calculated based
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on a minimal relevant intervention effect (MIREDIF) of 121.5 mg/dl, a standard
deviation of 243 mg/dl, a risk of type I error of 5%, a power of 80%, and a
diversity of 47%. The cumulated Z-curve (blue curve) does not cross the trial
sequential monitoring boundary implying that there is no firm evidence for a
beneficial effect of 121.5 mg/dl decrease in plasma immunoglobulin M
concentration when the cumulative meta-analysis is adjusted for sparse data
and multiple testing on accumulating data.
Image 63. Trial sequential analysis of the cumulative meta-analysis of the effect
of bezafibrate versus no intervention on concentration of serum bilirubin
concentration in patients with primary biliary cirrhosis. The diversity-adjusted
required information size (DARIS) of 126 patients is calculated based on a
minimal relevant intervention effect (MIREDIF) of 0.20 mg/dl, a standard
deviation of 0.40 mg/dl, a risk of type I error of 5%, a power of 80%, and a
diversity of 0%. The cumulated Z-curve (blue curve) does not cross the trial
sequential monitoring boundary implying that there is no firm evidence for a
potentially beneficial effect of 0.20 mg/dl decrease in serum bilirubin
concentration when the cumulative meta-analysis is adjusted for sparse data
and multiple testing on accumulating data.
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In fixed-effect meta-analyses, bezafibrate had no significant effect on the activity
of serum gamma-glutamyltransferase (MD -1.22 U/L, 95% CI -11.97 to 9.52, I² =
42%) (Image 64), serum alanine aminotransferase (MD -5.61 U/L, 95% CI -24.50
to 13.27, I² = 34%) (Image 65), total cholesterol (MD -12.51 mg/dl, 95% CI -32.65
to 7.64, I² = 82%) (Image 66), and triglyceride concentration (MD -20.12 mg/dl,
95% CI -47.73 to 7.49, I² = 1%) (Image 67).
Image 64: bezafibrate vs placebo or no intervention; outcome: serum gamma-
glutamyltransferase
Image 65: bezafibrate vs placebo or no intervention; outcome: serum alanin
aminotransferase
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Image 66: bezafibrate vs placebo or no intervention; outcome: total cholesterol
Image 67: bezafibrate vs placebo or no intervention; outcome: triglycerides
Liver biopsy findings (histological stage of primary biliary cirrhosis)
No data about liver biopsy findings after bezafibrate administration were
reported.
Number of patients having bezafibrate withdrawn due to adverse events
One patient had bezafibrate withdrawn due to an adverse event (RD 0.03, 95%
CI -0.09 to 0.16, I² = 0%) (Image 68).
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Image 68: bezafibrate vs placebo or no intervention; outcome: number of
patients having bezafibrate withdrawn due to an adverse events
Bezafibrate versus ursodeoxycholic acid (Table 17)
Two trials provided data on all-cause mortality, liver-related morbidity, adverse
events, number of patients having bezafibrate withdrawn due to adverse
events, the activity of serum alkaline phosphatases, serum gamma-
glutamyltransferase, serum alanine aminotransferase, and plasma
immunoglobulin M concentration (Kurihara et al, 2000; Iwasaki et al, 2008a).
Primary outcomes
All-cause mortality
Bezafibrate did not demonstrate any significant effect on all-cause mortality
(RD 0.00, 95% CI -0.08 to 0.08, I² = 0%) (Image 69). No deaths were reported in
the bezafibrate or ursodeoxycholic acid groups (0/32 versus 0/37 patients).
Image 69: bezafibrate vs UDCA; outcome: all-cause mortality
Liver-related morbidity
Bezafibrate had no significant effect on liver morbidity (RD 0.00, 95% CI -0.08 to
0.08, I² = 0%) (Image 70). Jaundice, upper gastrointestinal haemorrhage, ascites,
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hepatic encephalopathy, or hepato-renal syndrome occurred in 0/32 (0%)
versus 0/37 (0%) patients in the bezafibrate and ursodeoxycholic acid groups.
Image 70: bezafibrate vs UDCA; outcome: liver morbidity
Adverse events
A mild upper gastrointestinal pain was reported in the bezafibrate group
(Iwasaki et al, 2008a), but no discontinuation of bezafibrate administration
occurred. However, there was no statistically significant difference in the
occurrence of adverse events in patients in the bezafibrate group versus the
ursodeoxycholic acid group (2/32 versus 0/37 patients) (RR 6.19, 95% CI 0.31 to
122.05) (Image 71).
Image 71: bezafibrate vs UDCA; outcome: adverse events
Quality of life
No quality of life measurements were reported.
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Secondary outcomes
Pruritus and fatigue
None of the trials reported data regarding pruritus and fatigue.
Biochemical indices
These data were reported either as change from baseline (Kurihara et al, 2000)
or final values (Iwasaki et al, 2008a). The data were reported as means with
standard deviations (Iwasaki et al, 2008a) or as standard error of the mean;
therefore, we converted them to standard deviation (Kurihara et al, 2000). The
results reported in one trial were depicted graphically, and we extracted data
from the graphs (Kurihara et al, 2000). The data were reported as the degree of
change from baseline (%) (Kurihara et al, 2000), and we extracted data as final
values from the graphs. In fixed-effect meta-analyses, bezafibrate significantly
decreased the activity of serum alkaline phosphatases (MD -162.90 U/L, 95% CI
-199.68 to -126.12, I² = 0%) (Image 72), serum gamma-glutamyltransferase (MD -
58.18 U/L, 95% CI -76.49 to -39.88, I² = 89%) (Image 73), serum alanine
aminotransferase (MD -58.18 U/L, 95% CI -76.49 to -39.88, I² = 95%) (Image 74),
and plasma immunoglobulin M concentration (MD -99.90 mg/dl, 95% CI -
130.72 to -69.07, I² = 90%) (Image 75).
Image 72: bezafibrate vs UDCA; outcome: serum alkaline phosphatases
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Image 73: bezafibrate vs UDCA; outcome: serum gamma-glutamyltransferase
Image 74: bezafibrate vs UDCA; outcome: serum alanin aminotransferase
Image 75: bezafibrate vs UDCA; outcome: plasma immunoglobulin M
Trial sequential analysis of these data supports the finding in the meta-analysis
of activity of serum alkaline phosphatases (Image 72). The result of the trial
sequential analysis is shown by the cumulated Z-curve (blue curve) which
crosses the trial sequential monitoring boundary (red curve) implying that there
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is firm evidence for a beneficial effect of 45.5 U/L decrease in the activity of
serum alkaline phosphatases in the bezafibrate group (Image 76).
Image 76. Trial sequential analysis of the cumulative meta-analysis of the effect
of bezafibrate versus ursodeoxycholic acid on the activity of serum alkaline
phosphatases in patients with primary biliary cirrhosis. The diversity-adjusted
required information size (DARIS) of 127 patients is calculated based on a
minimal relevant intervention effect (MIREDIF) of 45.5 U/L, a standard
deviation of 91 U/L, a risk of type I error of 5%, a power of 80%, and a diversity
of 0%. The cumulated Z-curve (blue curve) crosses the trial sequential
monitoring boundary (red curve) implying that there is firm evidence for a
beneficial effect of 45.5 U/L decrease in the activity of serum alkaline
phosphatases when the cumulative meta-analysis is adjusted for sparse data
and multiple testing on accumulating data.
In random-effect meta-analyses, bezafibrate had no significant effect on the
activity of serum gamma-glutamyltransferase (MD 38.44 U/L, 95% CI -180.67 to
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257.55, I² = 89%), serum alanine aminotransferase (MD -2.34 U/L, 95% CI -34.73
to 30.06, I² = 95%), and plasma immunoglobulin M concentration (MD -20.23
mg/dl, 95% CI -218.71 to 178.25, I² = 90%).
Liver biopsy findings (histological stage of primary biliary cirrhosis)
No data about liver biopsy findings after bezafibrate administration were
reported.
Number of patients having bezafibrate withdrawn due to adverse effects
No patient had bezafibrate withdrawn due to adverse effects (RD 0.00, 95% CI -
0.08 to 0.08, I² = 0%) (Image 77).
Image 77: bezafibrate vs UDCA; outcome: number of patients having
bezafibrate withdrawn due to adverse effects
Subgroup analyses
Only a subgroup analysis on different durations of administration of
bezafibrate was performed. Due to the paucity of trials none of the other
planned analyses could be conducted.
Subgroup analysis on trials with low risk of bias compared to trials with high
risk of bias
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All included trials were judged to be at high risk of bias (Image 53). As such, a
subgroup analysis comparing trials with low risk of bias to trials with high risk
of bias was not possible.
Subgroup analysis on different doses of bezafibrate
Bezafibrate was given as one single dose of 400 mg in four trials; three trials
assessing bezafibrate versus no intervention (Nakai et al, 1999; Itakura et al,
2004; Iwasaki et al, 2008b) and in one trial assessing bezafibrate with
ursodeoxycholic acid (Iwasaki et al, 2008a). Bezafibrate was divided into two
orally administered doses, a post-breakfast and a post-dinner dose of 200 mg, in
one trial assessing bezafibrate versus no intervention (Kanda et al, 2003) and in
another trial assessing bezafibrate with ursodeoxycholic acid (Kurihara et al,
2000). As such, a subgroup analysis comparing different doses of bezafibrate
was not possible.
Subgroup analysis on duration of administration of bezafibrate
Subgroup analysis was performed in order to compare the duration of
bezafibrate administration. Bezafibrate was administered for six months in two
trials (Kanda et al, 2003; Itakura et al, 2004) and for 12 to 13 months in another
two trials (Nakai et al, 1999; Iwasaki et al, 2008b).
According to our subgroup analyses, the duration of bezafibrate administration
did not influence the serum alkaline phosphatases activity (MD -141.97 U/L,
95% CI -228.30 to -55.64, I² = 56% compared to MD -236.23 U/L, 95% CI -328.35
to -144.10, I² = 0%; test of interaction Chi² = 2.14; P = 0.14) (Image 78), nor did it
influence the serum gamma-glutamyltransferase activity (MD -1.23 U/L, 95%
CI -12.17 to 9.72, I² = 66% compared to MD -1.20 U/L, 95% CI -56.79 to 54.39, I²
= 55%; test of interaction Chi² = 0.00; P = 1.00) (Image 79).
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Image 78: subgroup analysis: bezafibrate vs placebo or no intervention;
outcome: serum alkaline phosphatases
Image 79: subgroup analysis: bezafibrate vs placebo or no intervention;
outcome: serum gamma-glutamyltransferases
Subgroup analysis on patients treated for primary biliary cirrhosis with a
different drug before bezafibrate administration compared to patients with
no pretreatment
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In five trials patients were treated with ursodeoxycholic acid before bezafibrate
was administrated (Nakai et al, 1999; Kanda et al, 2003; Itakura et al, 2004;
Iwasaki et al, 2008a; Iwasaki et al, 2008b). In one trial there are no data about
pretreatment of patients (Kurihara et al, 2000). As such, a subgroup analysis on
patients treated for primary biliary cirrhosis with a drug different than
bezafibrate before bezafibrate administration compared to patients with no
pretreatment was not possible. Duration of ursodeoxycholic acid administration
was different in each trial: one year or more (Nakai et al, 1999); at least six
months (Kanda et al, 2003); and more than 26 weeks (Iwasaki et al, 2008b). In
one trial three patients received treatment with ursodeoxycholic acid for 2 to 11
years, but before entry into this trial, patients discontinued the use of
ursodeoxycholic acid for at least three months (Itakura et al, 2004). In one trial it
was only reported that not all patients had been treated with ursodeoxycholic
acid or bezafibrate within the previous four weeks (Iwasaki et al, 2008a).
Subgroup analysis on patients with advanced compared to patients with non-
advanced primary biliary cirrhosis
A subgroup analysis on patients with advanced primary biliary cirrhosis
compared to patients with non-advanced primary biliary cirrhosis was not
possible.
Description of studies: tables of included studies (Table 13); tables of excluded
studies (Table 14); tables of ongoing studies (Table 15).
Table 13. Tables of included studies
Itakura 2004
Methods Randomised clinical trial with cross-over group design
(two interventions groups).
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Trial duration: six months.
Participants Country: Japan.
Number of patients randomised: 16, median age 54/61
years (89%/57% females).
Inclusion criteria:
- at least a 1.3-fold elevated alkaline phosphatase level;
- at least a 40-fold positive excess of anti-mitochondrial
antibodies;
- liver-biopsy proven primary biliary cirrhosis.
Exclusion criteria:
- histological overlapping with autoimmune hepatitis;
- positive serum antigen or antibody associated with the
hepatitis B virus;
- positive serum antibody of hepatitis C virus;
- positive serum antibody of human immunodeficiency
virus;
- history of drinking excessive amounts of alcohol or
drug use;
- ascites or oesophageal varices;
- renal insufficiency;
- cardiac failure;
- hepatocellular carcinoma.
Interventions Patients were randomly assigned to receive:
Intervention group 1: bezafibrate (400 mg per day) and
ursodeoxycholic acid (600 mg per day), n = 9;
Intervention group 2: ursodeoxycholic acid alone
(600 mg per day), n = 7.
Three patients received treatment with ursodeoxycholic
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acid for 2 to 11 years, but before entry into the trial, they
had discontinued the use of ursodeoxycholic acid for at
least three months.
Outcomes Outcome measure(s):
- clinical events;
- laboratory data (serum alkaline phosphatases, serum
gamma-glutamyltransferase, serum alanine
aminotransferase, IgM, total serum bilirubin, and total
cholesterol and triglyceride levels);
- adverse events.
Notes Additional information requested on 17th February 2011,
but no response has been received so far. We have used
the data from the first period of the cross-over trial.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information for
assessment of this domain, but it is not
likely to have been blinded.
Incomplete Low risk The numbers and reasons for dropouts and
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outcome data
All outcomes
withdrawals in all intervention groups
were described.
Selective reporting Low risk All expected outcomes are reported.
Other bias Unclear risk Industrial sponsorship was not addressed.
Iwasaki 2008a
Methods Multicenter randomised clinical trial with parallel group design
(two interventions groups).
Trial duration: 52 weeks.
Participants Country: Japan.
Number of patients randomised: 45, mean age 55 years (82%
females).
Inclusion criteria:
- a medical history and laboratory tests consistent with chronic
cholestatic liver disease;
- positive antimitochondrial antibody or antipyruvate
dehydrogenase complex (PDC);
- serum alkaline phosphatases elevation of at least 1.5 times the
upper limit of normal;
- the absence of biliary tract obstruction on imaging results;
- hyperlipoproteinaemia.
Exclusion criteria:
- treatment with D-penicillamine, corticosteroids, colchicine or
immunosuppressive agents within 4 weeks;
- diagnosis of cirrhosis;
- diuretic-resistant ascites, hepatic encephalopathy,
haemorrhage from oesophageal or gastric varices;
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- hyperbilirubinaemia (greater than 5.0 mg/dL);
- serum albumin level less than 3.0 g/dL;
- renal insufficiency;
- malignancy;
- pregnancy;
- below 19 years of age.
Interventions Patients were randomly assigned to receive:
Intervention group 1: bezafibrate (400 mg daily orally), n = 20;
Intervention group 2: ursodeoxycholic acid (orally at a dose of
600 mg daily), n = 25.
All patients had not been treated with ursodeoxycholic acid or
bezafibrate within the previous four weeks.
Outcomes Outcome measure(s):
- clinical events;
- laboratory data (serum alkaline phosphatases, serum gamma-
glutamyltransferase, serum alanine aminotransferase, IgM, total
serum bilirubin, and total cholesterol and triglyceride levels);
- adverse events.
Notes Additional information requested on 14th February 2011 and
reply received on 16th February 2011 through personal
communication with the principal author Dr. Shinji Iwasaki.
Dr. Shinji Iwasaki, provided data on the following:
- the method of sequence generation;
- the number of patients in each intervention group at the end of
treatment;
- tables with numeric values for biochemical indices;
- adverse events;
- all-cause mortality and liver-related morbidity.
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Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk It was generated by block method using
computer-generated random digits.
Allocation
concealment
Low risk Allocation was controlled by a central and
independent randomisation unit, so that
intervention allocations could not have been
foreseen in advance of, or during enrolment.
Blinding
All outcomes
High risk The trial was not blinded, so that the allocation
was known during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk All expected outcomes are reported.
Other bias Low risk The trial appears to be free of other components
that could put it at risk of bias.
Iwasaki 2008b
Methods Multicenter randomised clinical trial with parallel group
design (two interventions groups).
Trial duration: 52 weeks.
Participants Country: Japan.
Number of patients randomised: 22, mean age 54 years
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(86.4% females).
Inclusion criteria:
- a medical history and laboratory tests consistent with
chronic cholestatic liver disease;
- positive antimitochondrial antibody or antipyruvate
dehydrogenase complex (PDC);
- serum alkaline phosphatases elevation of at least
1.5 times the upper limit of normal after treatment with
ursodeoxycholic acid for more than 26 weeks before the
study started;
- the absence of biliary tract obstruction on imaging
results;
- hyperlipoproteinaemia.
Exclusion criteria:
- treatment with D-penicillamine, corticosteroids,
colchicine or immunosuppressive agents within 4 weeks;
- diagnosis of cirrhosis;
- diuretic-resistant ascites, hepatic encephalopathy,
haemorrhage from oesophageal or gastric varices;
- hyperbilirubinaemia (greater than 5.0 mg/dL);
- serum albumin level less than 3.0 g/dL;
- renal insufficiency;
- malignancy;
- pregnancy;
- below 19 years of age.
Interventions Patients were randomly assigned to receive:
Intervention group 1: bezafibrate plus ursodeoxycholic
acid, n = 12;
Intervention group 2: ursodeoxycholic acid, n = 10.
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Ursodeoxycholic acid was given orally at a dose of
600 mg daily, and bezafibrate was given at a dose of
400 mg daily for 52 weeks.
All patients were treated with ursodeoxycholic acid for
more than 26 weeks before the trial start.
Outcomes Outcome measure(s):
- clinical events;
- laboratory data (serum alkaline phosphatases, serum
gamma-glutamyltransferase, serum alanine
aminotransferase, IgM, total serum bilirubin, and total
cholesterol and triglyceride levels);
- adverse events.
Notes Additional information requested on 14th February 2011
and reply received on 16th February 2011 through
personal communication with the principal author
Dr. Shinji Iwasaki.
Dr. Shinji Iwasaki, provided data on the following:
- the method of sequence generation;
- the number of patients in each intervention group at
the end of treatment;
- tables with numeric values for biochemical indices;
- adverse events;
- all-cause mortality and liver-related morbidity.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random Low risk It was generated by block method using
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sequence
generation
computer-generated random digits.
Allocation
concealment
Low risk Allocation was controlled by a central and
independent randomisation unit, so that
intervention allocations could not have
been foreseen in advance of, or during
enrolment.
Blinding
All outcomes
High risk The trial was not blinded, so that the
allocation was known during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention groups
were described.
Selective
reporting
Low risk All clinically relevant and reasonably
expected outcomes are reported on.
Other bias Low risk The trial appears to be free of other
components that could put it at risk of bias.
Kanda 2003
Methods Randomised clinical trial with parallel group design (two
interventions groups).
Trial duration: six months.
Participants Country: Japan.
Number of patients randomised: 22, mean age 56 years
(86% females).
Inclusion criteria: elevated serum alkaline phosphatases
level despite receiving 600 mg/day of ursodeoxycholic
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acid, liver-biopsy proven primary biliary cirrhosis, no
positive serum antigen or antibody associated with the
hepatitis B virus, no positive serum antibody of
hepatitis C virus, human immunodeficiency virus
negativity, no other cause of liver disease (such as
excessive amount of alcohol use, metabolic disorders or
drug-induced liver injury), no ascites, hepatic
encephalopathy, oesophageal varices, or
hyperbilirubinaemia (total bilirubin ≥ 2.0 mg/dl), no
previous treatment with colchicine, corticosteroids, or
immunosuppressive drugs, no thyroid dysfunction or
renal insufficiency (serum creatine level ≥ 2.0 mg/dl), and
prior compliance with ursodeoxycholic acid therapy.
Exclusion criteria: none listed.
Interventions Patients were randomly assigned to receive:
Intervention group 1: bezafibrate (400 mg per day of
bezafibrate divided into two orally administered doses,
post-breakfast and post-dinner), plus 600 mg per day of
ursodeoxycholic acid divided into three orally
administered post-meal doses), n = 11. Bezafibrate was
administrated for a period of six months.
Intervention group 2: 600 mg per day of ursodeoxycholic
acid divided into three orally administered post-meal
doses, n = 11.
All patients had been treated with 600 mg per day of
ursodeoxycholic acid for at least six months.
All patients were given 600 mg per day of ursodeoxycholic
acid in the same manner before, during, and after the
6-month period of administration of bezafibrate.
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Outcomes Outcome measure(s):
- clinical variables (pruritus, ascites, upper gastrointestinal
bleeding, and hepatic encephalopathy);
- biochemical variables (serum alkaline phosphatases and
serum gamma-glutamyltransferase levels);
- adverse events.
Notes Additional information requested on 16th February 2011,
but no response has been received so far.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, even though the trial was
described as randomised and intervention
allocations may have been foreseen in
advance of, or during, enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information for
assessment of this domain, but it is not likely to
have been blinded.
Incomplete
outcome data
All outcomes
Low risk It was specified that all patients participated
until the end of the trial.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
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on.
Other bias High risk It was reported that Kissei Pharmaceutical,
Matsumoto, Japan provided bezafibrate, and
Mitsubishi-Tokyo Pharmaceuticals, Tokyo,
Japan supplied with ursodeoxycholic acid.
Kurihara 2000
Methods Randomised clinical trial with parallel group design (two
interventions groups).
Trial duration: 12 months.
Participants Country: Japan.
Number of patients randomised: 24, mean age 60 years
(95.8% females).
Inclusion criteria: patients with liver biopsy proven
primary biliary cirrhosis.
Exclusion criteria: none listed.
Interventions Patients were randomly assigned to receive:
Intervention group 1: bezafibrate (400 mg per day of
bezafibrate divided into two orally administered doses,
200 mg was taken in the morning and 200 mg in the
evening), n = 12;
Intervention group 2: 600 mg per day of ursodeoxycholic
acid divided into three orally administered doses
(200 mg was taken in the morning, afternoon, and evening),
n = 12.
Both drugs were taken for 12 months.
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Outcomes Outcome measure(s):
- biochemical variables (serum alkaline phosphatases,
serum gamma-glutamyltransferase levels, serum alanine
aminotransferase, and IgM levels);
- adverse events.
Notes Additional information requested on 18th February 2011,
and no response has been received so far.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but
the method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information for
assessment of this domain, but it is not
likely to have been blinded.
Incomplete
outcome data
All outcomes
Unclear risk It was not specifically stated if there had
been no dropouts or withdrawals.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on. We considered positively their
reporting equalising the term ''no adverse
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reaction'' with ''no adverse event''.
Other bias Unclear risk Industrial sponsorship was not addressed.
Nakai 1999
Methods Randomised clinical trial with parallel group design (two
interventions groups).
Trial duration: 12 months.
Participants Country: Japan.
Number of patients randomised: 22, mean age 58 years
(90.9% females).
Inclusion criteria: patients with primary biliary cirrhosis
who had positive mitochondrial antibody test and liver
biopsy-proven diagnosis.
Exclusion criteria: none listed.
Interventions Patients were randomly assigned to receive:
Intervention group 1: 400 mg per day of bezafibrate and
600 mg per day of ursodeoxycholic acid, n = 10;
Intervention group 2: 600 mg per day of ursodeoxycholic
acid, n = 12.
All patients had been treated with ursodeoxycholic acid for
one year or more.
Outcomes Outcome measure(s): changes in biochemical and
immunological variables (serum alkaline phosphatases,
serum gamma-glutamyltransferase levels, and IgM levels
after 3, 6, 9, and 12 months of treatment).
Notes Additional information requested on 18th February 2011,
but no response has been received so far.
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Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information for
assessment of this domain, but it is not likely
to have been blinded.
Incomplete
outcome data
All outcomes
Unclear risk It was not specifically stated if there had
been dropouts or withdrawals.
Selective
reporting
Unclear risk Not all pre-defined expected outcomes are
reported fully, or it is unclear whether data
on these outcomes were recorded or not.
Other bias Low risk The trial appears to be free of other
components that could put it at risk of bias.
Table 14. Tables of excluded studies
Study Reason for exclusion
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Fukuo 1996 Patients had hyperlipidaemia, not primary biliary cirrhosis.
Hazzan
2010
Not a randomised clinical trial.
The study group included 8 patients with primary biliary
cirrhosis, 52 to 76 years old, who had been treated with
ursodeoxycholic acid (900 to 1500 mg per day) for 2 to 11 years
with only a partial response (19% to 56% reduction in alkaline
phosphatase level). Bezafibrate (400 mg per day) was added to
ursodeoxycholic acid, and the patients were followed for 4 to 12
months.
There were no adverse effects attributable to the treatment.
Iwasaki
1999
Not a randomised clinical trial.
The aim of this study was to evaluate the efficacy of bezafibrate
in primary biliary cirrhosis (11 pre-cirrhotic patients with
primary biliary cirrhosis were treated with 400 mg per day of
bezafibrate for 12 to 21 months). Bezafibrate was
co-administered in seven patients who had been treated with
ursodeoxycholic acid but shown incomplete responses.
There were no side effects attributable to the treatment.
Miyaguchi
2000
Not a randomised clinical trial.
Bezafibrate was administered additionally to 13 out of 21
patients with primary biliary cirrhosis who were treated by
monotherapy of ursodeoxycholic acid for 18 months and whose
liver enzymes did not remain within normal range.
There were no adverse effects attributable to the treatment.
Ohmoto
2001
Not a randomised clinical trial.
The aim of this study was to evaluate the efficacy of bezafibrate
in ten patients with primary biliary cirrhosis (two men and
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eight women aged 43 to 66 years at the start of treatment: five in
stage I of Scheuer’s classification, two in stage II, two in stage III,
and one in stage IV), who had shown an inadequate response to
ursodeoxycholic acid monotherapy.
There were no adverse effects attributable to the treatment.
Table 15. Tables of ongoing studies
JPRN-C000000225
Trial name or
title
Randomised clinical trial of ursodeoxycholic acid with or
without bezafibrate in primary biliary cirrhosis.
Methods Randomised trial with parallel design.
Participants Primary biliary cirrhosis.
Interventions Intervention: ursodeoxycholic acid plus bezafibrate.
Control: ursodeoxycholic acid only.
Outcomes Primary outcome(s): serum alkaline phosphatases and serum
gamma-glutamyltransferases.
Secondary outcome(s): cytokines.
Starting date December 2003.
Contact
information
http://apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-
C000000225.
Notes Sponsor is Gunma Liver Study Group. Open public
recruiting.
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Table 16. Summary of findings table: bezafibrate compared with no
intervention for primary biliary cirrhosis
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Table 17. Summary of findings table: Bezafibrate compared with
ursodeoxycholic acid for primary biliary cirrhosis
161
Bisphosphonates (Paper III)
Results of the search
Our search strategy identified 77 publications, out of which 28 were duplicates.
Of the remaining 49 publications, 35 were excluded, either because they were
reviews or because they did not relate to primary biliary cirrhosis or because
they did not describe a randomised clinical trial investigating the effect of
bisphosphonates in participants with primary biliary cirrhosis. Fourteen full-
text articles were assessed for eligibility, out of which four were excluded with
listed reasons (Image 80).
Image 80. Flow chart
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We identified a total of 10 publications referring to six randomised clinical trials
(Tables of included studies). Four trials were all published as abstracts and as
full text articles (Guañabens et al, 1997; Wolfhagen et al, 1997; Guañabens et al,
2003; Zein et al, 2005). One trial was published only as a full text article (Lindor
et al, 2000), and another one was published only as an abstract (Pares et al,
2010). The primary authors were contacted for further information and for more
data relating to the trials. Dr. Albert Pares kindly provided data on the method
of sequence generation, blinding, mortality, fractures, and provided table with
numeric values of bone mineral density and markers of bone turnover in both
groups of treated participants (Pares et al, 2010). Dr. Frank Wolfhagen kindly
provided data on the method of sequence generation, allocation concealment,
blinding, and fractures (Wolfhagen et al, 1997). No other responses have been
received during the conductance of this review.
We contacted manufacturers of bisphosphonates and asked for any information
about unpublished or on-going trials on bisphosphonates in participants with
primary biliary cirrhosis. Louise M. Hageman from Warner Chilcott Nederland
B.V. replied on knowledge of trials.
A search for ongoing or planned trials in Clinicaltrials.gov
(http://clinicaltrials.gov/) and the WHO International Clinical Trials Registry
Platform (http://www.who.int/ictrp/en/) did not retrieve any trials.
Included studies
We identified and included six randomised clinical trials which assessed the
effect of alendronate, etidronate, and ibandronate (all of them
bisphosphonates), in a total of 207 participants with primary biliary cirrhosis.
The trials were conducted in Spain, the USA, and the Netherlands. From the
publications which reported sex of the participants, more than 92% were
females. Two trials were classified as primary prevention trials (Guañabens et
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al, 1997; Wolfhagen et al, 1997). Four trials were classified as secondary
prevention trials (Lindor et al, 2000; Guañabens et al, 2003; Zein et al, 2005;
Pares et al, 2010). In five trials, all patients had non-advanced primary biliary
cirrhosis according to inclusion and exclusion criteria (Wolfhagen et al, 1997;
Lindor et al, 2000; Guañabens et al, 2003; Zein et al, 2005; Pares et al, 2010). Data
about severity of primary biliary cirrhosis among patients and the exclusion
criteria were not reported in one trial (Guañabens et al, 1997).
All the six trials used parallel group designs. Three trials assessed a
bisphosphonate (etidronate or alendronate) versus placebo or no intervention in
106 participants (Wolfhagen et al, 1997; Lindor et al, 2000; Zein et al, 2005). Two
trials assessed a bisphosphonate (etidronate or alendronate) versus another
bisphosphonate (alendronate or ibandronate) in 62 participants (Guañabens et
al, 2003; Pares et al, 2010). One trial assessed a bisphosphonate (etidronate)
versus sodium fluoride in 32 participants (Guañabens et al, 1997). Alendronate
was given in a dose of 10 mg/day in one trial (Guañabens et al, 2003) and in a
dose of 70 mg weekly in two trials (Zein et al, 2005; Pares et al, 2010). Etidronate
was given in a dose of 400 mg/day (Guañabens et al, 1997; Wolfhagen et al,
1997; Lindor et al, 2000; Guañabens et al, 2003). Ibandronate was given monthly
in a dose of 150 mg (Pares et al, 2010). In four trials, the duration of
administration of bisphosphonates was 12 months (Wolfhagen et al, 1997;
Lindor et al, 2000; Zein et al, 2005; Pares et al, 2010), and in the remaining two
trials the duration of administration of bisphosphonates was two years
(Guañabens et al, 1997; Guañabens et al, 2003). In one trial, patients were
previously given immunosuppressive treatment consisting of 30 mg prednisone
during the first 4 weeks, 20 mg during the following 4 weeks, and 10 mg daily
thereafter for 40 weeks, combined with 50 mg azathioprine daily (Wolfhagen et
al, 1997). In five trials, patients were not previously treated with
glucocorticosteroids (Guañabens et al, 1997; Lindor et al, 2000; Guañabens et al,
2003; Zein et al, 2005; Pares et al, 2010). Also, in all included trials patients were
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not previously treated with sodium fluoride, bisphosphonates, or oestrogens. In
one trial most of the patients were treated previously with bisphosphonates, but
there was a washout period of at least one year before entering into the trial
(Pares et al, 2010).
All the trials reported similar outcome measures such as mortality, fractures,
bone mineral density, measurements of biochemical markers of bone turnover,
and adverse events. In one trial it was not reported in which participant group a
death occurred (Lindor et al, 2000). Fractures were not reported in one trial
(Wolfhagen et al, 1997). All trials reported on bone mineral density at lumbar
spine and proximal femur, and different markers of bone turnover.
Excluded studies
Four trials were excluded (Table 27). In three trials participants were patients
having liver transplantation for chronic liver disease (Valero et al, 1995;
Millonig et al, 2005; Crawford et al, 2006), and two out of the three trials were
not a randomised clinical trial (Valero et al, 1995; Millonig et al, 2005). One trial
was a randomised trial but evaluated the effects of cyclical etidronate on
osteopenia in 50 women with cirrhosis of the liver who had underlying
hepatitis viral infection (Shiomi et al, 2002).
Risk of bias in included studies
Risk of bias was assessed according to six bias risk domains: sequence
generation; allocation concealment; blinding; handling of incomplete outcome
data; selective outcome reporting; and other potential sources of bias. Of the six
included trials, five were assessed as having high risk of bias, and one as having
a low risk of bias (Zein et al, 2005) (Image 81).
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Image 81. Risk of bias summary: review authors' judgements about each risk of
bias item for each included study.
Therefore, the statistical analyses are based mostly on trials with high risk of
bias (Image 82).
Image 82. Risk of bias graph: review authors' judgements about each risk of bias
item presented as percentages across all included studies.
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Allocation
In three trials assessing a bisphosphonate versus placebo or no intervention,
sequence generation was achieved using a computer random number table in
two trials (Wolfhagen et al, 1997; Zein et al, 2005), and in one trial the method of
sequence generation was not specified (Lindor et al, 2000). Allocation
concealment was controlled by a central and independent randomisation unit
(Zein et al, 2005), opaque and sealed envelopes (Wolfhagen et al, 1997), and the
method used to conceal the allocation was not described in one trial (Lindor et
al, 2000).
In two trials assessing a bisphosphonate versus another bisphosphonate,
sequence generation was achieved using computer random number generation
(Guañabens et al, 2003; Pares et al, 2010). The method used to conceal the
allocation was not described.
In a trial assessing etidronate versus sodium fluoride, sequence generation was
achieved using computer random number generation, and the method used to
conceal the allocation was not described (Guañabens et al, 1997).
Blinding
From the three trials assessing a bisphosphonate versus placebo or no
intervention, only one trial was blinded (Zein et al, 2005). One trial was not
blinded (Wolfhagen et al, 1997), and in another one blinding was not reported
but it was unlikely to be blinded (Lindor et al, 2000).
From the two trials assessing two different bisphosphonates versus another
bisphosphonate, one trial was not blinded (Pares et al, 2010), and another one
did not report on blinding and was likely unblinded (Guañabens et al, 2003).
In the trial assessing etidronate versus sodium fluoride, blinding was not
reported, so it was likely unblinded (Guañabens et al, 1997).
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Incomplete outcome data
Two trials assessing a bisphosphonate versus placebo or no intervention
described withdrawals or dropouts from treatment (Wolfhagen et al, 1997; Zein
et al, 2005). The number of patients randomised in each group in the beginning
of the trial was not reported in one trial; only the number of patients
randomised in each group that completed one year therapy was reported, and it
was not stated in which group of patients withdrawals or dropouts from
treatment or adverse events occurred (Lindor et al, 2000).
Two trials assessing a bisphosphonate versus another bisphosphonate,
described withdrawals or dropouts from treatment (Guañabens et al, 2003;
Pares et al, 2010).
The trial assessing etidronate versus sodium fluoride described withdrawals or
dropouts from treatment (Guañabens et al, 1997).
Selective reporting
The protocols were not available for any of the trials.
From the three trials assessing a bisphosphonate versus placebo or no
intervention, two trials reported on expected outcomes (Wolfhagen et al, 1997;
Zein et al, 2005), and in one trial, one or more clinically relevant and reasonably
expected outcomes were not reported on (Lindor et al, 2000).
The reports included expected outcomes for two trials assessing a
bisphosphonate versus another bisphosphonate (Guañabens et al, 2003; Pares et
al, 2010).
The trial assessing etidronate versus sodium fluoride reported on expected
outcomes (Guañabens et al, 1997).
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Other potential sources of bias
The three trials assessing a bisphosphonate versus placebo or no intervention
reported the following support: Procter & Gamble Pharmaceuticals BV, The
Netherlands (Wolfhagen et al, 1997), Proctor and Gamble (Cincinnati, OH,
USA) (Lindor et al, 2000), and Merck Medical School grant (C.O.Z., K.D.L) (Zein
et al, 2005).
From the two trials assessing a bisphosphonate versus another bisphosphonate,
one trial reported that Merck Sharp & Dohme, Madrid, Spain supplied the
alendronate for the trial (Guañabens et al, 2003), and industrial sponsorship was
not addressed in another trial (Pares et al, 2010).
In the trial assessing etidronate versus sodium fluoride, it was reported that the
work was partly supported by The Field-Initiated Studies Program (FIS) grant
(Guañabens et al, 1997).
Risk of bias in assessed comparisons
Out of the three trials assessing a bisphosphonate versus placebo or no
intervention, only one trial was with low risk of bias with adequate allocation
sequence generation, allocation concealment, blinding, handling of incomplete
outcome data, and reporting (Zein et al, 2005). The other two trials were with
high risk of bias (Wolfhagen et al, 1997; Lindor et al, 2000) as well as the trials
assessing a bisphosphonate versus another bisphosphonate (Guañabens et al,
2003; Pares et al, 2010) and the trial assessing etidronate versus sodium fluoride
(Guañabens et al, 1997).
For an overview of the risk of bias of the included trials see image 82.
Effects of interventions (Table 18, 19)
Bisphosphonates versus placebo or no intervention
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Two trials assessed etidronate or alendronate versus placebo (Lindor et al, 2000;
Zein et al, 2005). One trial assessed etidronate versus no intervention
(Wolfhagen et al, 1997) (Table 18)
Primary outcomes
All-cause mortality
We could combine data from two trials (Wolfhagen et al, 1997; Zein et al, 2005).
However, there were no deaths reported for either group (0/23 versus 0/23
participants) (RD 0.00; 95% CI -0.12 to 0.12, I² = 0%) (Image 83).
Image 83: bisphosphonates vs placebo or no intervention; outcome: all-cause
mortality
New fractures
Three trials reported on fractures (Wolfhagen et al, 1997; Lindor et al, 2000; Zein
et al, 2005). There was no statistically significant difference in the number of
participants with new fractures in the treatment group compared with the
participants in the control group (5/52 versus 6/54 participants) (RR 0.87; 95%
CI 0.29 to 2.66, I² = 0%) (Image 84).
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Image 83: bisphosphonates vs placebo or no intervention; outcome: fractures
Adverse events
Two trials reported on adverse events (Wolfhagen et al, 1997; Zein et al, 2005).
There was no statistically significant difference in the occurrence of adverse
events in participants in the bisphosphonates group (8/23) versus the control
group (8/23) (RR 1.00; 95% CI 0.49 to 2.04) (Image 84).
Image 84: bisphosphonates vs placebo or no intervention; outcome: adverse
advent
In the alendronate group 7 out of 17 participants compared with 8 out of 17
participants in the placebo group reported gastrointestinal manifestations (eg,
abdominal pain, nausea, abdominal distention, heartburn, antral erosions and
anaemia, flatulence, or any other gastrointestinal adverse event), and only one
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patient in the alendronate group reported concurrent musculoskeletal pain
(Zein et al, 2005). One patient in the alendronate group and two patients in the
placebo group discontinued therapy as a result of adverse events (Zein et al,
2005). Data from the Wolfhagen trial did not show any adverse events in either
treatment or control group (Wolfhagen et al, 1997).
Quality of life
No quality of life measurements were reported.
Secondary outcomes
Bone mineral density (g/cm²)
Three trials reported on the bone mineral density measured at lumbar spine
and proximal femur by dual-energy X-ray absorptiometry (Wolfhagen et al,
1997; Lindor et al, 2000; Zein et al, 2005). Bisphosphonates had no significant
effect on the bone mineral density measured at the lumbar spine (MD 0.01
g/cm², 95% CI -0.00 to 0.03, I² = 8%) (Image 85) and proximal femur (MD 0.00
g/cm², 95% CI -0.01 to 0.02, I² = 0%) (Image 86) compared with placebo or no
intervention.
Image 85: bisphosphonates vs placebo or no intervention; outcome: lumbar
spine bone mineral density
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Image 86: bisphosphonates vs placebo or no intervention; outcome: proximal
femur bone mineral density
Liver-related mortality or liver transplantation
There were no liver-related deaths reported for any of the two groups (0/23
versus 0/23 participants), and none of the patients underwent liver
transplantation (RD 0.00; 95% CI -0.12 to 0.12, I² = 0%) (Image 87).
Image 87: bisphosphonates vs placebo or no intervention; outcome: liver
mortality or liver transplantation
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Liver-related morbidity
Bisphosphonates had no significant effect on liver morbidity (RD 0.00; 95% CI -
0.12 to 0.12, I² = 0%) (Image 88). Jaundice, upper gastrointestinal haemorrhage,
ascites, hepatic encephalopathy, or hepato-renal syndrome occurred in 0/23
(0%) versus 0/23 (0%) participants in the bisphosphonate and control groups.
Image 88: bisphosphonates vs placebo or no intervention; outcome: liver-related
morbidity
Biochemical markers of bone turnover
Three trials reported on serum osteocalcin (Wolfhagen et al, 1997; Lindor et al,
2000; Zein et al, 2005), and two trials reported on NTx (Lindor et al, 2000; Zein
et al, 2005).
These data were reported either as change from baseline (Lindor et al, 2000) or
final values (Wolfhagen et al, 1997; Zein et al, 2005). In two trials the data were
reported as means with standard deviations (Lindor et al, 2000; Zein et al, 2005).
In one trial only standard error of the mean was reported; therefore, we
converted it to standard deviation (Wolfhagen et al, 1997). To assess the effect of
bisphosphonates on serum osteocalcin concentration, we used the standardised
mean difference (SMD) because one trial (Wolfhagen et al, 1997) reported
different measure unit for serum osteocalcin compared to the other two trials
(Lindor et al, 2000; Zein et al, 2005).
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In fixed-effect meta-analyses, bisphosphonates significantly decreased serum
osteocalcin (SMD -0.81; 95% CI -1.22 to -0.39, I² = 34 %) (Image 89) and NTx
concentration (MD -16.93 nmol bone collagen equivalents (BCE)/mmol
creatinine (Cr), 95% CI -23.77 to -10.10, I² = 0%) (Image 90) compared with
placebo or no intervention.
Image 89: bisphosphonates vs placebo or no intervention; outcome: serum
osteocalcin
Image 90: bisphosphonates vs placebo or no intervention; outcome: NTx
concentration
Trial sequential analysis supports the finding in Analysis 1.9 (Image 91). The
result of the trial sequential analysis is shown by the cumulated Z-curve (blue
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curve) which crosses the trial sequential monitoring boundary (red curve)
implying that there is firm evidence for a beneficial effect of 11.5 nmol
BCE/mmol Cr decrease in NTx concentration in the bisphosphonates group
(Image 91).
Image 91. Trial sequential analysis of the cumulative meta-analysis of the effect
of bisphosphonates versus placebo or no intervention on the urinary amino
telopeptides of collagen I (NTx) concentration in participants with primary
biliary cirrhosis. The diversity-adjusted required information size (DARIS) of
168 patients is calculated based on a minimal relevant intervention effect
(MIREDIF) of 11.5 nmol bone collagen equivalents (BCE)/mmol creatinine (Cr),
a standard deviation of 23 nmol bone collagen equivalents/mmol creatinine, a
risk of type 1 error of 5%, a power of 80%, and a diversity of 0%. The cumulated
Z-curve (blue curve) crosses the trial sequential monitoring boundary (red
curve) implying that there is firm evidence for a beneficial effect of 11.5 nmol
bone collagen equivalents/mmol creatinine decrease in NTx concentration
when the cumulative meta-analysis is adjusted for sparse data and multiple
testing on accumulating data.
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Number of patients having bisphosphonates withdrawn due to adverse
events
Discontinuation of bisphosphonate administration occurred in 1/23 patients in
bisphosphonates group versus 2/23 patients in the control group due to
adverse events (RD -0.04; 95% CI -0.21 to 0.12, I² = 0%) (Image 92).
Image 92: bisphosphonates vs placebo or no intervention; outcome: number of
patients having bisphosphonates withdrawn due to adverse events
Bisphosphonates versus another bisphosphonate
One trial assessed alendronate versus etidronate (Guañabens et al, 2003), and
another trial assessed alendronate versus ibandronate (Pares et al, 2010) (Table
19).
Primary outcomes
All-cause mortality
Two trials reported on mortality (Guañabens et al, 2003; Pares et al, 2010); 0 out
of 32 patients died in the bisphosphonates group versus 1 out of 30 patients in
the control group (RD -0.03; 95% CI -0.14 to 0.07, I² = 0%) (Image 93).
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Image 93: bisphosphonates versus another bisphosphonate; outcome: all-cause
mortality
One patient who died as a consequence of liver failure was in the etidronate
group in the trial assessing alendronate versus etidronate (Guañabens et al,
2003).
New fractures
Two trials reported on fractures (Guañabens et al, 2003; Pares et al, 2010). There
was no statistically significant difference in the number of participants with
new fractures in the alendronate group compared with the participants in the
control group (2/32 versus 2/30 participants) (RR 0.95; 95% CI 0.18 to 5.06, I² =
0%) (Image 94).
Image 94: bisphosphonates versus another bisphosphonate; outcome: fractures
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Adverse events
Two trials reported on adverse events (Guañabens et al, 2003; Pares et al, 2010).
There was no statistically significant difference in the occurrence of adverse
events among the participants in the bisphosphonates group (5/32) versus the
participants in the control group (5/30) (RR 0.95; 95% CI 0.31 to 2.94, I² = 0%)
(Image 95).
Image 95: bisphosphonates versus another bisphosphonate; outcome: adverse
advents
One patient in the etidronate group died during the first year of treatment as a
consequence of liver failure; one patient in the alendronate and two patients in
the etidronate group left the trial because of gastrointestinal symptoms; and
two patients in the alendronate group left the trial within the first six months
because they wanted to withdraw (Guañabens et al, 2003).
Two patients in the alendronate group discontinued treatment because of minor
gastrointestinal events; two patients in the ibandronate group discontinued
because of osteoarticular pain and minor gastrointestinal symptoms; and other
two patients discontinued treatment because of violation of the protocol and a
coincident disorder (Pares et al, 2010).
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Quality of life
No quality of life measurements were reported.
Secondary outcomes
Bone mineral density (g/cm²)
Two trials reported on bone mineral density measured at the lumbar spine and
proximal femur by dual-energy X-ray absorptiometry (Guañabens et al, 2003;
Pares et al, 2010). Alendronate had no significant effect on the bone mineral
density measured at the lumbar spine (MD 0.02 g/cm², 95% CI -0.05 to 0.10,
I²=0%) (Image 96) and proximal femur (MD 0.01 g/cm², 95% CI -0.03 to 0.05,
I²=40%) (Image 97) compared with another bisphosphonate.
Image 96: bisphosphonates versus another bisphosphonate; outcome: lumbar
spine bone mineral density
Image 97: bisphosphonates versus another bisphosphonate; outcome: proximal
femur bone mineral density
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Liver-related mortality or liver transplantation
Alendronate had no significant effect on liver-related mortality or liver
transplantation compared with another bisphosphonate. One patient died due
to liver failure in the etidronate group versus 0/32 in the alendronate group
(RD -0.03; 95% CI -0.14 to 0.07, I² = 0%) (Image 98).
Image 98: bisphosphonates versus another bisphosphonate; outcome: liver-
related mortality or liver transplantation
Liver-related morbidity
Bisphosphonates had no significant effect on liver morbidity (RD 0.00; 95% CI -
0.09 to 0.09, I² = 0%) (Image 99). Jaundice, upper gastrointestinal haemorrhage,
ascites, hepatic encephalopathy, or hepato-renal syndrome occurred in 0/32
(0%) versus 0/30 (0%) participants in the alendronate and control groups.
Image 99: bisphosphonates versus another bisphosphonate; outcome: liver-
related mortality
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Biochemical markers of bone turnover
Two trials reported data on serum osteocalcin, PINP, and NTx (Guañabens et
al, 2003; Pares et al, 2010).
These data were reported as final values. In one trial the data were reported as
means with standard deviations (Pares et al, 2010). The results reported in
another trial regarding markers of bone turnover were depicted graphically,
and we extracted data from the graphs (Guañabens et al, 2003). Data were
reported as standard error of the mean; therefore, we converted these data to
standard deviation (Guañabens et al, 2003).
In fixed-effect meta-analyses, alendronate significantly decreased serum
osteocalcin (MD -4.40 ng/ml, 95% CI -6.75 to -2.05, I² = 82%) (Image 100), PINP
(MD -8.79 ng/ml, 95% CI -15.96 to -1.63, I² = 38%) (Image 101), and NTx
concentration (MD -14.07 nmol BCE/mmol Cr, 95% CI -24.23 to -3.90, I² = 0%)
(Image 102) when compared with another bisphosphonate.
Image 100: bisphosphonates versus another bisphosphonate; outcome: serum
osteocalcin
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Image 101: bisphosphonates versus another bisphosphonate; outcome: PINP
concentration
Image 102: bisphosphonates versus another bisphosphonate; outcome: NTx
concentration
In random-effect meta-analyses, alendronate had no significant effect on serum
osteocalcin concentration (MD -3.61 ng/ml, 95% CI -9.41 to 2.18, I² = 82%) when
compared with another bisphosphonate.
Trial sequential analyses on these data do not support the finding (image 101,
102). Eventhough the Z-curves (blue curves) lie in the direction of a decrease in
PINP and NTx concentrations in the alendronate group, they do not cross the
trial sequential monitoring boundaries, implying that there is no firm evidence
183
for a beneficial effect of 9 ng/ml decrease in PINP concentration (Image 103)
and of 12.5 nmol BCE/mmol Cr decrease in NTx concentration (Image 104).
Image 103. Trial sequential analysis of the cumulative meta-analysis of the effect
of alendronate versus another bisphosphonate on concentration of the
procollagen type I N-terminal propeptide (PINP) in participants with primary
biliary cirrhosis. The diversity-adjusted required information size (DARIS) of
168 patients is calculated based on a minimal relevant intervention effect
(MIREDIF) of 9 ng/ml, a standard deviation of 18 ng/ml, a risk of type 1 error
of 5%, a power of 80%, and a diversity of 38%. The cumulated Z-curve (blue
curve) does not cross the trial sequential monitoring boundary implying that
there is no firm evidence for a beneficial effect of 9 ng/ml decrease in PINP
concentration when the cumulative meta-analysis is adjusted for sparse data
and multiple testing on accumulating data.
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Image 104. Trial sequential analysis of the cumulative meta-analysis of the effect
of alendronate versus another bisphosphonate on concentration of the urinary
amino telopeptides of collagen I (NTx) in participants with primary biliary
cirrhosis. The diversity-adjusted required information size (DARIS) of 87
patients is calculated based on a minimal relevant intervention effect
(MIREDIF) of 12.5 nmol bone collagen equivalents/mmol creatinine, a standard
deviation of 25 nmol bone collagen equivalents/mmol creatinine, a risk of type
1 error of 5%, a power of 80%, and a diversity of 0%. The cumulated Z-curve
(blue curve) does not cross the trial sequential monitoring boundary implying
that there is no firm evidence for a beneficial effect of 12.5 nmol bone collagen
equivalents/mmol creatinine decrease in NTx concentration when the
cumulative meta-analysis is adjusted for sparse data and multiple testing on
accumulating data.
Number of patients having alendronate withdrawn due to adverse events
Discontinuation of alendronate administration occurred in 3/32 patients in
alendronate group versus 5/30 patients in the control group due to adverse
events (RR 0.56; 95% CI 0.14 to 2.17, I² = 0%) (Image 105).
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Image 105: bisphosphonates versus another bisphosphonate; outcome: number
of patients having alendronate withdrawn due to adverse events
Bisphosphonates versus any other drug
One trial assessed etidronate versus sodium fluoride in 32 patients (Guañabens
et al, 1997).
Primary outcomes
All-cause mortality
Death occurred in 1/16 (6.25%) and 0/16 (0%) participants in the etidronate and
sodium fluoride groups. There was no significant difference using Fisher's exact
test (P = 0.50) (Table 20).
Table 20 Etidronate versus sodium fluoride.
Outcome
measures
Type of data Etidronate
group
Sodium
fluoride
group
Statistical
test
P value
All-cause
mortality
Dichotomous 1/16 (6.25%) 0/16
(0%)
Fisher’s
exact test
0.50
Fractures Dichotomous 3/16 (18.75%) 4/16 Fisher’s 0.30
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(25%) exact test
Adverse
events
Dichotomous 0/16 (0%) 3/16
(18.75%)
Fisher’s
exact test
0.11
Liver-related
mortality or
liver
transplantation
Dichotomous 1/16 (6.25%) 0/16
(0%)
Fisher’s
exact test
0.50
New fractures
New fractures occurred in 3/16 (18.75%) and 4/16 (25%) participants in the
etidronate and sodium fluoride groups. There was no significant difference
using Fisher's exact test (P = 0.30) (Table 21).
Table 21 Etidronate versus sodium fluoride.
Outcome
measures
Type of data Etidronate
group
Sodium
fluoride
group
Statistical
test
P
value
All-cause
mortality
Dichotomous 1/16
(6.25%)
0/16 (0%) Fisher’s
exact test
0.50
Fractures Dichotomous 3/16
(18.75%)
4/16 (25%) Fisher’s
exact test
0.30
Adverse
events
Dichotomous 0/16 (0%) 3/16
(18.75%)
Fisher’s
exact test
0.11
Liver-related Dichotomous 1/16 0/16 (0%) Fisher’s 0.50
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mortality or
liver
transplantation
(6.25%) exact test
Adverse events
Adverse events occurred in 0/16 (0%) and 3/16 (18.75%) participants in the
etidronate and sodium fluoride groups. There was no significant difference
using Fisher's exact test (P = 0.11) (Table 22).
Table 22 Etidronate versus sodium fluoride.
Outcome
measures
Type of data Etidronate
group
Sodium
fluoride
group
Statistical
test
P value
All-cause
mortality
Dichotomous 1/16 (6.25%) 0/16 (0%) Fisher’s
exact test
0.50
Fractures Dichotomous 3/16
(18.75%)
4/16 (25%) Fisher’s
exact test
0.30
Adverse
events
Dichotomous 0/16 (0%) 3/16
(18.75%)
Fisher’s
exact test
0.11
Liver-related
mortality or
liver
transplantation
Dichotomous 1/16 (6.25%) 0/16 (0%) Fisher’s
exact test
0.50
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Quality of life
No quality of life measurements were reported.
Secondary outcomes
Bone mineral density (g/cm²)
Etidronate compared with sodium fluoride had no significant effect on the bone
mineral density measured at the lumbar spine, proximal femur, Ward's triangle
(area having the lowest bone mineral density in the femoral head), or
trochanter. There was no significant difference using the independent groups T-
test (Table 23).
Table 23 Etidronate versus sodium fluoride.
Outcome
measure
Bone
mineral
density
(g/cm2)
Type of
data
Etidronate
group
(mean ±
SD)
Sodium
fluoride
group
(mean ±
SD)
Statistical
test
Degrees
of
freedom
T
value
P value
Lumbar
spine
Continuo
us
0.904 ±
0.14
0.869 ±
0.08
T test 21 0.704
7
0.49
Proximal
femur
Continuo
us
0.712 ±
0.11
0.765 ±
0.07
T test 21 1.327
1
0.20
Ward's
triangle
Continuo
us
0.585 ±
0.15
0.616 ±
0.07
T test 21 0.602
6
0.55
Trochanter Continuo
us
0.607 ±
0.10
0.655 ±
0.09
T test 21 1.190
7
0.25
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Liver-related mortality or liver transplantation
Liver-related death occurred in 1/16 (6.25%) and 0/16 (0%) participants in the
etidronate and sodium fluoride groups. There was no significant difference
using Fisher's exact test (P = 0.50) (Table 24).
Table 24 Etidronate versus sodium fluoride.
Outcome
measures
Type of data Etidronate
group
Sodium
fluoride
group
Statistical
test
Pvalue
All-cause
mortality
Dichotomous 1/16
(6.25%)
0/16 (0%) Fisher’s
exact test
0.50
Fractures Dichotomous 3/16
(18.75%)
4/16 (25%) Fisher’s
exact test
0.30
Adverse events Dichotomous 0/16 (0%) 3/16
(18.75%)
Fisher’s
exact test
0.11
Liver-related
mortality or
liver
transplantation
Dichotomous 1/16
(6.25%)
0/16 (0%) Fisher’s
exact test
0.50
Liver-related morbidity
Data on liver-related morbidity were not provided.
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Biochemical markers of bone turnover
The trial reported data on serum osteocalcin, urinary hydroxyproline, and
parathyroid hormone. Data were reported as standard error of the mean;
therefore, we converted them to standard deviation (Higgins and Green, 2011).
The results for serum osteocalcin and urinary hydroxyproline are depicted
graphically, and we extracted data from the graphs.
Etidronate compared with sodium fluoride significantly decreased serum
osteocalcin, urinary hydroxyproline, and parathyroid hormone concentration
(Table 25).
Table 25 Etidronate versus sodium fluoride.
Outcome
measure
Markers of
bone turnover
Type of
data
Etidronate
group
(mean ±
SD)
Sodium
fluoride
group
(mean
± SD)
Statistical
test
Degrees
of
freedom
T
value
P
value
Serum
osteocalcin
(ng/ml)
Continuous 13.81 ±
6.56
24.66 ±
16.06
T test 21 2.219 0.04
Urinary
hydroxyproline
(nmol/mmol
creatinine)
Continuous 59.5 ±
23.05
103.89 ±
49.37
T test 21 2.8742 0.009
Parathyroid
hormone
(pg/ml)
Continuous 27.4 ±
13.34
40.7 ±
14.55
T test 21 2.2795 0.03
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Number of patients having etidronate withdrawn due to adverse events
It was not possible to evaluate this outcome as it was only reported in the
etidronate group; one patient died because of liver failure, and two patients
were withdrawn with no reasons listed. For the sodium fluoride group it was
reported that 6 out of 16 patients were withdrawn (three had gastrointestinal
symptoms, one withdrew voluntarily, and for two patients, there were no
reasons listed).
Subgroup analyses
Subgroup analysis on trials with low risk of bias compared to trials with high
risk of bias
We had insufficient data to perform a subgroup analysis comparing trials with
low risk of bias with trials with high risk of bias per each comparison (Image
82).
Subgroup analysis on different doses of a bisphosphonate
Alendronate was given in a dose of 10 mg/day only in one trial (Guañabens et
al, 2003) and in a dose of 70 mg weekly in two trials (Zein et al, 2005; Pares et al,
2010). In four trials, etidronate was given in the same dose of 400 mg/day
(Guañabens et al, 1997; Wolfhagen et al, 1997; Lindor et al, 2000; Guañabens et
al, 2003). Ibandronate was given in one trial monthly in a dose of 150 mg (Pares
et al, 2010). Sodium fluoride was given in a dose of 50 mg/day (as 25 mg
enteric-coated tablets twice a day) in another trial (Guañabens et al, 1997). A
subgroup analysis comparing the different doses of bisphosphonates was not
possible.
Subgroup analysis on different duration of administration of a
bisphosphonate
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Duration of all trials assessing a bisphosphonate versus placebo or no
intervention was 12 months (Wolfhagen et al, 1997; Lindor et al, 2000; Zein et al,
2005). We only included two trials assessing a bisphosphonate versus another
bisphosphonate, and the duration of administration of alendronate was 2 years
and 12 months, respectively (Guañabens et al, 2003; Pares et al, 2010). A
subgroup analysis comparing different durations of administration of a
bisphosphonate was not possible.
Subgroup analysis on patients treated for primary biliary cirrhosis with
glucocorticoids before administration of a bisphosphonate compared to
patients with no pretreatment with glucocorticoids
A subgroup analysis was performed to compare patients treated for primary
biliary cirrhosis with glucocorticoids before administration of a bisphosphonate
to patients with no pretreatment with glucocorticoids. From three trials
assessing a bisphosphonate versus placebo or no intervention, only in one trial
patients were previously treated with glucocorticoids (Wolfhagen et al, 1997),
and in the other two trials, patients were not (Lindor et al, 2000; Zein et al,
2005).
According to our subgroup analyses, pretreatment with glucocorticoids did not
influence the bone mineral density measured at lumbar spine (MD 0.00; 95% CI
-0.18 to 0.18 compared to MD 0.01; 95% CI -0.00 to 0.03, I² = 36%; test of
interaction Chi² = 0.02; P = 0.88) (Image 85) and proximal femur (MD 0.00; 95%
CI -0.11 to 0.11 compared to MD 0.00; 95% CI -0.01 to 0.02, I² = 0%; test of
interaction Chi² = 0.00; P = 0.97) (Image 86). Furthermore, according to our
subgroup analysis, pretreatment with glucocorticoids did not influence serum
osteocalcin (SMD -0.08; 95% CI -1.21 to 1.06 compared to SMD -0.92; 95% CI -
1.36 to -0.48, I² = 14%; test of interaction Chi² = 1.85; P = 0.17) (Image 89).
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Description of studies: tables of included studies (Table 26) and tables of
excluded studies (Table 27)
Table 26 tables of included studies
Guañabens 1997
Methods Randomised clinical trial with parallel group design
(two interventions groups).
Trial duration: two years.
Participants Country: Spain.
Number of participants randomised: 32, mean age 57
years (100% females).
Inclusion criteria: women with primary biliary cirrhosis.
Exclusion criteria: none listed.
There were no significant differences between the two
groups in age, severity of cholestasis, postmenopausal
status, and bone mineral density at baseline.
Interventions Participants were randomly assigned to receive:
Intervention group 1: etidronate (400 mg/day orally,
taken on an empty stomach followed by a 13-week
period without etidronate), n = 16;
Intervention group 2: sodium fluoride (given as 25 mg
enteric-coated tablets twice a day), n = 16.
All patients received calcium supplements (1000 to 1500
mg/day) and low doses of vitamin D orally
(266 μg of 25-hydroxyvitamin D every 2 week), except
for the patients in the etidronate group on the days they
took this treatment.
None of the patients had previously received sodium
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fluoride, bisphosphonates, oestrogens, or
glucocorticosteroids.
Fourteen patients received 15 mg/kg/day of ursodiol
during the trial.
Patients did not receive any other treatment that could
influence calcium metabolism.
Outcomes Outcome measures:
- mortality;
- fractures;
- bone mineral density at the lumbar spine and femur;
- measurements of biochemical markers of bone turnover;
- adverse events.
Notes Additional information was requested on 22nd February
2011, but no response was received.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence
generation
Low risk Sequence generation was achieved using
computer random number generation.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocation may have been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information on
this domain, but it is not likely to have
been blinded.
Incomplete Low risk The numbers and reasons for dropouts
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outcome data
All outcomes
and withdrawals in all intervention
groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are
reported on.
Other bias Low risk The trial appears to be free of other
components that could put it at risk of bias.
Guañabens 2003
Methods Randomised clinical trial with parallel group design
(two interventions groups).
Trial duration: two years.
Participants Country: Spain.
Number of participants randomised: 32, mean age 59
years (100% females).
Inclusion criteria:
- women with primary biliary cirrhosis and osteopenia.
Osteopenia was defined as a bone mineral density
value ≥ 1 SD below the young normal mean.
Exclusion criteria:
- previous gastrointestinal bleeding;
- known peptic ulcer;
- hiatal hernia;
- renal failure (serum creatinine > 1.5 mg/dl);
- bilirubin concentration > 10 mg/dl.
Interventions Participants were randomly assigned to receive:
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Intervention group 1: etidronate (400 mg/day orally,
taken on an empty stomach
(at the midpoint of a 4-h fast) for 2 weeks, followed by a
13-week period without etidronate), n = 16;
Intervention group 2: alendronate (10 mg/day orally,
taken on rising in the morning with a glass of water,
before the first food or beverage of the day), n = 16.
All patients received calcium supplements
(1000 to 1500 mg/day) and low doses of vitamin D
orally (266 μg of 25-hydroxyvitamin D every 2 week),
except for patients in the etidronate group on the days
they took this treatment.
None of the patients had previously received sodium
fluoride, bisphosphonates, estrogens, or
glucocorticosteroids.
All patients received 14 to 16 mg/ kg/day of
ursodeoxycholic acid during the study and did not
receive any other treatment that could influence calcium
metabolism.
Outcomes Outcome measures:
- mortality;
- liver transplantations;
- fractures;
- bone mineral density at the lumbar spine and femur;
- measurements of biochemical markers of bone turnover;
- adverse events.
Notes Additional information requested on 22nd February 2011,
but no response was received.
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Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence
generation
Low risk Sequence generation was achieved using
computer random number generation.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information on
this domain, but the trial is not likely to
have been blinded.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts
and withdrawals in all intervention
groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are
reported on.
Other bias High risk Alendronate was supplied by Merck Sharp
& Dohme, Madrid, Spain.
Lindor  2000
Methods Randomised, placebo-controlled trial with parallel group
design (two interventions groups).
Trial duration: one year.
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Participants Country: USA.
Number of participants randomised: 67, mean age
61 years (85% females).
Inclusion criteria:
- well-established diagnosis of primary biliary cirrhosis
(positive antimitochondrial antibodies and histologic
confirmation of primary biliary cirrhosis);
- bone mineral density of the lumbar spine (L2-L4)
less than a T-score of -2.0;
- an estimated survival based on a Mayo risk score
of more than 80% at two years;
- age between 18 and 70 years;
- a negative pregnancy test prior to entry or needed
to use adequate contraceptive measures for women of
childbearing age.
Exclusion criteria:
- a history of peptic ulcer disease;
- renal insufficiency (creatinine concentration of more
than 2.0 mg/dL);
- thyroid disease;
- treatment with drugs that are known to affect bone
metabolism (including calcitonin, sodium fluoride,
bisphosphonates, glucocorticosteroids, testosterone,
vitamin D in excess of 1000 units per day, chronic heparin,
diphenyl hydantoin, carbamazepine, or phenobarbital
therapy) within six months of entry into the trial;
- oestrogen use within one year or stopping estrogens
within the previous six months.
Interventions Participants were randomly assigned to receive:
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Intervention group 1: etidronate
(oral dose of 400 mg per day for 14 days followed
by 76 days of 500 mg of calcium carbonate:
the 90-day cycle was repeated 4 times each year), n = 29;
Intervention group 2: placebo
(placebo regimen was identical and a placebo was
substituted for the etidronate), n = 31.
Supplemental calcium (500 mg elemental calcium) ) was
administered on the days patients did not receive
etidronate.
All patients were treated with ursodeoxycholic acid
(13 to 15 mg/kg/day) for their underlying liver disease.
Outcomes Outcome measures:
- fractures;
- bone mineral density of the spine and femur;
- measurements of biochemical markers of bone turnover;
- adverse events.
Notes Of the 67 patients entered, 60 completed at least one year
of therapy. The number of patients that completed
one year of therapy were randomised as follows:
etidronate group n = 29; and placebo group n = 31.
The trial did not report on number of patients randomised
in each group at the beginning of the trial.
Additional information requested on 21st February 2011,
but no response was received.
Risk of bias
Bias Authors'
judgement
Support for judgement
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Random
sequence
generation
Unclear risk The trial is described as randomised, but the
method of sequence generation was not
specified.
Allocation
concealment
Unclear risk The trial was described as randomised,
but the method used to conceal the
allocation was not described, so that
intervention allocation may have been
foreseen in advance of, or during enrolment.
Blinding
All outcomes
Unclear risk The trial did not provide information on this
domain, but it is not likely to have been
blinded.
Incomplete
outcome data
All outcomes
Unclear risk The report showed that there had been
dropouts, but the number of patients who
dropped-out was not specifically stated
for each of the two groups.
Selective
reporting
High risk One or more clinically relevant and
reasonably expected outcomes were not
reported on.
Other bias High risk There are other factors in the trial that
could put it at risk of bias
(baseline imbalance in bone mineral
density in the proximal femur),
and the drugs
and placebo were supplied by Proctor and
Gamble (Cincinnati, OH, USA).
Pares 2010
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Methods Randomised clinical trial with parallel group design (two
interventions groups).
Trial duration: 12 months.
Participants Country: Spain.
Number of participants randomised: 30, mean age 63
years (100% females).
Inclusion criteria: postmenopausal women with primary
biliary cirrhosis if they had a bone mineral density of
osteoporosis or osteopenia and fragility fractures.
Exclusion criteria: none listed.
Interventions Participants were randomly assigned to receive:
Intervention group 1: weekly alendronate (70 mg), n = 16;
Intervention group 2: monthly ibandronate (150 mg), n =
14.
Outcomes - bone mineral density of the lumbar spine and proximal
femur;
- liver function tests, 25-hydroxyvitamin D, and
parathyroid hormone;
- markers of bone turnover;
- adherence assessed by the Morisky-Green score.
Notes Additional information requested on 23rd February 2011
and reply was received on 1st March 2011 through
personal communication with the principal author Dr.
Albert Pares.
Dr. Albert Pares provided data on the following:
- the method of sequence generation (sequence generation
was achieved using computer random number
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generation);
- blinding (the trial was not blinded);
- mortality (no one died);
- fractures (only one patient in ibandronate group
developed fractures);
- bone mineral density and markers of bone turnover in
both groups of treated participants (the tables with
numeric values were provided).
Regarding the severity of primary biliary cirrhosis and
patients pre-treatment, Dr. Albert Pares provided the
following data:
- all patients received ursodeoxycholic acid (14 to 16
mg/kg/day) and there was no other specific treatment
for primary biliary cirrhosis nor for the bone disease;
- most of the patients were treated previously with
bisphosphonates, but there was a washing period of at
least one year before entering into the trial;
- no patients received hormone replacement or calcitonin,
nor glucocorticoids;
- no patient had cirrhosis, and most of them were in
stages I-II, as this was in agreement with the liver
elasticity assessment performed within six months to
enrolment.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random sequence Low risk Sequence generation was achieved using
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generation computer random number generation.
Allocation
concealment
Unclear risk The method used to conceal the allocation
was not described, so that intervention
allocations may have been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
High risk The trial was not blinded.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for drop-outs
and withdrawals in all intervention
groups were described.
Selective reporting Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are
reported on.
Other bias Unclear risk Industrial sponsorship was not addressed.
Wolfhagen 1997
Methods Randomised clinical trial with parallel group design
(two interventions groups).
Trial duration: one year.
Participants Country: Netherlands.
Number of participants randomised: 12 (6/6), mean age
57/49 years (83%/66% females).
Inclusion criteria:
- patients with an established diagnosis of primary biliary
cirrhosis, participating in a double-blind, placebo
controlled trial with prednisone/azathioprine.
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Exclusion criteria:
- patients with Child-Pugh Class B or C disease;
- previous treatment with oestrogen replacement,
bisphosphonates, sodium fluoride or calcitonin;
- renal impairment;
- other gastrointestinal diseases;
- insulin-dependent diabetes mellitus;
- pituitary dysfunction;
- hyperparathyroidism;
- alcoholism;
- immobility;
- age over 70 years;
- presence of osteoporotic vertebral fractures (ie, > 20%
reduction in vertebral height).
Interventions Participants were randomly assigned to receive:
Intervention group 1: etidronate (3-monthly cycles of
etidronate 400 mg daily during 2 weeks, taken with
water with two hours intervals between meals,
alternated with 11 weeks of 1250 mg calcium carbonate
(500 mg elementary calcium), n = 6;
Intervention group 2: calcium alone 500 mg, n = 6.
Both regimens were started one month before entry in
the trial with immunosuppressives and maintained
during the whole study period.
The immunosuppressive treatment consisted of 30 mg
prednisone during the first four weeks, 20 mg during the
following four weeks, and 10 mg daily thereafter for 40
weeks, combined with 50 mg azathioprine daily.
All patients had been receiving ursodeoxycholic acid
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during at least one year, and this treatment was
continued.
One patient stopped the prednisone/azathioprine
medication one month after the start of the
immunosuppressives because of general malaise.
Outcomes Outcome measures:
- bone mineral density of the spine and femur;
- measurements of biochemical markers of bone turnover.
Notes Additional information requested on 21st February 2011
and reply was received on 12th March 2011 through
personal communication with the principal author
Dr. Frank Wolfhagen.
Dr. Frank Wolfhagen provided data on:
- the method of sequence generation
(sequence generation was achieved using a random
number table);
- allocation concealment (allocation was controlled by
opaque and sealed envelopes);
- blinding (the trial was not blinded);
- fractures (no fractures were found in either group of
treated patients).
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Sequence generation was achieved using a
random number table.
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Allocation
concealment
Low risk Allocation was controlled by opaque and
sealed envelopes so intervention
allocations could not had been foreseen in
advance of, or during enrolment.
Blinding
All outcomes
High risk The trial was not blinded, so that the
allocation was known during the trial.
Incomplete
outcome data
All outcomes
Low risk It was specified that there were no
dropouts or withdrawals (‘’all patients
completed the study and no adverse effects of
etidronate were noted’’).
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias High risk It was stated that grant support was
received from Procter & Gamble
Pharmaceuticals BV, The Netherlands.
Zein 2005
Methods Randomised, double-blind, placebo-controlled trial with
parallel group design (two intervention groups).
Trial duration: one year.
Participants Country: USA.
Number of participants randomised: 34, mean age 61 years
(94% females).
Inclusion criteria:
- well-established diagnosis of primary biliary cirrhosis
(positive antimitochondrial antibodies (≥ 1: 40) and liver
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biopsy proven primary biliary cirrhosis);
- bone loss evidenced by a lumbar spine (L2-L4) bone
mineral density T-score below -1.5;
- an estimated survival based on a Mayo risk score of more
than 80% at two years;
- age between 18 and 70 years;
- written informed consent.
Exclusion criteria:
- a history of peptic ulcer disease;
- oesophageal varices;
- creatinine concentration of more than 1.8 mg/dL;
- thyroid disease;
- treatment with drugs that are known to affect bone
metabolism (including calcitonin, sodium fluoride,
glucocorticosteroids, testosterone, vitamin D in excess of
1,000 IU/d, chronic heparin, diphenyl hydantoin,
carbamazepine, or phenobarbital) within six months of
entry into the trial;
- oestrogen use within one year or stopping estrogens
within the previous six months;
- patients in whom the decreased bone density could be due
to osteomalacia;
- patients with low serum 25-OH vitamin D or elevated
parathyroid hormone;
- decompensated liver disease (ascites, hepatic
encephalopathy, or significant coagulopathy indicated by
INR > 1.8).
Interventions Participants were randomly assigned to receive:
Intervention group 1: alendronate (oral dose of 70 mg per
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week), n = 17;
Intervention group 2: placebo, n = 17.
Both formulations were white, oblong pills with no
markings, no discernible odour, and no difference to taste.
All patients received calcium (1,000 mg/day orally) and
vitamin D (5,000 U/wk orally).
Outcomes Outcome measures:
- efficacy of alendronate in comparison with placebo in
patients with primary biliary cirrhosis-associated bone loss;
- vertebral fractures;
- measurements of biochemical markers of bone turnover;
- adverse events.
Notes
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Sequence generation was achieved using a
random number table.
Allocation
concealment
Low risk Allocation was controlled by a central and
independent randomisation unit so that
intervention allocations could not have been
foreseen in advance of, or during enrolment.
Blinding
All outcomes
Low risk The trial was described as blinded, the parties
that were blinded, and the method of
blinding was described, so that knowledge of
allocation was adequately prevented during
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the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported
on.
Other bias Low risk The trial appears to be free of other
components that could put it at risk of bias.
Table 27 tables of excluded studies
Study Reason for exclusion
Crawford
2006
It is a randomised, double-blind, placebo-controlled trial, but it
assesses zoledronic acid in 62 participants having liver
transplantation for chronic liver disease.
Millonig
2005
It is not a randomised trial, and participants were patients waiting
for liver transplantation; 10 out of 136 with primary biliary
cirrhosis and primary sclerosing cholangitis. A total of 98 patients
(72%) received alendronate after liver transplantation.
Shiomi
2002
It is a randomised trial that evaluated the effects of cyclical
etidronate on osteopenia in 50 women with cirrhosis of the liver
who had underlying hepatitis viral infection.
Valero
1995
It is not a randomised trial, and participants were liver-
transplanted patients, 12 out of 120 with primary biliary cirrhosis.
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Table 18. Summary of findings table: Bisphosphonates compared to placebo or
no intervention for osteoporosis in primary biliary cirrhosis
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Table 19. Summary of findings table: Bisphosphonates compared to another
bisphosphonates (Alendronate vs etidronate or ibandronate) for osteoporosis in
primary biliary cirrhosis
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Hormone replacement (Paper IV)
Results of the search
Our search strategy identified 42 publications, out of which 16 were duplicates.
Of the remaining 26 publications, 22 were excluded, either because they were
reviews, or because they did not relate to primary biliary cirrhosis, or because
they did not describe a randomised clinical trial investigating the effect of
hormone replacement in women with primary biliary cirrhosis (Image 106).
Image 106. Study flow diagram
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We identified a total of two publications referring to two randomised clinical
trials (Table 35). The two trials were published as full text articles (Ormarsdottir
et al, 2004; Boone et al, 2006). The primary authors were contacted for data and
other information on the trials. Dr. Jenny Heathcote kindly responded to our
inquiry, but she could not provide data on the trial that had been initiated
almost 20 years ago (Boone et al, 2006). No other responses were received.
We contacted manufacturers of oestrogens and progestins and asked for any
information about unpublished or on-going trials using oestrogens and
progestins involving participants with primary biliary cirrhosis. Novartis, Novo
Nordisk, and Noven Pharmaceuticals kindly replied that they knew only of two
trials we had already included.
We have not identified any registered ongoing or planned trials through
Searching Clinicaltrials.gov (http://clinicaltrials.gov/) and the WHO
International Clinical Trials Registry Platform (http://www.who.int/ictrpen/).
Included studies
We identified and included two randomised clinical trials which assessed the
effect of hormone replacement in a total of 49 participants with primary biliary
cirrhosis. The trials were conducted in Canada and Sweeden. Both trials were
multicenter trials with parallel group design (Ormarsdottir et al, 2004; Boone et
al, 2006). Hormone replacement versus placebo was assessed in 31 participants
in one trial (Boone et al, 2006), and hormone replacement versus no intervention
was assessed in 18 participants in another trial (Ormarsdottir et al, 2004).
Participants in both trials were postmenopausal women with primary biliary
cirrhosis. Those women had previously not been treated with drugs known to
affect the bone metabolism. In both trials, hormone replacement was given
transdermally. In one trial hormone replacement was given as oestradiol patch
in combination with medroxyprogesterone (Ormarsdottir et al, 2004).
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Oestradiol patch was given in a dose of 50 µg per day twice weekly, and
medroxyprogesterone in a dose of 2.5 mg daily continuously (if more then 2
years from menopause), or in a dose of 10 mg daily for 12 days per month (if
less then 2 years from menopause) (Ormarsdottir et al, 2004). In the other trial,
hormone replacement was given as 7β-estradiol for two weeks followed by two
weeks of combined transdermal norethisterone acetate and 17β-estradiol
(Boone et al, 2006). 7β-estradiol was given in a dose of 0.05 mg daily and
norethisterone acetate in a dose of 0.25 mg daily. The duration of administration
of hormone replacement was two years in both trials. All patients received
vitamin D and calcium. In one trial, vitamin D was given in a dose of 0.25 µg
daily, and calcium in a dose of 1 g daily (Ormarsdottir et al, 2004). In the other
trial, vitamin D was given in a dose of 1000 IU daily, and calcium in a dose of
1500 mg daily (Boone et al, 2006). Both trials reported similar outcome
measures: bone mineral density measured at the lumbar spine and proximal
femur, clinical events, fractures, changes in biochemical variables, and adverse
events.
Excluded studies
We excluded two studies because they were not randomised clinical trials
(Menon et al, 2003; Pereira et al, 2004) (Table 36).
Risk of bias in included studies
Risk of bias was assessed according to six domains: sequence generation;
allocation concealment; blinding; handling of incomplete outcome data;
selective outcome reporting; and other potential sources of bias. One was
assessed as having a low risk of bias (Boone et al, 2006), and the other as having
a high risk of bias (Ormarsdottir et al, 2004) (Image 107).
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Image 107. Risk of bias summary: review authors' judgements about each risk
of bias item for each included study.
Statistical analyses, which include both trials, are, therefore, based on trials with
high risk of bias (Image 108; Table 37)
Image 108. Risk of bias graph: review authors' judgements about each risk of
bias item presented as percentages across all included studies.
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Allocation
In the trial assessing hormone replacement versus placebo, sequence generation
was achieved using a randomisation table (Boone et al, 2006). The method of
sequence generation was not specified In the trial assessing hormone
replacement versus no intervention (Ormarsdottir et al, 2004). Allocation
concealment was performed by independent pharmacist who had no role in
patient contact or follow-up, nor did he/she participate in data analysis (Boone
et al, 2006) and control by sealed envelopes (Ormarsdottir et al, 2004).
Blinding
One trial was blinded (Boone et al, 2006). The other trial did not report on
blinding and was likely unblinded (Ormarsdottir et al, 2004).
Incomplete outcome data
The numbers and reasons for dropouts and withdrawals in all intervention
groups were described in both included trials.
Selective reporting
The protocols were not available for any of the trials, but pre-defined, or
clinically relevant and reasonably expected outcomes were reported.
Other potential sources of bias
The trial assessing hormone replacement versus placebo seems to be free from
other potential sources of bias, apart from the fact that it reported that
transdermal oestrogen/progestin and placebo were supplied by Novartis
(Boone et al, 2006). Novartis was not involved in the collection, analysis, or
presentation of the data (Boone et al, 2006). The trial assessing hormone
replacement versus no intervention reported sponsorship from Novartis, but it
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did not report if Novartis was involved in the collection and data analysis in
presentation of the results (Ormarsdottir et al, 2004).
Effects of interventions (Table 37)
Primary outcomes
All-cause mortality
No deaths were reported for any of the two groups (0/24 versus 0/25
participants) (RD 0.00; 95% CI -0.11 to 0.11; I² = 0%) (Image 109).
Image 109: hormone replacement versus placebo or no intervention; outcome:
all-cause mortality
New fractures
In the trial assessing hormone replacement versus no intervention, no fractures
were found in either groups (Ormarsdottir et al, 2004). In the trial assessing
hormone replacement versus placebo, 2/15 participants in the placebo group
reported fractures compared with 0/16 participants in the treatment group
(Boone et al, 2006). There was no statistically significant difference in the
number of participants with new fractures in the treatment group compared
with controls (RD -0.08; 95% CI -0.24 to 0.07; I² = 0%) (Image 110).
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Image 110: hormone replacement versus placebo or no intervention; outcome:
fractures
Adverse events
There was a statistically significant increase in the occurrence of adverse events
in the hormone replacement group (10/24) versus the control group (2/25) (RR
5.26; 95% CI 1.26 to 22.04; I² = 0%) (Image 111).
Image 110: hormone replacement versus placebo or no intervention; outcome:
adverse advents
Reasons for withdrawal of participants due to the occurrence of adverse events
are provided in Table 28 and Table 29.
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Table 28 Reasons for withdrawals from treatment due to adverse events
(Ormarsdottir 2004)
Adverse events Hormone replacement Placebo
Temporary spotty vaginal bleeding 1/8 0/10
Slight increase in systolic blood pressure 1/8 0/10
Increase in liver enzymes 1/8 0/10
Increase in bilirubin concentration 0/8 1/10
Table 29 Reasons for withdrawals from treatment due to adverse events
(Boone 2006)
Adverse event Hormone
replacement
Placebo
Generalised pruritus 1/16 0/15
Pneumonia, pulmonary embolism 1/16 0/15
Abdominal pain, headache 1/16 0/15
Local pruritus at patch site 1/16 0/15
Heavy vaginal bleeding 1/16 0/15
Breast pain, chest pain, generalised pruritus,
dysuria
1/16 0/15
Local pruritus at patch site 1/16 0/15
Diffuse painful rash of lower back 0/16 1/15
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For assessment of harm, besides the data provided by the two randomised trials
(Ormarsdottir et al, 2004; Boone et al, 2006) (Table 28, 29) we also considered the
data from two non-randomised studies which reported on harm (Menon et al,
2003; Pereira et al, 2004). In Menon 2003, in the hormone replacement group,
there were 6 patients out of 46 who experienced adverse events versus 0
patients out of 46 in the control group (Table 30).
Table 30 Adverse events (Menon 2003)
Adverse event Hormone replacement No intervention
Breast tenderness 1/46 0/46
Vaginal spotting 1/46 0/46
Increase in bilirubin concentration 4*/46 0/46
*In three of the four patients with increase in bilirubin concentration, this was
because of worsening liver function, as manifest by worsening ascites and
development of oesophageal varices. The remaining patient developed
elevations in her serum bilirubin and alkaline phosphatase after stopping
ursodeoxycholic acid therapy.
In Pereira 2004, in the hormone replacement group, there were 2 patients out of
21 who experienced an adverse event versus 0 patients out of 21 in the control
group (Table 31).
Table 31 Adverse events (Pereira 2004)
Adverse events Hormone replacement patches No intervention
Monthly
bleeding
2/21 0/21
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Quality of life
No quality of life measurements were reported.
Secondary outcomes
Change in per cent in bone mineral density per year (g/cm2 year-1)
Hormone replacement had no significant effect on bone mineral density
measured at the lumbar spine compared with placebo or no intervention (MD
1.25 g/cm² yearֿ¹; 95% CI -0.91 to 3.42; I² = 0%) (Image 111).
Image 111: hormone replacement versus placebo or no intervention; outcome:
change in per cent of lumbar spine bone mineral density per year
Hormone replacement seemed to significantly decrease bone mineral density at
the proximal femur (MD 2.24 g/cm² yearֿ¹; 95% CI 0.74 to 3.74; I² = 0%) (Image
112).
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Image 112: hormone replacement versus placebo or no intervention; outcome:
change in per cent of proximal femur bone mineral density per year
Trial sequential analysis on data for bone mineral density at the proximal femur
does not support the findings in Analysis 1.5. The cumulated Z-curve (blue
curve) did not cross the trial sequential monitoring boundary (red curve)
implying that there is no firm evidence that hormone replacement decreases
bone mineral density measured at proximal femur (Image 113).
Image 113. Trial sequential analysis of the cumulative meta-analysis of the effect
of hormone replacement versus control on bone mineral density measured at
proximal femur in women with primary biliary cirrhosis. The diversity-
adjusted required information size (DARIS) of 130 patients is calculated based
on a minimal relevant intervention effect (MIREDIF) of 1.6 g/cm² yearֿ¹, a
standard deviation of 3.2 g/cm² yearֿ¹, a risk of type 1 error of 5%, a power of
80%, and a diversity of 0%. The cumulated Z-curve (blue curve) did not cross
the trial sequential monitoring boundary (red curve) implying that there is no
firm evidence for an effect of 1.6 g/cm² yearֿ¹ decrease in bone mineral density
measured at proximal femur when the cumulative meta-analysis is adjusted for
sparse data and multiple testing on accumulating data.
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Liver-related mortality or liver transplantation
Hormone replacement had no significant effect on liver-related mortality or
liver transplantation. There were no liver-related deaths reported for any of the
two groups (0/24 versus 0/25 participants) (RD 0.00; 95% CI -0.11 to 0.11; I² =
0%) (Image 114).
Image 114: hormone replacement versus placebo or no intervention; outcome:
liver-related mortality or liver transplantation
Liver-related morbidity
Hormone replacement did not seem to have significant effect on liver-related
morbidity. Liver-related complications occurred in 1/24 participants in the
hormone replacement group versus 1/25 participants in the control group (RR
1.07; 95% CI 0.15 to 7.63; I² = 0%) (Image 115).
Image 115: hormone replacement versus placebo or no intervention; outcome:
liver-related morbidity
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One woman in the control group had an increase in bilirubin after twelve
months (> 100% increase from baseline) and developed ascites afterwards in the
following six months (Ormarsdottir et al, 2004). One women in the treatment
group experienced two episodes of variceal haemorrhage (at months 4 and 17 of
the trial period) requiring hospital admission, blood transfusion, and band
ligation.
Biochemical indices
Two trials reported on serum bilirubin concentration. In one trial the data were
reported as percentage change from baseline presented as median with ranges,
and in addition they provided the table with final values presented as median
with ranges (Ormarsdottir et al, 2004). We used only data presented as final
values. In another trial, the data were reported as final values presented as
means with ranges (Boone et al, 2006). In order to perform our meta-analysis,
we estimated standard deviation to be approximately one quarter of the typical
range of data values (Higgins and Green, 2011). In fixed-effect meta-analysis,
hormone replacement versus placebo or no intervention had no significant
effect on serum bilirubin concentration (MD 4.60 µmol/L; 95% CI -3.42 to 12.62;
I² = 0%) (Image 116).
Image 116: hormone replacement versus placebo or no intervention; outcome:
bilirubin
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One trial reported that the relative change of serum alkaline phosphatases,
serum alanine aminotransferase, and albumin concentration over baseline
values did not differ when the two treatment groups were compared
(Ormarsdottir et al, 2004). The data were reported as percentage change from
baseline presented as median with ranges (Table 32).
Table 32 Biochemical indices (Ormarsdottir 2004)
Outcome measure
(maximum change %
from baseline value)
Type of data Oestrogen + vitD +
Ca (median(range))
n = 7
vitD + Ca
(median(range))
n = 10
P
Serum alkaline
phosphatases (µkat/L)
Continuous -4 (-34 to 29) -2 (-10 to 35) NS
Serum alanine
aminotransferase
(µkat/L)
Continuous -5 (-24 to 483) 8 (-7 to 140) NS
Albumin (g/L) Continuous -5 (-12 to 0) -5 (-14 to 5) NS
µkat/L = 60 U/L
No trial reported on serum aspartate aminotransferase activity and biochemical
markers of bone turnover.
Number of patients having hormone replacement withdrawn due to adverse
events
There was a statistically significant increase in the number of patients having
hormone replacement withdrawn due to adverse events in the hormone
replacement group (10/24) versus the control group (2/25) (RR 5.26; 95% CI
1.26 to 22.04, I² = 0%) (Image 117).
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Image 117: hormone replacement versus placebo or no intervention; outcome:
number of patients having hormone replacement withdrawn due to adverse
events
Reasons for withdrawal of participants due to the occurrence of adverse events
are provided in Table 33, 34.
Table 33 Reasons for withdrawals from treatment due to adverse events
(Ormarsdottir 2004)
Adverse events Hormone replacement Placebo
Temporary spotty vaginal bleeding 1/8 0/10
Slight increase in systolic blood pressure 1/8 0/10
Increase in liver enzymes 1/8 0/10
Increase in bilirubin concentration 0/8 1/10
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Table 34 Reasons for withdrawals from treatment due to adverse events
(Boone 2006)
Adverse event Hormone
replacement
Placebo
Generalised pruritus 1/16 0/15
Pneumonia, pulmonary embolism 1/16 0/15
Abdominal pain, headache 1/16 0/15
Local pruritus at patch site 1/16 0/15
Heavy vaginal bleeding 1/16 0/15
Breast pain, chest pain, generalised pruritus,
dysuria
1/16 0/15
Local pruritus at patch site 1/16 0/15
Diffuse painful rash of lower back 0/16 1/15
Subgroup analyses
It was not possible to perform the planned subgroup analyses due to the
paucity of trials.
Description of studies: tables of included studies (Table 35) and tables of
excluded studies (Table 36).
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Table 35. tables of included studies
Ormarsdottir 2004
Methods Multicentre randomised clinical trial with parallel group design
(two interventions groups).
Trial duration: two years.
Participants Country: Sweden.
Number of participants randomised: 18, median age 57 years.
Inclusion criteria:
- postmenopausal women between the age of 40 and 70 years
with the diagnosis of primary biliary cirrhosis (presence of anti-
mitochondrial antibodies and liver histopathology compatible
with primary biliary cirrhosis), and Child-Pugh score A.
* postmenopausal status was defined as loss of menstruations
for at least one year and elevated follicle-stimulating hormone
compatible with a postmenopausal status.
Exclusion criteria:
- other bone disorders than osteoporosis related to liver disease
or postmenopausal status;
- history of cancer;
- unexplained vaginal bleeding;
- unexplained uterus enlargement or lump in the breasts;
- history of thromboembolic disorder;
- hyperthyroidism;
- impairment of the renal function;
- severe heart disease;
- uncontrolled hypertension (diastolic blood pressure > 100
mmHg);
- history of drug or alcohol abuse;
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- treatment with calcitonin, high-dose vitamin D (more than
50,000 IU weekly), systemic corticosteroids, high dose heparin,
oestrogen (except for local preparations not containing
oestradiol), progestagens, fluorides, or bisphosphonates.
Interventions Participants were randomly assigned to receive:
Intervention group 1: transdermal hormone replacement
(oestradiol patch, 50 µg per day twice weekly in combination
with medroxyprogesterone), n = 8. Duration of administration
of hormone replacement was two years.
Intervention group 2: no hormone replacement, n = 10.
A dose for medroxyprogesterone was 2.5 mg daily continuously
if more than two years from menopause, and 10 mg daily for 12
days per month if less than two years from menopause.
All patients received vitamin D (alfacalcidol) 0.25 µg daily and
calcium 1 g daily.
Outcomes Outcome measure(s):
- bone mineral density of the lumbar spine and proximal femur;
- fractures;
- biochemical variables (serum bilirubin, liver enzymes,
albumin);
- adverse events.
Notes Additional information requested on 18th March 2011, but no
response was received.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random Unclear risk The trial is described as randomised, but the
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sequence
generation
method of sequence generation was not
specified.
Allocation
concealment
Low risk Allocation was controlled by sealed envelopes
so that intervention allocation could not have
been foreseen in advance of, or during
enrolment.
Blinding
All outcomes
Unclear risk The trial did not discuss this domain and was
likely unblinded.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were
described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and
reasonably expected outcomes are reported on.
Other bias Unclear risk The trial reported sponsorship from Novartis,
but it did not report if Novartis was involved
in the collection and analysis of the data.
Boone 2006
Methods Multicentre randomised clinical trial with parallel group design (two
interventions groups).
Trial duration: two years.
Participants Country: Canada.
Number of participants randomised: 31, mean age 55 years.
Inclusion criteria:
- postmenopausal women ≤ 65 years with primary biliary cirrhosis
(alkaline phosphatases > 110 U/L, positive anti-mitochondrial
antibody, and/or compatible liver biopsy).
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* postmenopausal status was defined as no menstrual periods for at
least six consecutive months, or a hysterectomy with conservation of
at least one ovary and the typical symptoms of oestrogen deficiency,
and an elevated follicle-stimulating hormone in the postmenopausal
range (> 34.4 IU/L);
- a normal pelvic examination, normal Papanicolaou test, and breast
examination;
- haemoglobin > 80 mg/L;
- voluntary informed consent.
Exclusion criteria:
- patients who did not meet the inclusion criteria;
- a liver transplanted patients;
- serum bilirubin > 120 µmol/L;
- current treatment with oestrogen or progestin (or patients that had
received treatment for more then six months since the onset of
menopause);
- vitamin D deficiency;
- contraindications to oestrogen use;
- treatment with drugs known to affect bone metabolism;
- other chronic disease affecting bone metabolism;
- severe spinal deformities that would preclude accurate BMD
measurement;
- patients that had been immobile for more then three months in the
preceding year;
- allergy to components of the patch or bandages.
Interventions Participants were randomly assigned to receive:
Intervention group 1: 17β-estradiol (0.05 mg daily) for 14 days
followed by 14 days of combined transdermal norethisterone acetate
(0.25 mg daily) and 17β-estradiol (0.05 mg daily) transdermally, n =
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16.
Duration of administration of hormone replacement was two years.
Intervention group 2: identical placebo patches applied in the same
manner, dose, and frequency, n = 15.
All patients received vitamin D 1000 IU daily and elemental calcium
1500 mg daily.
Outcomes Outcome measure(s):
- clinical variables;
- fractures;
- bone mineral density of the lumbar spine and proximal femur;
- measurements of biochemical markers of bone turnover (bone
alkaline phosphatases and the amino telopeptides of collagen I);
- biochemical variables (serum bilirubin, liver enzymes, lipid profile,
prothrombin time, etc);
- adverse events.
Notes Additional information requested on 21st March 2011. Dr. Jenny
Heathcote kindly responded on 24th March but she could not provide
data on the trial that had been initiated almost 20 years ago.
Risk of bias
Bias Authors'
judgement
Support for judgement
Random
sequence
generation
Low risk Sequence generation was achieved using randomisation
table.
Allocation
concealment
Low risk Allocation was performed by independent pharmacist
who had no role in patient contact or follow-up, nor did
he/she participate in data analysis, so the intervention
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allocation could not have been foreseen in advance of,
or during enrolment.
Blinding
All outcomes
Low risk The trial was described as blinded, the parties that were
blinded, and the method of blinding was described, so
that knowledge of allocation was adequately prevented
during the trial.
Incomplete
outcome data
All outcomes
Low risk The numbers and reasons for dropouts and
withdrawals in all intervention groups were described.
Selective
reporting
Low risk Pre-defined, or clinically relevant and reasonably
expected outcomes are reported on.
Other bias Low risk The trial seems to be free from other potential sources of
bias.
The trial reported that transdermal oestrogen/progestin
and placebo were supplied by Novartis, and that
Novartis was not involved in the collection, analysis, or
presentation of these data.
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Table 36. tables of excluded studies
Study Reason for exclusion
Menon
2003
Not a randomised clinical trial.
The aim of this study was to determine the safety and the efficacy
of oestrogen replacement therapy in postmenopausal women with primary
biliary cirrhosis.
Forty-six unselected postmenopausal women with primary biliary cirrhosis
receiving oestrogens for at least six months before being included in this
study were randomly matched for age, gender,
and ethnic group with another patient with primary biliary
cirrhosis but not receiving oestrogen therapy. All patients were
taking ursodeoxycholic acid (13 to 15 mg/kg/day) during the
study. Thirty-five women were taking estrogens alone, and 11
women were taking a combined oestrogen/progesterone regimen. Twenty-
one women were receiving oral replacement therapy, 23 topical replacement
therapy, and two women long-acting
parenteral therapy.
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Pereira
2004
Not a randomised clinical trial.
Forty-two post-menopausal women with primary biliary
cirrhosis were treated with calcium and vitamin D. They could
choose to receive it either alone (n ¼ 21) or together with
transdermal hormone replacement therapy (n ¼ 21).
The two groups were well matched for age, duration of
menopause (mean, 10.7 years; range, 1 to 26 years), body mass
index (mean, 24.2 kg/m2; range, 17.3 to 31.8 kg/m2),
histological stage, serum bilirubin level (mean, 16.9 lm; range,
4 to 65 lm) and Mayo Clinic R score (mean, 3.3; range, 1.0 to 4.6).
There were no adverse events attributable to treatment, apart
from two patients who stopped HRT because of monthly
bleeding and declined continuous combination therapy
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Table 37. Summary of findings table: Hormone replacement vs placebo or no
intervention for osteoporosis in primary biliary cirrhosis
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Discussion
Summary of main results
Cochrane systematic reviews included in this doctoral thesis investigated the
benefits and harms of interventions in patients with primary biliary cirrhosis
and osteoporosis in primary biliary cirrhosis. Data from 30 randomised clinical
trials with a total of 1847 participants were included. Twenty seven trials were
with high risk of bias. Our key findings, in each of the systematic reviews, are
that there is lack of statistical significant difference between the interventions
we investigated versus control interventions regarding all-cause mortality or
liver-related morbidity. However, the trials and meta-analyses of the
investigated interventions are under-powered to draw firm conclusions on
patient-important outcomes.
Ursodeoxycholic acid is the only drug approved by the U.S. Food and Drug
Administration for primary biliary cirrhosis, but the effects of ursodeoxycholic
acid remain controversial. Sixteen randomised clinical trials, with 1447 patients
included, provided an updated evidence for the systematic review which
assessed effects of ursodeoxycholic acid on patients with primary biliary
cirrhosis. All but one of the included trials had high risk of bias. With the
inclusion of updated data from 2007 to January 2012, this systematic review did
not demonstrate any significant benefits of ursodeoxycholic acid on all-cause
mortality, all-cause mortality or liver transplantation, or symptoms (pruritus
and fatigue). Portal pressure, varices, bleeding varices, ascites, and hepatic
encephalopathy were not significantly affected by ursodeoxycholic acid.
Ursodeoxycholic acid seemed to have a beneficial effect on liver biochemistry
measures and on histological progression compared with placebo or no
intervention. According to the results of the trial sequential analyses, there
seems to be firm evidence for a beneficial effects of ursodeoxycholic acid on
decreasing serum bilirubin concentration and the activity of serum alkaline
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phosphatases in patients with primary biliary cirrhosis compared with placebo
or 'no intervention'. However, these beneficial effects may still be due to
systematic errors (bias), as estimated intervention effects were calculated using
data from trials assessed as having ’high risk of bias’ except one. The
relationship between ursodeoxycholic acid effect and the severity of primary
biliary cirrhosis was indicated in the classical meta-regression (Sharp, 1998),
suggesting that ursodeoxycholic acid effect on mortality (if any) is more likely
to be observed in patients with more severe primary biliary cirrhosis. However,
this relationship was not supported by our univariate and multivariate meta-
regression analyses, which included 'severity' as a co-variate. Therefore,
whether the intervention effect of ursodeoxycholic acid (if any) is related to the
severity of primary biliary cirrhosis should be investigated further.
Six randomised clinical trials, with 151 Japanese patients included, all with high
risk of bias, provided information for the systematic review which looked at the
effect of bezafibrate in patients with primary biliary cirrhosis. Four trials
compared bezafibrate with no intervention, and two trials compared
bezafibrate with ursodeoxycholic acid. Bezafibrate did not demonstrate any
significant effect on mortality, liver-related morbidity, or adverse events when
compared with no intervention, or when compared with ursodeoxycholic acid.
Bezafibrate did not demonstrate any significant effect on pruritus compared
with no intervention. It was not possible to evaluate changes in quality of life
and fatigue since none of the trials reported these outcome measures. A possible
positive intervention effect of bezafibrate versus no intervention on liver
biochemistry measures can be real but could also be due to systematic errors or
random errors. The results of trial sequential analysis imply that there is firm
evidence for a beneficial effect of bezafibrate on decreasing  the activity of
serum alkaline phosphatases when compared with no intervention, or when
compared with ursodeoxycholic acid. The results of trial sequential analysis
imply that there is no firm evidence for a beneficial effect of bezafibrate on
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decreasing plasma immunoglobulin M concentration and serum bilirubin
concentration when compared with no intervention.
Six randomised clinical trials, with 200 participants included, provided
information for the review which looked at the effect of bisphosphonates for
osteoporosis in patients with primary biliary cirrhosis. Three trials with 106
participants, of which two trials with high risk of bias, compared etidronate or
alendronate with placebo or no intervention; two trials with 62 participants
with high risk of bias compared etidronate or alendronate with alendronate or
ibandronate; and one trial with 32 participants and with high risk of bias
compared etidronate with sodium fluoride. Having conducted statistical
analyses, we found no evidence of effect of any of the aforementioned three
bisphosphonates on mortality, fractures, adverse events, liver-related mortality,
liver transplantation, liver-related morbidity or bone mineral density measured
by dual-energy X-ray absorptiometry in patients with primary biliary cirrhosis.
The data seem to indicate a possible positive intervention effect of
bisphosphonates on decreasing urinary amino telopeptides of collagen I (NTx)
concentration compared with placebo or no intervention with no risk of random
error. The results of trial sequential analysis imply that there is no firm evidence
for a beneficial effect of alendronate on decrease in the procollagen type I N-
terminal propeptide (PINP) and NTx concentration compared with another
bisphosphonate. Serum osteocalcin concentration was measured in a different
units, so the standardised mean differences was used in meta-analysis of the
data from these trials. Therefore we could not apply trial sequentially analysis
to confirm or reject a beneficial effect of bisphosphonates on decrease in serum
osteocalcin concentration, and exclude the risk of random error, as trial
sequential analysis has not been developed for standardised mean difference.
Etidronate compared with sodium fluoride significantly decreased serum
osteocalcin, urinary hydroxyproline, and parathyroid hormone concentration.
Two randomized clinical trials, with 49 participants included, of which one trial
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with low risk of bias, assessed the effect of hormone replacement on treatment
of osteoporosis in women with primary biliary cirrhosis. Hormone replacement
had no significant effect on mortality, fractures, liver-related mortality, liver
transplantation, or liver-related morbidity compared with placebo or no
intervention in women with primary biliary cirrhosis. It seems that hormone
replacement given to women with primary biliary cirrhosis is connected with a
significant increase in the occurrence of adverse events compared with placebo
or no intervention. Hormone replacement had no significant effect on lumbar
spine bone mineral density measured by dual-energy X-ray absorptiometry
compared with placebo or no intervention. On the other hand, hormone
replacement seemed to significantly decrease bone mineral density measured at
the proximal femur compared with the control group, and this result was not
supported by trial sequential analysis. It seems that hormone replacement had
no significant effect on serum bilirubin concentration compared with placebo or
no intervention. However, the data are scarce, and we cannot exclude
substantial risks of type II errors.
Overall completeness and applicability of evidence
To identify all available evidence from randomised clinical trials, we conducted
an extensive search for trials, included publications in all languages, and had no
restriction on the outcomes reported in the trials. We could not obtain all
relevant data regarding all reasonably expected outcomes, as the trials
identified insufficiently addressed all of the objectives of our Cochrane reviews.
The lack of significant differences in mortality, mortality or liver
transplantation, liver morbidity, and adverse events may be related to the small
number of patients involved and the short duration of the trials. Most of the
included trials in our Cochrane reviews reported on biochemical and
immunological indices. These data were reported either as change from
baseline or final values, so we combined them in our meta-analysis using mean
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difference method in RevMan. Mean differences based on changes from
baseline can usually be assumed to be addressing exactly the same underlying
intervention effects as analyses based on final measurements (Higgins and
Green, 2011). Ursodeoxycholic acid and bezafibrate seemed to improve
biochemical outcomes, but there is no evidence favouring the ursodeoxycholic
acid and bezafibrate interventions for the disease because it is not based on
results from randomised trials using clinically and patient relevant outcomes
(Gluud et al, 2007).
There is a theoretical possibility that ursodeoxycholic acid may still delay
progression from early stage disease to late stage disease and then ultimately
prolong survival. However, the effects of ursodeoxycholic acid should
primarily be assessed via patient relevant outcomes.
The Mayo Risk Score Model has identified several prognostic biomarkers for
primary biliary cirrhosis, e.g., serum bilirubin. These biomarkers may respond
to ursodeoxycholic acid and may be predictive of survival (Dickson et al, 1989).
But they do not necessarily predict clinical benefit of the intervention in
question because 'a perfect correlation does not a surrogate make' (Baker and
Kramer, 2003). In the absence of validated surrogate outcomes in
ursodeoxycholic acid for primary biliary cirrhosis, confirmatory trials assessing
the ursodeoxycholic acid effect should only be based on clinical outcomes, e.g.,
mortality. We believe that evaluation based on such clinical outcomes-based
evaluation will benefit patients in the long run (Gluud et al, 2007).
Other two systematic reviews examined the evidence  for bisphosphonates or
hormone replacement treatment of osteoporosis in patients with primary biliary
cirrhosis. We could not obtain all relevant data regarding all reasonably
expected outcomes, as the trials identified were insufficient to address all of the
objectives of these reviews.
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Unfortunately, not all trials per each comparison reported on mortality  and
fractures, and the results were inconclusive. The lack of significant differences
in mortality or fractures may be related to the small numbers of participants
involved and the short duration of the trials. It is important to evaluate the
effects of bisphosphonates on fracture prevention in patients with primary
biliary cirrhosis. Cochrane systematic reviews have demonstrated that
bisphosphonates have statistically significant and clinically important benefit in
the secondary prevention of fractures in postmenopausal women (Wells et al,
2008a; Wells et al, 2008c). Since fractures occur at a variable length of time after
the onset of osteoporosis, it is not surprising that clinical trials of one year
duration are unable to show significant differences between treatment groups.
Longer follow-up of much larger patient groups is required to ascertain the
efficacy of bisphosphonates in fracture prevention.
From a bisphosphonate safety perspective, we could not find any statistically
significant difference in the occurrence of adverse events between the
bisphosphonates and control groups. Regarding safety of hormone replacement
in women with primary biliary cirrhosis, we found statistically significant
difference in the occurrence of adverse events between the treatment and
control groups. It seems that hormone replacement given to women with
primary biliary cirrhosis is connected with a significant increase in the
occurrence of adverse events compared with placebo or no intervention. On the
other hand, when participants are aware of the treatment they are receiving,
they may be more or less likely to report adverse events. The judgment of
individuals who collect and interpret patient data may be affected when the
assessor is aware of the treatment a participant is receiving. Lack of blinding in
half of the trials included in both reviews that reported on adverse events as
well as short follow-up and small numbers of participants may result in biased
results, so no conclusions can be drawn regarding adverse events of
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bisphosphonates or hormone replacement for osteoporosis in patients with
primary biliary cirrhosis (Ioannidis, 2009).
In the absence of fracture outcome data in most clinical trials of osteoporosis,
the intermediate outcome of bone mineral density may give fair information
regarding fracture risk. It appears that bisphosphonates have no significant
effect on the lumbar and proximal femur bone mineral density compared with
placebo or no intervention, or another bisphosphonate in patients with primary
biliary cirrhosis. It should be noted that the correlation between bone mineral
density and fracture risk has been established in post-menopausal osteoporosis
and not osteoporosis in primary biliary cirrhosis. Therefore, we do not yet know
if bone mineral density is a valid surrogate outcome measure in patients with
primary biliary cirrhosis (Gluud et al, 2007).
Most of the included trials reported on serum or urine markers of bone
turnover, or both. The clinical significance and utilisation of these biochemical
markers of bone turnover are not universally utilised; however, the assumption
is that they act as a surrogate outcome measure for efficacy of therapy. This
assumption, however, needs to be confirmed (Gluud et al, 2007).
There is a theoretical concern of worsening cholestasis by application of
hormone replacement to patients with primary biliary cirrhosis (Schreiber and
Simon, 1983). Both included trials reported on serum bilirubin concentration to
reflect their concern of possible worsening of cholestasis by application of
hormone replacement to women with primary biliary cirrhosis. These data were
reported using ranges rather than standard deviations, and we considered this
as an indicator that the outcome distribution in trials is possibly skewed. Even
though ranges should not be used to estimate the standard deviations, we used
an approach which estimates the standard deviation to be approximately one
quarter of the typical range of data values. Accordingly, the result of our meta-
analysis for this outcome is not a robust result, and we cannot conclude that
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hormone replacement influences serum bilirubin concentration in women with
primary biliary cirrhosis.
Quality of the evidence and potential biases in the review process
All Cochrane systematic reviews included in this doctoral thesis were
conducted according to The Cochrane Handbook for Systematic Reviews of
Interventions (Higgins and Green, 2011) and the Cochrane Hepato-Biliary
Group Module (Gluud et al, 2011). The results of our meta-analyses, however,
are only as strong as the primary trials included. For the different comparisons
in our Cochrane systematic reviews, a large proportion of the trials had
methodological limitations, small number of participants, small number of
events, and short trial duration. The different comparisons did not have
sufficient power to draw firm conclusions.
Risk of bias is known to impact on the estimated intervention effect, with trials
with high risk of bias tending to overestimate beneficial intervention effects and
underestimate harmful intervention effects. The risk of bias was high in twenty
seven trials in our Cochrane systematic reviews. Among the 30 trials included
in our reviews, three trials were classified as having low risk of bias according
to all bias domains (generation of the randomisation sequence, concealment of
the randomisation sequence, blinding of patients and personnel, blinding of
outcome assessors, incomplete outcome data, selective outcome reporting, for
profit bias). The main limitations in the design and implementation was the lack
of clarity of the generation of allocation sequence, concealment of allocation,
blinding, and the small number of patients enrolled in the trials and this might
have influenced the outcomes of the trials. Therefore, the estimated intervention
effect may possibly be due to systematic errors, and our evidence base is
therefore severely limited even when trial sequential analyses did not show risk
of random errors.
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We explored the presence of statistical heterogeneity by the chi-squared test
and measured the quantity of heterogeneity by I² (Higgins et al, 2003). The chi-
squared test has low power in the situation of a meta-analysis when trials have
small sample size or are few in number as in our included trials. This means
that while a statistically significant result may indicate a problem with
heterogeneity, a non-significant result must not be taken as evidence of no
heterogeneity. This is also why we used a P value of 0.10 to determine
statistical significance regarding heterogeneity. To reflect our concern with
heterogeneity, we looked at both fixed-effect and random-effects models in
order to provide more conservative estimates of effect. Indeed, our reviews
showed some significant results when the fixed-effect model was applied,
which were not statistically significant when the random-effects model was
applied. This makes our findings less robust. Available case analysis was
performed for all continuous outcomes including data only on those patients
whose results were known. Variation in the degree of missing data may also be
considered as a potential source of bias and heterogeneity in our analyses.
Regarding precision of our results, included trials in our meta-analysis include
few patients and few events and thus have wide confidence intervals around
the estimate of effect which might both hide beneficial and harmful effects.
Random errors are unpredictable variations in outcome measures, i.e., the play
of chance. The risk of random error is higher when data come from small
information sizes (or 'sample sizes' for individual trials), so information sizes
need to be sufficiently large for the risk of random error to be reduced and the
chance of observing a true intervention effect to be increased. To reduce the risk
of random errors we applied trial sequential analysis on the different outcomes
for the different comparisons, and found that we lack firm evidence to draw
firm conclusions both regarding benefits and harms of aforementioned
interventions in patients with primary biliary cirrhosis and osteoporosis in
primary biliary cirrhosis. Therefore, we conclude that there is a need for well-
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designed, randomised clinical trials with larger sample sizes and minimised
risk of bias. Multi-centre trials would be appropriate for patient recruitment as
primary biliary cirrhosis is a relatively rare disease. Such trials ought to be
reported according to the CONSORT guidelines (http://www.consort-
statement.org/). We also realise that the challenge of performing a new trial on
intervention for primary biliary cirrhosis is high. The estimated median survival
of primary biliary cirrhosis is 10 to 15 years. To spend 15 years planning and
carrying out a trial for each new potential treatment of primary biliary cirrhosis
would consume many patients' lifetimes, not to mention the expense and
difficulty of retaining patients in such a long trial (Mayo, 2005). Nevertheless,
there are at least an estimated one million patients with primary biliary
cirrhosis world-wide. Therefore, it is possible to conduct large trials with
appropriate statistical power if international groups of primary biliary cirrhosis
investigators collaborate. Such large trials do not need to be conducted for more
than two to four years.
Agreements and disagreements with other studies or reviews
In consistency with previous meta-analyses and reviews (Goulis et al, 1999;
Gluud and Christensen, 2001b; Gong et al, 2008), an updated systematic review
assessing the effects of ursodeoxycholic acid in patients with primary biliary
cirrhosis did not demonstrate any benefit of ursodeoxycholic acid on all-cause
mortality, and all-cause mortality or liver transplantation in these patients. This
observation is in contrast to some previous attempts to aggregate data from
studies assessing ursodeoxycholic acid interventions for primary biliary
cirrhosis (Simko et al, 1994; Poupon et al, 1997; Poupon, 2000). However, Simko
et al included non-randomised studies in their meta-analysis that are more
liable to bias, that is systematic overestimation of benefit (Simko et al, 1994).
Poupon only included three and five out of the 16 randomised clinical trials in
their meta-analyses, respectively (Poupon et al, 1997; Poupon, 2000). Such meta-
analyses largely run the risk of trial selection bias (Gluud and Christensen,
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2001a). Furthermore, updated evidence from randomised clinical trials and
analyses on longer follow-up data from our previous review (Gong et al, 2008)
did not seem to support long-term ursodeoxycholic acid treatment for primary
biliary cirrhosis. The main finding in our present updated review does not seem
to support long-term ursodeoxycholic acid intervention, which was suggested
in observational studies (Rust and Beuers, 2005; Pares et al, 2006). Thus, the
results suggest no benefit of ursodeoxycholic acid on mortality.
On the other hand, ursodeoxycholic acid seemed to improve biochemical
outcomes. This seems to place clinicians and researchers in a dilemma: if
therapeutic decisions are based on clinical outcomes (e.g., mortality), there is
insufficient evidence to support the use of ursodeoxycholic acid in primary
biliary cirrhosis, but if based on non-validated 'surrogate' outcomes (e.g., serum
bilirubin level or serum alkaline phosphatases), there is evidence favouring the
ursodeoxycholic acid interventions for the disease (Gluud et al, 2007). We
believe that clinical practice should be based on results from randomised trials
using clinically and patient relevant outcomes.
We could not compare our results with the results from other systematic
reviews or meta-analysis, as we could not identify any meta-analyses or
systematic reviews assessing bezafibrate in primary biliary cirrhosis, nor
bisphosphonates or hormone replacement for osteoporosis in people with
primary biliary cirrhosis that have summarised the evidence in a systematic
way. Cochrane systematic reviews have demonstrated that bisphosphonates
have statistically significant and clinically important benefit in the secondary
prevention of vertebral, non-vertebral, and hip fractures in postmenopausal
women (Wells et al, 2008a; Wells et al, 2008c). In the review assessing effects of
bisphosphonates for osteoporosis in primary biliary cirrhosis, two trials were
classified as primary prevention trials, and the remaining four trials as
secondary prevention trials. More randomised clinical trials on participants
receiving bisphosphonates as secondary prevention are needed in order to
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conclude whether there is an effect of bisphosphonates for secondary
prevention of osteoporosis in patients with primary biliary cirrhosis. If an effect
exists, then primary prevention trials could be conducted. There is evidence
that hormone replacement increases bone mineral density (Wells et al, 2002)
and reduces the incidence of vertebral and non-vertebral fractures (Torgerson
and Bell-Syer, 2001a; Torgerson and Bell-Syer, 2001b) in postmenopausal
women. On the other hand, there is an increasing concern about the adverse
events of hormone replacement among women. Apart from the fact that
oestrogen deficiency is considered to be a major factor leading to bone loss in
postmenopausal women, there is strong evidence that hormone replacement
significantly increases the risk of venous thromboembolism, heart attack, stroke,
breast cancer, gallbladder disease, and in women over 65 years, the risk of
dementia (Farquhar et al, 2009).
One could argue that patients with primary biliary cirrhosis plus osteoporosis
should be treated as women without primary biliary cirrhosis having
osteoporosis. This may turn out to be correct. However, we do not know if this
is so. First, the pathogenesis of osteoporosis in patients with primary biliary
cirrhosis may be different from osteoporosis in patients without cirrhosis.
Second, the metabolism and effects of antiosteoporotic drugs may change in
patients with primary biliary cirrhosis. Accordingly, without proper trials we
cannot assure ourselves that data from osteoporotic patients can be transferred
to osteoporotic patients with primary biliary cirrhosis. Without solid evidence
patients may not get the appropriate treatment they need.
Recommendations for future research
Randomised clinical trials which assess ursodeoxycholic acid or bezafibrate
versus placebo in primary biliary cirrhosis with larger sample sizes, long-term
follow-up and minimised risk of bias are needed. Trials should mainly be based
on clinical outcomes, e.g., mortality. Outcome measures should include quality
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of life.
In order to have evidence on whether bisphosphonates or hormone replacement
should be used for treating osteoporosis in primary biliary cirrhosis or not,
randomised clinical trials which assess bisphosphonates as secondary
prophylaxis in primary biliary cirrhosis, or hormone replacement in primary
biliary cirrhosis with larger sample sizes and varying degrees of osteoporosis,
and minimised risk of bias are needed. Multi-centre trials would be appropriate
for participant recruitment as primary biliary cirrhosis is a relatively rare
disease, and such trials ought to be reported according to the CONSORT
Statement (www.consort-statement.org/).
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CONCLUSIONS
Updated Cochrane review confirms and extends previous observations
showing no benefit of ursodeoxycholic acid on all-cause mortality and on all-
cause mortality or liver transplantation. Although based on a small number of
trials with risk of bias, ursodeoxycholic acid seems to improve liver biochemical
variables, including serum bilirubin concentration, and liver histology. This
review does not support or refute short-term or long-term use of
ursodeoxycholic acid.
Bezafibrate has no statistically significant effects on mortality, liver-related
morbidity, adverse events, and quality of life of patients with primary biliary
cirrhosis. A possible positive intervention effect of bezafibrate on liver
biochemistry measures can be real but could also be due to systematic errors or
random errors.
We found no evidence of effect of bisphosphonates on mortality, fractures,
adverse events, quality of life, and bone mineral density in patients with
primary biliary cirrhosis. Bisphosphonates seem to decrease NTx concentration
in patients with primary biliary cirrhosis with no risk of random error, but we
lack data from low risk of bias trials, so we do not have enough evidence in
order to draw practical conclusions from the data.
Hormone replacement has no statistically significant effects on mortality,
fractures, and on the lumbar bone mineral density in women with primary
biliary cirrhosis. It seems that hormone replacement given to women with
primary biliary cirrhosis is connected with a significant increase in the
occurrence of adverse events. On the other hand, hormone replacement may
decrease bone mineral density measured at the proximal femur.
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Accordingly, treatment of primary biliary cirrhosis with ursodeoxycholic acid,
bezafibrate, bisphosphonates, and hormone replacement can neither be
supported nor refuted based on the best current evidence available.
The benefits and harms of interventions for patients with primary biliary
cirrhosis and osteoporosis in primary biliary cirrhosis need further assessment
in randomised clinical trials. Such trials ought to be conducted with impeccable
methodology to reduce the risks of random errors and sufficiently large patient
groups to reduce the risks of random errors.
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